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Abstract 
In patients with complex regional pain syndrome (CRPS), sensory disturbances 
commonly spread outside the affected limb, in particular hemilaterally. Hyperalgesia to 
pressure-pain was, for instance, documented in the forehead ipsilateral to the affected limb 
[7]. The aim of this thesis was to investigate potential mechanisms involved in this spread. 
Firstly, the effect of experimental limb pain (the cold pressor test) on sensory changes to 
pressure-pain and sharpness outside the immersed limb was investigated on each side of the 
forehead in samples of 45 and 32 healthy volunteers. Prior to pain induction, differences in 
pressure-pain or sharpness sensitivity between the left and right side of the forehead were 
generally small or non-existent. The induction of severe limb pain in healthy volunteers 
produced a bilateral reduction in forehead sensations to pressure-pain and sharpness with 
greater analgesia to pressure in the ipsilateral forehead. Central inhibitory pain control 
mechanisms may have mediated this effect.  
The second study attempted to disrupt inhibitory pain control prior to cold-induced 
limb pain (cold pressor test) in 85 healthy volunteers and investigated the effect of these 
procedures on sensitivity to pressure-pain and sharpness on each side of the forehead. 
Optokinetic stimulation was employed to disrupt inhibitory pain control as increased 
forehead sensitivity was reported following this form of motion sickness-producing 
stimulation [4; 6]. Sensitivity to pressure-pain and sharpness increased in the forehead after 
optokinetic stimulation. However, during the subsequent cold pressor test, forehead 
sensitivity to these stimuli decreased in the most pain sensitive participants, suggesting that 
inhibitory pain control mechanisms remained intact.  
The finding of a previous study that unilateral carageenan-induced hindpaw 
inflammation in the rat produces thermal hyperalgesia both in the inflamed hindpaw and   iv 
the non-inflamed forepaw, but not in the contralateral paws [16] prompted us to investigate 
a link between limb inflammation and hemilateral hyperalgesia. Pressure-pain and 
sharpness sensations were assessed on each side of the forehead in 17 healthy volunteers 
during 48 hours of topical treatment of the forearm with the inflammatory agent, capsaicin. 
Capsaicin-treatment evoked a bilateral reduction in forehead sensitivity to sharpness and an 
ipsilateral reduction in forehead sensitivity to pressure-pain. Differences in the tissue 
affected (muscle in the rat study and skin in the human study) may explain the differing 
results from the rat study.  
The issue of inflammation-induced hemilateral sensory disturbances was explored 
further in patients with CRPS. NMDA-receptors are up-regulated in inflamed human skin 
[15] and appear to be involved in sensitizing primary afferent nociceptors during 
inflammation and tissue injury [2; 8; 10]. In a double-blind placebo-controlled trial, the 
NMDA antagonist, topical ketamine, was applied to the affected or unaffected limb of 20 
patients with CRPS and the effect on sensitivity to a range of sensory stimuli (touch, 
pinprick, thermal, pressure, brushing) was investigated in the affected and unaffected limb 
and on each side of the forehead. Hyperalgesia to sharpness, pressure, cold and heat, and 
allodynia to brushing, were detected in the ipsilateral forehead before treatment. This was 
generally associated with heightened sensitivity in the affected limb. The topical 
application of ketamine reduced allodynia and sharpness hyperalgesia in the affected limb. 
As allodynia to brushing the skin and sharpness hyperalgesia are mediated by sensitized 
spinal nociceptive and wide dynamic range neurons that receive input from nociceptive A-
delta fibers and non-nociceptive A-beta fibers [12; 13], peripheral NMDA-receptors may 
play a role in the sensitization of central neurons in CRPS. In some patients with allodynia 
in the forehead, forehead allodynia was reduced following treatment of the affected limb   v 
with ketamine, suggesting that a similar mechanism may contribute to the heightened 
sensitivity in the forehead. 
Prior to this thesis, a small number of studies suggested that central inhibitory pain 
control is disrupted in patients with CRPS [3; 5; 14]. The laterality of such mechanisms, 
and their potential contribution to hemilateral hyperalgesia, was explored. CRPS pain 
increases during startle with a loud tone [3; 5]. Whether this increase in pain to acoustic 
startle differs between startle in the ipsilateral and contralateral ear was investigated in 28 
CRPS patients. Acoustic startle in the ear ipsilateral to the affected limb induced greater 
limb pain than startle in the contralateral ear. In addition, auditory discomfort was greater to 
ipsilateral than contralateral ear stimulation and in patients with increased pain to startle 
than in a small group of non-responders, suggesting not only that inhibitory pain control is 
disrupted in CRPS but that central neurons both in the somatosensory and auditory systems 
are facilitated, in particular to stimulation on the ipsilateral side of the body.  
The laterality of a dysfunction in inhibitory pain control was explored further by 
investigating pressure-pain and sharpness sensations on each side of the forehead in 22 
CRPS patients during noxious cold stimulation of the affected limb versus noxious cold 
stimulation of the contralateral unaffected limb. Cold water immersion of the healthy limb 
decreased forehead sensitivity to pressure-pain bilaterally and decreased clinical pain in the 
affected limb. In contrast, immersion of the symptomatic limb increased pressure-pain 
sensitivity on both sides of the forehead. Sharpness ratings in the forehead remained 
unchanged to immersion of either limb. Nociceptive afferent input from the CRPS affected 
limb may thus either fail to evoke inhibitory processes or simultaneously evoke a pain 
facilitatory mechanism that masks inhibitory influences.   vi 
Finally, pressure-pain and sharpness sensations were investigated on each side of 
the forehead in 35 chronic pain patients without CRPS (neuropathic or nociceptive limb 
pain, back pain or acute herpes zoster/postherpetic neuralgia) and were compared to similar 
measurements obtained in 34 patients with CRPS. Ipsilateral forehead hyperalgesia to 
pressure-pain was more common in CRPS patients (59%) than patients without CRPS 
(14%). Non-CRPS patients mainly reported symmetrical (within normal range) forehead 
sensations. Ipsilateral forehead hyperalgesia to sharpness occurred in 38% of CRPS patients 
which was similar to that in patients without CRPS. Nonetheless, symmetrical sharpness 
sensations dominated in both groups. In general, heightened sensitivity to pressure and 
sharpness in the ipsilateral forehead was present in patients with greater pain, sharpness 
hyperalgesia and swelling at the pain site.  
In sum, the results of this thesis indicate that ipsilateral forehead hyperalgesia, in 
particular to pressure-pain, may be specific to CRPS. Nociceptive input from the inflamed 
CRPS limb may sensitize neurons in the dorsal horn and neurons at supraspinal sites that 
receive input from the affected limb such as the contralateral thalamus. Hyperexcitability in 
thalamic nuclei contralateral to the affected limb which receive convergent input from 
hemilateral body sites could not only explain the presence of hemilateral hyperalgesia but 
could also explain heightened sensitivity to other forms of sensory input (e.g., auditory 
input). Failure of inhibitory pain control, in particular to stimulation on the symptomatic 
side of the body, or a shift toward facilitatory control in mechanisms with a bidirectional 
role in pain modulation such as the noradrenergic actions from the locus coeruleus, the 
serotonergic actions from the raphe nuclei or diffuse noxious facilitatory versus inhibitory 
controls [1; 9; 11; 17; 18] may further promote the transfer of nociceptive messages to   vii 
higher brain sites. The ipsilateral noradrenergic actions from the locus coeruleus is a 
particular candidate for the hemilateral facilitation of nociception in CRPS. 
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limb pain and back pain patients with ipsilateral forehead hyperalgesia, 
symmetrical forehead sensations and ipsilateral forehead analgesia to 
sharpness. 
 
Figures from Chapter 12.0 
Figure 1  Ascending pain pathway from the CRPS limb and   307 
coeruleospinal pain modulation. Heightened nociceptive input  
from the CRPS limb (red) may produce hyperexcitability both in the  
dorsal horn (DH) and the contralateral thalamus (TH) in patients  
with CRPS. A disruption of descending inhibitory control from the  
locus coeruleus (LC) (purple) may unmask the further facilitation of  
neurons in the ipsilateral dorsal horn. In addition a shift toward  
facilitatory control from the LC may facilitate neurons in the  
ipsilateral trigeminal nucleus caudalis (TNC) that transmit  
nociceptive messages from the forehead to the thalamus (blue), and may  
also facilitate neurons in the ipsilateral cochlear nucleus (CN) that 
transmit auditory impulses from the ipsilateral ear to thalamic nuclei  
(green). This could explain the heightened sensitivity both to sensory  
and auditory stimuli on the symptomatic side of the body in CRPS.  
The convergence of these stimuli in an already hyperexcitable thalamus  
may also explain such findings. The shift from inhibitory to  
facilitatory pain control in diffuse bidirectional pain control  
mechanisms such as diffuse noxious facilitatory versus diffuse    xxviii 
noxious inhibitory controls or serotonergic projections from raphe  
nuclei may explain findings of generalized sensory disturbances in  
CRPS patients. For clarity, descending influences from the LC are  
presented schematically.    1 
CHAPTER 1 
INTRODUCTION TO COMPLEX REGIONAL PAIN 
SYNDROME 
 
1.1  The problem of complex regional pain syndrome 
Complex regional pain syndrome (CRPS) is a painful condition of the extremities 
that may develop following traumatic injury (most commonly fractures) or surgery [10; 21; 
23; 104]. Although a relatively rare condition (i.e. 20.57-26 per 100,000 person years) [23; 
81], the pain and symptoms are usually severe and often spread to other parts of the body 
[28] resulting in considerable disability [80].  
Unfortunately, the condition is not only under-recognised [65] but also difficult to 
treat because the exact physiological underpinnings of the syndrome are not yet fully 
understood. This has devastating consequences for the individual CRPS sufferer as loss of 
employment, domestic and social disruptions, litigation and financial problems usually 
follow [4; 24; 35; 52]. Depression resulting from social isolation and helplessness add to 
such problems, in particular in chronic CRPS [24; 78].  
Current treatments include medication, sympathetic blocks, sympathectomy, 
acupuncture, physiotherapy, psychological treatment, peripheral nerve stimulation and 
spinal cord stimulation with limited success [15; 19; 20; 38; 41; 44; 48; 64; 73; 74; 91-94; 
106; 110]. In order to find a successful treatment for CRPS, more research into the 
physiological mechanisms responsible for the ongoing pain and related symptoms is 
required. Improving the clinical management of pain through such efforts is an important   2 
step towards minimizing the psychological, physical and financial costs to patients, as well 
as society.  
 
1.2  Diagnosis and clinical features 
In 1994, the International Association for the Study of Pain (IASP) introduced the 
umbrella term CRPS to encompass a number of painful limb conditions with similar 
etiology. These included amongst others algodystrophy, shoulder-hand syndrome, causalgia 
and reflex sympathetic dystrophy [6; 14; 71; 85]. This was done in an attempt to clarify and 
improve clinical recognition and diagnosis of what was believed to be a shared underlying 
disorder [46]. A set of diagnostic criteria was proposed based on expert advice [91]. These 
are displayed in Table 1. Extreme pain, hyperalgesia or allodynia along with evidence of 
autonomic disturbances were considered essential for the diagnosis of CRPS which also 
required the exclusion of other potential causes for the pain. 
 
Table 1 
IASP diagnostic criteria for CRPS (criteria 2-4 must be satisfied) [61] 
 
 
 
 
If no sign of nerve damage, diagnose CRPS I. If major nerve damage, diagnose CRPS II 
 
Two subsets of CRPS, CRPS I and CRPS II, were considered to exist [91]. CRPS II 
is diagnosed when there is obvious evidence of peripheral nerve lesion clinically (sensory 
loss, muscle weakness, reflex loss) or during neurophysiological assessment (nerve 
1. The presence of an initiating noxious event, or a cause of immobilization. 
2. Continuing pain, allodynia, or hyperalgesia with which the pain is   
    disproportionate to any inciting event. 
3. Evidence at some time of edema, changes in skin blood flow, or abnormal  
    sudomotor activity in the region of pain. 
4. This diagnosis is excluded by the existence of conditions that would otherwise  
    account for the degree of pain and dysfunction.   3 
conduction, electromyography) [42] whereas type I is diagnosed when no lesion of major 
nerves is detected [61]. However, as minor nerve damage such as injuries to small distal 
nerve branches arising from broken bones or dislocations may go undetected [13], the 
involvement of nerve damage in CRPS I has also been suggested  [13; 69]. In support of 
this, loss of normal C and Aδ fibers [2] as well as abnormalities in C fibers [100] have been 
detected in CRPS I patients. More recently a study reported a distal degeneration of small-
diameter axons (by 29%) in 17/18 CRPS I patients [69], supporting the involvement of 
minimal distal nerve injury in CRPS I. For such reasons, some researchers and clinicians no 
longer discriminate between the two subtypes [13]. However, others question such 
assertions [49; 70; 75]. In this thesis, the general term CRPS will be used mainly for ease of 
communication and is not a reflection of the author’s stand on this issue.  
The diagnosis of CRPS is at present mainly by clinical examination based on the 
1994 IASP criteria. Concerns have been raised about this as evaluation of these criteria 
suggested poor inter-observer reliability [99] and, although they appeared to be quite 
sensitive at detecting CRPS, they appeared to have low specificity leading to over-
diagnosis [17; 33; 40].  
Based on a factor and cluster analysis of 123 patients meeting the IASP criteria for 
CRPS, Harden and colleagues suggested alternative diagnostic criteria which considered 
both sensory, vasomotor, sudomotor/edema and motor/trophic changes important for the 
diagnosis of CRPS [40]. The contribution of self-reported symptoms to diagnostic 
accuracy, in addition to signs detected at physical examination was emphasized [33; 40].  
Based on an evaluation of these latter criteria, a consensus group of international 
CRPS experts meeting in Budapest in 2003 to revise the current 1994 diagnostic criteria 
proposed two slightly different sets of criteria for CRPS which differed in their research   4 
versus clinical use [45] (Table 2). For clinical purposes, a decision rule requiring two of 
four neurological sign categories and three of four symptom categories to be satisfied were 
considered sensitive enough [17] whereas a requirement of four of four symptom categories 
and two of four sign categories were considered specific enough for research purposes [17; 
45]. These changes have been proposed to the Committee for Classification of Chronic Pain 
of the IASP for inclusion in future revisions of their taxonomy and diagnostic criteria [43].  
 
Table 2 
Proposed CRPS diagnostic criteria [40; 45]  
 
For research purposes, diagnostic decision rule should be at least one symptom in all four symptom 
categories and at least one sign (observed at evaluation) in two or more sign categories. 
General description of CRPS: 
CRPS describes an array of painful conditions that are characterized by a continuing 
(spontaneous and/or evoked) regional pain that is seemingly disproportionate in time or degree 
to the usual course of any known trauma or other lesion. The pain is regional (not in a specific 
nerve territory or dermatome) and usually has a distal predominance of abnormal sensory, 
motor, sudomotor, vasomotor, and/or trophic findings. The syndrome shows variable 
progression over time. 
 
To make  the clinical diagnosis, the following criteria must be met: 
 
 
1. Continuing pain, which is disproportionate to any inciting event. 
2. Must report at least one symptom in three of the four following categories: 
  Sensory: reports of hyperesthesia and/or allodynia. 
 
Vasomotor: reports of temperature asymmetry and/or skin colour changes and/or skin 
colour asymmetry. 
  Sudomotor/edema: reports of edema and/or sweating changes and/or sweating asymmetry. 
 
Motor/trophic: reports of decreased range of motion and/or motor dysfuntion (weakness, 
tremor, dystonia) and/or trophic changes (hair, nail, skin). 
3. Must display at least one sign at time of evaluation in two or more of the following     
    categories: 
 
Sensory: evidence of hyperalgesia (to pinprick) and/or allodynia (to light touch and/or 
temperature sensation and/or deep somatic pressure and/or joint movement). 
 
Vasomotor: evidence of temperature asymmetry (>1˚C) and/or skin colour changes and/or 
asymmetry. 
 
Sudomotor/edema: evidence of edema and/or sweating changes and/or sweating 
asymmetry. 
4. 
Motor/trophic: evidence of decreased range of motion and/or motor dysfunction 
(weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin). 
There is no other diagnosis that better explains the signs and symptoms.   5 
1.2.1   Pain and sensory disturbances 
The first criterion for a diagnosis of CRPS in both the original IASP criteria and the 
revised criteria is continuing pain. Nonetheless, some patients may display symptoms 
consistent with CRPS without pain [30]. Usually, the pain is of greater duration, 
distribution and severity (typically described as moderate to severe by patients) than what 
would normally be expected from the inciting injury [57; 59; 76; 80]. A deep pain that is 
often more permanent than lancinating is generally reported [10; 76]. The pain may be 
burning, aching, throbbing, tearing, pricking, shooting, stinging, dull or sharp [10; 12; 76; 
80]. 
  The pain is usually worsened by additional sensory disturbances in more than 70% 
of cases [10; 40; 104]. These occur in a variety of combinations and to a variety of stimuli 
[88]. Hyperalgesia (a heightened sensitivity to painful stimuli) exists in some form in the 
majority of patients [12; 40; 104]. Hyperalgesia to heat pain, cold pain, pinprick, pressure, 
pinch and impact stimuli has been documented in the symptomatic limb [10; 28; 47; 53; 76; 
77; 87; 88; 90]. Allodynia (pain arising from normally non-painful stimuli) to warm and 
cool temperatures, touch, vibration, movement and dynamic brushing may also occur [10; 
50; 53; 55; 76; 77; 88]. In addition, wind-up related pain from repetitive stimulation may be 
enhanced in the affected limb [88; 90].  
CRPS patients may also experience a loss of sensation. This was found to stimuli 
such as touch, heat pain, cold pain, warm thresholds and pinprick [10; 28; 47; 53; 87; 104]. 
Interestingly, these negative disturbances may co-exist with positive sensory disturbances 
[28; 47; 104]. A feeling of numbness in the limb has also been described [12].  
 
   6 
1.2.2  Vasomotor disturbances 
Vasomotor dysfunction manifests as changes in skin temperature and red (flushed) 
or bluish (cyanotic) skin. Altered skin temperature is evident in the majority (60-90%) of 
CRPS patients [10; 80; 104]. The limb may express itself as warm or cold [80; 88; 104; 
108]. The limb appears to be warmer in acute stages and colder in later and chronic stages 
[9; 10; 47]. However, a warm limb was also found in patients with CRPS for up to 12 years 
[104] and some patients report decreased skin temperature from the onset of CRPS [18]. 
Separate warm and cold CRPS phenotypes have been suggested [29]. Regardless of 
whether hot or cold, the typical temperature difference between the affected and unaffected 
limb is more than 1.0 °C [57; 108]. Temperature asymmetry has been found to accurately 
discriminate between CRPS and non-CRPS patients [16; 108; 109]; however, there is 
debate as to the diagnostic utility of this due to the changing nature of temperature 
asymmetry within patients [22; 39; 57; 67; 89]. 
  Discolouration of the limb occurs in more than 50% of patients [80; 100; 104]. The 
affected CRPS limb may appear a purple-bluish or red colour signifying underlying 
changes in blood flow (vasoconstriction or vasodilatation) [9; 83; 88; 100; 107; 108]. Red 
skin has been suggested to be more common in acute stages and cyanotic blue skin in 
chronic stages [10].  
 
1.2.3  Sudomotor disturbances/edema 
Edema and changes in sweating are common in CRPS (70-80%) [10; 28; 53; 88; 
104]. The majority of patients report swelling in the affected limb. However, this appears to 
be an intermittent and changing feature [80]. There is evidence of a higher incidence of 
edema in acute stages [10; 47]. Sweating abnormalities in the affected limb appear to be   7 
less common [8; 51; 80] and may be marked by hyperhidrosis (increased sweating) or 
hypohidrosis (decreased sweating) [10; 11; 28; 51; 53; 88; 104].  
 
1.2.4  Motor/trophic disturbances 
Motor disturbances occur in the majority of CRPS patients. Most predominant is a 
decreased range of movement and weakness in the affected limb which occurs in 80- 90% 
of patients [10; 76; 100; 104]. Other motor disturbances may be present in various 
combinations. They include paresis, myoclonic jerks or muscle contractions, muscle 
spasms, tremor, exaggerated tendon reflexes, muscular incoordination, bradykinesia 
(slowness of repetitive movements), and, less common, dystonia [7; 10; 27; 36; 57; 60; 66; 
76; 80; 86; 87; 98; 101; 102; 104]. In addition, some patients report a neglect-like 
phenomenon [32; 34; 57] with difficulty initiating movement and with feelings of the 
symptomatic limb as foreign or strange or larger than its actual size [31; 58; 63].  
  Trophic changes may also accompany CRPS and does so in 20-50% of cases [80; 
104] possibly as a consequence of disuse [46]. Increased hair growth (hypertrichosis) and 
hair loss (hypotrichosis) of the affected limb have been documented [51; 53; 88; 104]. Nails 
of the affected extremity may also become brittle and display changes such as 
discolouration, breakage, increased or decreased growth [51; 53; 68; 88; 95; 103; 104]. 
Increased hair and nail growth seems to occur early on in the disorder and to be replaced 
later by reduced hair and nail growth as well as atrophy of the skin [12]. Skin atrophy may 
present as coarsening, thickening or thinning of the skin with a brown-grey scaly 
pigmentation or shiny appearance [53; 100; 104].  In severe cases, atrophy of the muscles 
with fibrosis may also be experienced [88; 100]. Although osteoporosis is not described as   8 
an essential component of CRPS, a number of studies have demonstrated patchy 
osteoporosis in CRPS [37; 54; 56; 62; 82; 111].  
 
1.3  Spread of symptoms 
The symptoms of CRPS may be limited to the affected area in a cuff-, glove- or 
stocking-like distribution or may be limited to the glabrous skin of hands or feet [10]. 
However, the spread of CRPS pain and symptoms to other parts of the body has been 
widely documented [5; 25; 26; 28; 54; 55; 59; 76; 77; 86; 97; 104; 105]. CRPS pain may 
even present itself remote from the injured area (e.g., after myocardial infarction) [1].  
A number of studies have demonstrated CRPS symptoms in more than one limb, in 
rare cases in all four limbs [3; 5; 7; 59; 72; 79; 84; 86; 90; 96; 102; 104; 105]. These studies 
were all largely based on subjective patient reports as to the areas of the body affected by 
CRPS. Maleki and colleagues [59] mapped the spread of CRPS in 27 patients and 
suggested three types of spread: contiguous spread (enlargement of the affected area), 
independent spread (to an area remote from the initial area i.e., from an arm to a leg) and 
mirror spread (to the contralateral limb).  
More recently it has become clear that even when no subjective reports of a spread 
of CRPS are sought from patients, sensory disturbances can be detected outside the primary 
CRPS area. Quantitative sensory testing by Rommel and colleagues [76; 77] found 
hypoalgesia on the entire ipsilateral side of the body or in the ipsilateral upper quadrant in 
50% of CRPS I patients. This was demonstrated both to pinprick, touch and thermal 
thresholds. Thimineur’s group [97] similarly detected hypoalgesia to thermal stimuli and 
motor weakness ipsilateral to the affected limb in half of their CRPS participants. These 
participants, in addition, exhibited bilateral sensory and motor deficits in comparison to   9 
controls or CRPS patients without hemilateral differences. Nonetheless, the deficits were 
more pronounced ipsilaterally.  
More recently, findings of hemilateral involvement were confirmed by Drummond 
and Finch [28]. A loss of sensitivity to touch in the affected limb was found to be 
associated with diminished sensitivity to sharpness, cold and heat-pain in the ipsilateral 
forehead. In addition, hemilateral hyperalgesia was reported in 78% of patients. Most 
marked was the finding of lower pressure-pain thresholds on the side of the forehead 
ipsilateral to the affected limb compared with the contralateral forehead, suggestive of 
ipsilateral mechanical hyperalgesia. In addition, sharpness sensations to pinprick were 
associated with similar sensations in the affected limb. Huge et al. [47] have since 
discovered cold hyperalgesia both in the affected and contralateral unaffected limb in acute 
and chronic CRPS compared to controls. Interestingly, hyperalgesia to heat was also 
detected bilaterally in acute CRPS but was evident only in the symptomatic limb in chronic 
CRPS.  
From these studies, it is clear that CRPS is commonly marked by a spread of 
sensory disturbances outside the injured area that typically extends ipsilaterally.  The cause 
of this spread is unknown. Is it simply a result of pain in a limb? Is it the result of 
anomalies in central pain modulation? Do neurogenic inflammation or central sensitization, 
that seem to accompany CRPS, contribute to this spread? Determining the underlying 
mechanisms of the spread in CRPS is important if we are to find appropriate treatments to 
deter this debilitating development in patients. The current thesis seeks answers to the 
above questions in an attempt to bring us closer to an understanding of the underlying 
mechanisms of spread of sensory disturbances in CRPS.   10 
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CHAPTER 2 
NORMAL PAIN PROCESSING 
 
2.1  Pain and its function 
The International Association for the Study of Pain (IASP, p. 250) [78] defines pain 
as “an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage.” The IASP definition refers mainly to 
acute pain which is associated with injury and many diseases. Acute pain serves an 
important function. It signals to the brain that real or potential tissue injury is taking place 
and induces withdrawal or escape as a protective response [43]. Or, in the case of sickness, 
hyperalgesia and allodynia is associated with inactivity and increased sleep probably to 
help conserve energy to assist recuperation [68; 112]. On such grounds, it has been argued 
that the ability to experience pain evolved because it was adaptive and increased the 
probability of survival [30]. However, in CRPS, where pain persists beyond tissue healing 
and develops into a chronic and debilitating state, pain can hardly be considered beneficial. 
  
2.2  Nociception 
The early idea that the transmission of pain occurs through a single pathway from 
the skin to the brain has long been refuted. Instead pain processing is a rather complex 
process involving both the peripheral and central nervous systems [44].  
 
2.2.1  Peripheral nociception 
The first step in the pain process is the detection of a painful stimulus in the 
periphery by primary afferent fibers. Neurons responding to noxious stimuli in the   23 
periphery contain small-diameter thinly myelinated fast conducting Aʴ fibers or small 
diameter unmyelinated slowly conducting C fibers [8]. These mediate respectively „first‟ 
(rapid, acute, sharp, well-localised) and „second‟ (delayed, dull, burning, diffuse) pain [8; 
21; 83]. Aʴ fibers respond to intense mechanical stimuli [83] and extreme thermal stimuli 
(<5°C or >45°C) [8] whereas many C fibers are polymodal and respond both to noxious 
thermal (41°C to 49°C), mechanical and chemical stimuli although some seem to respond 
to heat only [21; 83]. C fibers are considered more common than Aʴ fibers [21]. An 
additional class of nociceptors are the so called „silent‟ nociceptors which seem to respond 
only when they have become sensitized by tissue injury or inflammation [87]. Finally, 
peripheral neurons responding to innocuous (non-painful) stimuli contain large diameter 
myelinated fast-conducting Aβ axons [83]. The free nerve endings of all these fibers are 
distributed throughout the skin and deep tissues [8]. 
 When the primary afferent fibers are activated, action-potentials are generated 
which travel along the afferent axons to the dorsal horn of the spinal cord [8]. In the dorsal 
horn, the fibers synapse either directly or indirectly (via interneurons) with second-order 
projection neurons via the release of a number of neurotransmitters such as the excitatory 
amino acid glutamate or the peptide substance P [43; 175]. The cells of the dorsal horn 
contain specific receptors for these substances such as the receptor for glutamate, the N-
methyl-D-aspartate (NMDA) receptor [21]. The transmission of action-potentials to dorsal 
horn neurons contains a range of information including the onset, intensity, quality, 
location and duration of the peripheral noxious (painful) stimulus [8] . 
 
2.2.2  Central nociception 
The dorsal horn of the spinal cord is an important site for the further processing of 
nociceptive information. It is separated into various layers (laminas). Most of the neurons   24 
that respond to direct input from Aʴ and C fibers are located in the superficial dorsal horn 
(laminas I and II) [8; 21; 125]. Lamina I contains mostly nociceptive-specific neurons that 
project to higher brain centers whereas lamina II (the substantia gelatinosa) contains almost 
exclusively interneurons (inhibitory and excitatory neurons) which respond only to 
nociceptive input although some also respond to non-noxious stimuli [8]. Wide dynamic 
range neurons which are activated by input from Aβ, Aʴ or C fibers (directly or via 
excitatory interneurons) are primarily located in lamina V (some in lamina I) [8; 54]. 
Neurons in ventral horn lamina VII and VIII similarly receive noxious input, but via more 
complex processes. Interestingly, many lamina VII neurons respond to stimulation of either 
side of the body unlike most dorsal horn neurons which receive input from only one side 
[8]. 
  Segmental and widespread modulation of nociception occurs in the dorsal horn and 
influences the perception of pain. Descending influences in the dorsal horn may emanate 
from a number of brain sites and occurs via the dorsolateral funiculus pathway [21]. The 
modulation of nociceptive input in the dorsal horn may be inhibitory or facilitatory 
depending on the mechanisms and receptors activated. Major pain modulatory mechanisms 
include gate control, diffuse noxious inhibitory controls (DNIC), coeruleospinal pain 
modulation, stress-induced analgesia (SIA) and stress-induced hyperalgesia. In addition, 
peripheral and central sensitization promotes the transmission of pain to higher centers. 
Nociceptive signals are transmitted from the dorsal horn to the brain via the spinothalamic, 
spinohypothalamic and spinoreticular tracts [21]. The thalamus, in particular, plays an 
important role as a processing and relay station for nociceptive input from the dorsal horn 
to other brain sites such as the somatosensory cortex and the limbic system which are 
involved in, respectively, the discriminatory and emotional aspects of pain [21].    25 
The transmission of pain from the head and neck has many of the same 
characteristics as the dorsal horn nociceptive system [21]. The face is densely innervated 
with primary nociceptive afferent fibers that originate primarily from cranial nerve V and 
from cranial nerves VII, IX, and X as well as from the upper cervical spinal nerves [21]. 
The cranial nerve fibers project mainly to nuclei of the trigeminal system whereas the upper 
cervical nerves project to second-order neurons in the dorsal horn of the spinal cord [21]. 
Ascending pathways from trigeminal nuclei include the dorsal and ventral 
trigeminothalamic tracts that terminate in the thalamus [21] . 
 
2.2.3  Pain modulation mechanisms 
Gate control of nociceptive input. The perception of pain can be reduced by 
stimulation of the painful area with innocuous stimuli such as ice, vibration, mild 
transcutanoues electrical nerve stimulation (TENS) or passive movement [52; 85; 119]. The 
mechanism proposed to underlie this is the competitive balance between dorsal horn input 
from activity in large diameter non-nociceptive Aβ fibers and activity in small diameter Aʴ 
and C nociceptors [120; 125]. The relative increase in large diameter input suppresses pain 
[7]. The theory is based on findings that non-nociceptive large diameter afferents inhibit 
activity of neurons in lamina V (wide dynamic range neurons) by activating inhibitory 
interneurons in lamina II, and that nociceptive small diameter afferents excite lamina V 
neurons and inhibit the activity of inhibitory interneurons in lamina II [8]. This opening of 
the gate for pain by Aʴ and C fibers and the closing by Aβ fibers is referred to as the gate 
control mechanism of pain. The mechanism accounts for localized pain control in that the 
area of the body in which pain is modulated is linked anatomically to the segments of the 
dorsal horn where the nociceptive and non-nociceptive afferents terminate [8].  
   26 
Diffuse noxious inhibitory controls (DNIC). Remote heterotopic analgesic effects 
have been demonstrated to a range of noxious conditioning stimuli in humans (e.g., 
thermal, mechanical, electrical, ischemic and chemical (capsaicin) stimuli) [4; 5; 20; 42; 
51; 61; 63; 84; 91; 96; 106; 107; 134; 135; 137; 171; 177; 184; 187]. Complementary 
studies in animals suggest that noxious stimulation selectively inhibits activity in spinal 
[24; 25; 100; 127; 148] and trigeminal wide dynamic range neurons outside the area of 
segmental excitation [45; 76; 129]. Such inhibitory effects have been termed 
counterstimulation or diffuse noxious inhibitory controls (DNIC) and are activated by Aʴ 
and C fibers [104]. Transection of the spinal cord in animals deters this effect, suggesting 
the involvement of a supraspinal loop [24; 99; 127] with ascending and descending 
pathways in the ventrolateral quadrant and the dorsolateral funiculus respectively [40; 173]. 
A reduction in DNIC following lesioning of the subnucleus reticularis dorsalis in the caudal 
medulla suggests the involvement of the medulla in this loop [19; 102; 174]. Serotonin and 
endogenous opioids are believed to at least partly mediate the descending control in DNIC 
[32; 41; 46; 103; 186]. However, lesions of the rostral ventromedial medulla (RVM), the 
main distributor of serotonin in the central nervous system, and lesions at brain sites 
involved in opioid-mediated stress-induced analgesia such as the periaqueductal gray 
(PAG), do not modify DNIC [102]. See section on stress-induced analgesia, page 28. Thus, 
although there seems to be some convergence at the level of neurotransmitter/neuropeptides 
between these endogenous analgesia mechanisms, DNIC can be considered a 
neuroanatomically separate mechanism [23]. 
The DNIC effect is, as the name implies, diffuse, affecting both sides of the body. 
Bilateral DNIC effects were detected by recordings from spinal and trigeminal convergent 
neurons in rats following immersion of the paws, tail and muscle in hot water [18; 19]. To 
the best of my knowledge, bilateral DNIC effects have been assessed in humans in only one   27 
study. Pain sensitivity was reduced to a similar extent in the left and right thigh during 
tourniquet-induced left arm pain [171]. 
  More intense conditioning stimuli induce greater DNIC effects [58; 101; 172; 174; 
184] but whether the extent of DNIC is related to the perception of pain is less clear with 
research providing support both for and against an association [5; 62; 98; 140]. Some 
research even suggests that pain is not necessary for the induction of DNIC [92; 97; 98].  
   
Coeruleospinal pain modulation. The nucleus locus coeruleus (LC), located in the 
dorsolateral pons, may induce antinociception when stimulated electrically or chemically 
[81; 113; 180]. It is thought to inhibit nociceptive activity in the dorsal horn [33; 72; 82; 
126] and the trigeminal subnucleus caudalis [168] via noradrenergic projections [57; 71; 
181] that act on ʱ2-adrenoceptors [81; 82].  
Electrical stimulation of primary afferent Aʴ fibers produces excitation of 
descending noradrenergic neurons from the LC, resulting in an increase in the level of 
noradrenaline in the dorsal horn [71]. Inhibitory influences projecting from the LC have 
also been associated with stress-producing stimuli [10] and inflammation [115; 166-169]. 
The PAG may activate noradrenergic projections from the LC via opioidergic mechanisms 
(directly or via the RVM [125]) or via substance P containing fibers [139; 192]. 
Projections from the LC appear to be bilateral [34; 35; 150; 170] and to involve all 
segments of the spinal cord [138]. Injection of anterograde transport of Phaseolus vulgaris 
leucoagglutinin (PHA-L) in the LC resulted in consistent labeling in cervical, thoracic and 
lumbar segments of the spinal cord [138]. Interestingly, more recent studies have found that 
activation of the LC during unilateral carageenan-induced hindpaw inflammation is evident 
only in the ipsilateral dorsal horn and not the contralateral dorsal horn [163-165; 167]. In 
addition, measurements of response thresholds to thermal stimuli on all four paws of the rat   28 
during unilateral hindpaw inflammation found shorter paw withdrawal latencies of the 
inflamed hindpaw as well as the non-inflamed, but hyperalgesic, ipsilateral forepaw in rats 
with bilateral LC lesions than in sham operated rats [169]. This was not observed in the 
contralateral hind- or forepaw, suggesting that the LC may inhibit nociception 
hemilaterally. The findings of a bilateral increase in Fos expression during unilateral 
hindpaw inflammation [166], and that unilateral lesions of the LC either contralateral or 
ipsilateral to the inflamed paw do not alter the inhibitory influences from the LC [111], 
suggests that the ipsilateral activation originates bilaterally, but perhaps travels through the 
dorsolateral funiculus ipsilaterally [111].  
Noradrenergic projections from the locus coeruleus may also facilitate nociception 
[70]. This effect appears to be mediated by ʱ1-adrenoceptors, rather than ʱ2-adrenoceptors 
[22; 53; 70; 132]. In addition, coeruleospinal action at ʱ1-adrenoreceptors in the RVM may 
activate ON-cells that facilitate nociception both in the spinal cord and the trigeminal 
nucleus caudalis [55; 121] 
 
Stress-induced analgesia (SIA). A stressor can be defined as anything that poses a 
real or perceived threat to a person‟s homeostasis [191]. In animals an increase in pain-
threshold (SIA) has been documented to a variety of stressors including inescapable foot 
shock, forced swims, food deprivation and immobilization/restraint [1; 2; 12-16; 31; 48; 59; 
65; 66; 110; 151; 159]. In humans, analgesia was documented following exposure or re-
exposure to stimuli such as repeated cold pressor stimulation, noxious hand or foot shocks, 
anticipation of an aversive event, startle with a loud tone and during mentally stressful tasks 
(e.g., mental arithmetic) [6; 49; 56; 143; 176; 183; 185]. 
Multiple mechanisms seem to underlie SIA. The most well-documented is the 
endogenous opioid system [17; 31; 110; 144; 151]. Serotonergic release (5-  29 
hydoxytryptamine or 5-HT) from raphe nuclei such as the RVM during stress, is also 
associated with SIA [23; 75; 131; 146]. Other neurotransmitters/neuropeptides thought to 
be involved in SIA include GABA, glutamate and endocannabinoids  as well as the former 
mentioned noradrenergic release from the LC (see section on coeruleospinal pain 
modulation, page 27) [23; 125]. 
The descending inhibitory pathway that mediates SIA appears to originate in 
neurons in higher brain regions such as the cortex [118], hypothalamus [124] and amygdala 
[179], the amygdala being a region that is particularly activated by stress/fear [105]. 
Neurons from these regions project to brain stem sites such as the PAG and raphe nuclei 
which in turn project to the dorsal horn [23; 123; 182]. 
 The intensity, duration and type of stressor may determine the type of SIA as well 
as the degree of the subsequent analgesia. The sequential exposure of rats to a series of 
inescapable foot shocks, for instance, resulted in both an early naltrexone-insensitive and a 
late naltrexone-sensitive analgesia [48]. Naltrexone is an opioid receptor antagonist [2]. In a 
forced swim, SIA increased with more extreme temperatures  [38], and the degree of SIA 
differed with the frequency and pulse-width of electric foot shock [188].  
Under some experimental conditions, stress can even induce hyperalgesia instead of 
analgesia (stress-induced hyperalgesia) [108]. Brief or prolonged stressors such as 
horizontal oscillations or exposure to ether vapours, exposure to a novel or cold 
environment, acute or chronic restraint, and repeated swim stress produced hyperalgesia in 
animals [59; 69; 88; 93; 141; 147; 154]. Increased pain sensitivity has also been observed 
in humans to stress and, in particular, anxiety-producing stimuli (e.g., public speaking, 
academic examinations, the Stroop test, Velten-style emotion induction, shock threat, 
repetitive shocks and noxious electrical stimulation) [27; 109; 122; 143; 157].   30 
The mechanisms underlying stress-induced hyperalgesia are poorly understood. 
Activation of serotonergic receptors may produce hyperalgesia instead of analgesia 
depending on the receptor subtype activated [125] and serotonin was shown to play a role 
in stress-induced hyperalgesia [79; 114]. On such characteristics, it mimics the bidirectional 
actions of noradrenaline [125] which similarly has been postulated to play a role in the 
facilitation of pain during stress [141]. Serotonergic receptor types 5-HT2, 5-HT3 and 5-HT4 
enhance neuronal activity whereas receptor types 5-HT1A and 5-HT1B suppress neuronal 
activity [125]. The location of the 5-HT receptor in the dorsal horn, i.e. on excitatory versus 
inhibitory interneurons or projection neurons, may further determine the resulting outcome 
[125].  
Overactivation and desensitization of opioid receptors was suggested to contribute 
to hyperalgesia during prolonged stress as naloxone, an opioid antagonist, and ketamine, an 
NMDA antagonist, deterred repeated swim-stress hyperalgesia [154]. Tolerance to the 
analgesic effects of opioids is associated with hyperalgesia and increased activity of 
NMDA receptors [116; 117; 162]. 
 
  Peripheral sensitization and inflammation. Upon tissue damage, additional 
facilitatory processes are activated [89]. Tissue inflammation, mechanical tissue damage, 
mild burn injury and treatment with algesic chemicals such as capsaicin, bradykinin, 
serotonin and mustard oil produce hyperalgesia at the site of injury or stimulation (primary 
hyperalgesia) [9; 39; 67; 87; 89; 90; 94; 95; 145; 158; 161]. This hyperalgesia is the 
product of the release of a wide array of inflammatory mediators. These include hydrogen 
and potassium ions (cells), bradykinin (plasma), serotonin (platelets), histamine (mast 
cells), TNF-ʱ (mast cells), cytokines (macrophages), nerve growth factor (keratinocytes), 
endothelin-1 (inflammatory cells, keratinocytes), prostaglandins and leukotrienes (via the   31 
arachidonic acid pathway) [3; 36; 60; 64]. In addition, nociceptors are activated and release 
a number of neuropeptides, most importantly substance P and calcitonin gene-related 
peptide (CGRP) adding to the chemical soup [153; 155].  
Some of these inflammatory mediators (bradykinin, histamine, substance P) activate 
nociceptive terminals directly [152] whereas others (prostaglandins, leukotrienes, 
potassium ions, nerve growth factor, endothelin-1, TNF-ʱ) sensitize nociceptive terminals 
[11; 128; 133]. This sensitization is associated with changes both in the firing thresholds, 
kinetics and the excitability of peripheral nociceptors, causing them to fire more readily 
[43] and may also include the activation of silent nociceptors responsive only to chemical 
or inflammatory stimuli [160]. NMDA-receptors are furthermore up-regulated in inflamed 
human skin [156] and appear to be involved in sensitizing primary afferent nociceptors [26; 
50; 80].  
The pain and primary hyperalgesia resulting from the increased activation and 
sensitization of nociceptors during tissue damage is restricted to the site of inflammation 
[39; 87; 90; 94; 142] which furthermore exhibits rubor and calor (redness and heat from 
vasodilatation), tumor (swelling from leakage of plasma proteins and fluid into the tissue), 
and function laesa (loss of function) [74; 153]. In addition, secondary hyperalgesia of the 
surrounding tissue can be observed signifying central sensitization [43].   
 
Central sensitization. In response to continuous C fiber input to the superficial 
layers of the dorsal horn, such as during inflammation, the activation threshold of dorsal 
horn neurons decreases and their receptive fields and responsiveness increase [37]. This is 
referred to as central sensitization and has been demonstrated to a number of stimuli 
including electrical stimulation, burn injury, experimental inflammation and noxious pinch 
[28; 29; 37; 73; 77; 86; 148; 149; 189; 190].   32 
 The increased excitability from the periphery results in the recruitment of previous 
subthreshold input to dorsal horn neurons and is probably mediated by NMDA receptor 
activation [21]. These changes are not restricted to the activated synapses, and prolonged 
excitation of central neurons causes them to become more responsive to all subsequent 
afferent input  [43]. This explains the pain produced after peripheral injury or inflammation 
to input from normally non-painful stimuli (allodynia) as well as the spread of pain 
hypersensitivity to areas outside the tissue injury (secondary hyperalgesia) [43].  
Central sensitization manifests within seconds of an appropriate stimulus and can 
outlast the stimulus for several hours [189] and may not be confined to the dorsal horn but 
has also been reported in spinothalamic neurons [47; 86] as well as the rostroventral 
medulla, anterior cingulate cortex and amygdala [130; 136; 178].    33 
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CHAPTER 3 
CRPS PATHOLOGY 
 
The exact underlying pathology of CRPS is yet to be elucidated. However, current evidence 
points to disturbances both in peripheral and central systems. Whether such disturbances 
contribute to the spread of pain and sensory disturbances in CRPS is unclear. 
  
3.1  Peripheral pathology 
3.1.1   Peripheral sensitization and exaggerated inflammation 
The appearance of a painful, red, swollen and hyperthermic limb in CRPS is 
consistent with inflammation, in particular in the acute stages [56]. In addition, the presence 
of hyperalgesia to heat [56] as well as to pinprick and blunt pressure [102] is suggestive of 
peripheral sensitization [5].  
For such reasons, the involvement of an exaggerated inflammatory response to 
trauma or surgery has been suggested [12; 13; 64; 116; 120]. Indicators of inflammation in 
the affected limb include increased levels of pro-inflammatory mediators such as 
bradykinin, IL-6, TNF-ʱ and endothelin-1 [14; 50; 55; 74; 107; 120] as well as increased 
vascular permeability for macromolecules [84]. In addition, skin lactate levels are high [7] 
and oxygen consumption is low, consistent with inflammation [54; 64].  
As inflammation in the classical sense (i.e., immune-induced inflammation) has not 
been documented [10; 20; 90; 108], a chronic release of neuropeptides from primary 
afferent fiber terminals (neurogenic inflammation) was suggested to underlie the 
inflammatory response in CRPS [12; 13; 64; 119]. As mentioned earlier, neuropeptides 
such as CGRP and substance P are released from the endings of primary afferent fibers   54 
during trauma-related activation and sensitization [104; 105], and cytokines increase the 
neuropeptide release of these afferents [83].  
In support of exaggerated neurogenic inflammation, CGRP and substance P was 
significantly increased in serum samples from the CRPS-affected limb [11; 96]. 
Furthermore, when nerve fibers were stimulated by transcutaneous electrical stimulation 
greater protein extravasation (mediated by substance P) and vasodilation (mediated by 
CGRP) were seen in patients than controls both in the affected and unaffected limb [11; 
119]. Similarly, perfusion of substance P through dermal microdialysis fibers showed that 
substance P was significantly more effective at inducing plasma protein extravasation in 
CRPS patients than controls [64]. Again this response was evident both in the affected and 
unaffected limb. On the basis of such findings, it was suggested that an increase in 
neuropeptide release from primary afferent fibers in combination with a diffuse impaired 
inactivation of neuropeptides is present in CRPS [12]. Consistent with this, lower levels of 
anti-inflammatory mediators such as IL-4 and IL-10 were detected in CRPS compared to 
controls [107]. Perhaps this combination produces an ongoing cycle of inflammatory 
mediator release and activation/sensitization of primary afferents [13]. As neuropeptides 
are not only released in the periphery but also from the central endings of primary afferents 
[12], their release could contribute to central sensitization [12]. The presence of increased 
pro-inflammatory cytokines has been documented in CRPS cerebrospinal fluid [1; 2]. A 
very recent study additionally found microglial and astrocytic cell activation in spinal cord 
tissue from a patient with longstanding CRPS who died from cardiopulmonary arrest [27], 
consistent with spinal inflammation.  
Besides the classical symptoms of inflammation present in CRPS, neurogenic 
inflammation could explain the presence of other CRPS symptoms [13]. The release of   55 
CGRP in CRPS may, for instance, explain the increased sweating [97] and increased hair 
growth in the affected limb [13; 51]. In addition, TNF-ʱ and substance P activate 
osteoclasts and may account for the high turnover osteoporosis in CRPS which is marked 
by increased osteoclastic activity [13; 66]. Although the presence of a cold limb may seem 
inconsistent with inflammation, increased levels of the inflammatory mediator endothelin-
1, which is produced by the endothelium and is a potent vasoconstrictor, were found in cold 
extremity CRPS [13; 50]. 
 
3.1.2  Sympathetic nervous system dysfunction 
Under normal circumstances, the sympathetic nervous system (SNS) is not directly 
involved in nociception [6; 32; 38; 39]. Aʴ fibers and C fibers are not activated or 
sensitized by sympathetic activity [38; 39; 57]. In CRPS, however, sympathetic arousal 
following startle with a loud tone was shown to increase spontaneous pain [32]. Also, 
activation of the SNS during whole body or forehead cooling increases pain and the spatial 
distribution of mechanical dynamic and punctuate hyperalgesia [6; 32]. Another argument 
for the involvement of the SNS in CRPS is the reduction of pain and hyperalgesia 
following sympathetic block [22; 88; 95; 98; 106] which is rekindled following intradermal 
injection of adrenergic agonists into the sympathectomised limb [3; 106] or by stimulation 
of the SNS [6; 32]. However, sympathetic block is only effective in a subgroup of patients 
(who are subsequently considered to have sympathetically maintained pain (SMP)), and 
randomized placebo controlled trials suggest no efficacy of sympathetic block over placebo 
in unselected groups of CRPS patients [69; 98].  
The mechanism underlying the interaction between sympathetic activity and pain 
and hyperalgesia in CRPS is unclear. Direct or indirect coupling between sympathetic   56 
efferents and nociceptive afferents has been suggested [12; 47; 58; 95]. In support of this, 
electrophysiological recordings in a human with SMP showed the direct activation of 
nociceptive fibers by increased endogenous sympathetic activity and by intradermal 
injection of noradrenaline [60]. The activated fibers appeared to be mechano-insensitive 
nociceptors which are known to be associated with pain and hyperalgesia as well as 
neurogenic inflammation. Findings such as increased excitability in dorsal root ganglion 
neurons to phenylephrine (ʱ1-agonist) in vitro [87], in addition to close physical association 
between sympathetic neurons and sensory neurons in nerve bundles and near blood vessels 
in the upper dermis of normal human and rat skin [47], support the possibility of a close 
link between sympathetic efferents and nociceptive afferents.  
The sympathetic response in CRPS does not involve sympathetic overflow as 
initially thought; in fact lower levels of noradrenaline rather than increased levels were 
demonstrated in the CRPS limb [21; 28; 93; 115]. Hence, it was suggested that decreased 
noradrenaline levels result in increased sensitivity (supersensitivity) of ʱ-adrenoceptors or 
the direct expression of these on nociceptive afferents [33]. Neurogenic inflammation was 
suggested as a possible co-contributor to such changes [12; 47; 58]. Sprouting of new 
sympathetic nerves in the dorsal horn [89] or in the upper dermis of the skin [94] may be 
triggered by inflammatory mediators [118].  Moreover, the density of ʱ-adrenoceptors is 
increased in sensitized skin from CRPS patients [29]. Consistent with this, transcutaneous 
iontophoresis of noradrenaline (the sympathetic neurotransmitter) and tyramine (which 
augments the release of noradrenaline) into healthy skin, sensitized by the inflammatory 
agent capsaicin, exacerbate thermal hyperalgesia independent of reduced regional blood 
flow resulting from vasoconstriction [30; 31; 42]. In addition, pharmacological depletion of 
neural noradrenaline stores induces adrenergic supersensitivity and increases thermal   57 
hyperalgesia in similarly sensitized skin [68]. Noradrenaline may contribute to pain and 
inflammation by increasing the turnover of inflammatory mediators and algesic substances 
such as nerve growth factors and prostaglandins [49] or may directly trigger neuropeptide 
release from nociceptive neurons by activating ʱ-adrenoceptors on nociceptive afferents 
[67] thus contributing to peripheral sensitization [47; 58]. Perhaps inflammation unmasks 
latent ʱ-adrenoceptors on nociceptors [47]. Alternatively, ʱ-adrenoceptors may not be 
expressed on nociceptive fibres but on closely associated cells capable of activating 
nociceptive fibers such as Schwann cells [47]. Spinal cord glia have been implicated in the 
generation and maintenance of chronic pain [117]. Interestingly, sweating and trophic 
disturbances including the presence of a cold limb [13] which have long been considered 
the result of sympathetic nervous system activity [25] can be explained as neuropeptide 
effects [12]. A further hypothesis about the generation of pain by the sympathetic nervous 
system in CRPS is that reduced sympathetic activity, perhaps along with chronic 
neurogenic inflammation, may contribute to pain and hyperalgesia by causing extreme 
vasoconstriction [34; 82] thus producing painful hypoxia and acidosis in the affected area 
[8; 9; 12; 54; 109].  
 
3.2  Central pathology 
The appearance of pain and hyperalgesia outside the territory of a single peripheral 
nerve in CRPS suggests changes within the central nervous system [35; 58; 73].  
 
3.2.1 Central sensitization 
Sustained C fiber activation such as peripheral sensitization in response to 
inflammation leads to increased responsiveness of neurons in the spinal dorsal horn (central   58 
sensitization) [24] and is assumed to underlie the hyperalgesia and allodynia of CRPS [58; 
63; 91; 120; 121], although this has not been well studied [25] . As mentioned earlier, in 
particular the NMDA receptor appears to play a role in central sensitization [15]. One 
indicator of central sensitization in CRPS is that NMDA-receptor antagonists such as 
memantine and ketamine appear to be effective at relieving pain and motor symptoms [48; 
62; 101; 103], although double-blind placebo controlled trials are missing. In CRPS, central 
sensitization may be induced and maintained by inflammation, peripheral sensitization and 
sympathetic activity.  
 
3.2.2  Central disinhibition 
Central disinhibition may also contribute to sustaining central sensitization. A lack 
of DNIC is apparent following noxious forehead cooling which increases CRPS pain rather 
than reducing it [32]. In addition, CRPS pain is increased during startle with a loud tone 
whereas startle decreases thermal hyperalgesia in capsaicin-sensitized skin in healthy 
controls, suggesting that stress-induced analgesia is ineffective in CRPS (although this 
might alternatively imply adrenergic supersensitivity, see section on sympathetic nervous 
system dysfunction, page 55) [32]. In a very recent study, Seifert et al. [100] stimulated 
CRPS patients and controls with repetitive noxious electrical stimulation and showed that 
inhibitory control was decreased both in the affected and unaffected limb in comparison to 
controls. In addition, facilitatory control was upregulated in the affected limb compared to 
the contralateral limb and controls. On this basis, they suggested that continuous peripheral 
nociceptive input decreases the inhibitory capacity in CRPS patients, or that a general lack 
of inhibitory pain control is a pre-emptive factor in the development of CRPS. An 
alternative suggestion was a combination of the two [100]. In any case, a lack of inhibitory   59 
control probably results in unchecked neuronal sensitization. Interestingly, SPECT-
scanning in CRPS revealed high activity in the contralateral thalamus in the acute stages of 
the disease [43]. As the thalamus is highly involved in nociceptive processing, this was 
suggested to reflect activation of normal pain inhibitory mechanisms [34]. In the later 
chronic stages of the disease, activity of the contralateral thalamus decreased [43] which 
may indicate a fatigue or failure of modulatory mechanisms.  
 
3.2.3  Cortical changes 
Cortical changes in CRPS are thought to reflect central sensitization  [73]. Primary 
somatosensory cortex activation to tactile stimuli in the allodynic limb is enhanced 
compared to stimulation in the unaffected limb, consistent with central hyperexcitability 
[61; 71; 111]. The somatotopic map within the primary somatosensory cortex contralateral 
to the affected limb was also shown to be reorganised in CRPS with shrinkage of the area 
representing the affected limb as well as a shift of the affected hand towards the lip [61; 71; 
85]. In some [71; 85], but not all studies [61], the extent of this cortical reorganization was 
associated with the intensity of pain and mechanical hyperalgesia and hence attributed to 
central sensitization. Juottonen and colleagues [61] suggested that disuse due to severe pain 
may mediate the effect on cortical organisation. Interestingly, cortical reorganisation was 
reversed during recovery from CRPS [72; 86]. 
Changes in cortical organisation in response to central sensitization may explain the 
presence of referred sensations in CRPS [75; 77] as the intensity of referred pain was found 
to be related to the presence of mechanical hyperalgesia [75]. Cortical changes may also 
account for the impaired self perception of the affected limb in CRPS [41; 75] and 
hemilateral sensory deficits [75; 76], although research is yet to confirm this.   60 
Changes in the motor cortex have also been described. Both a reduction and an 
enlargement of the motor cortical representation of the affected limb have been reported 
[65; 76]. Such changes correlate with the extent of motor dysfunction [65; 76]. Similar to 
changes in the somatosensory cortex, hyperexcitable central neurons may underlie these 
changes. Consistent with this, transcranial stimulation revealed hyperexcitability of the 
motor cortex of CRPS patients [37; 99]. A lack of intracortical motor inhibition was 
documented in the motor cortex contralateral to the affected limb [37; 61; 99] and, in some 
studies, in the ipsilateral motor cortex, although to a lesser extent [61; 99]. The extent of 
disinhibition was related to pain intensity [99], and immobilisation or disuse has similarly 
been argued to underlie this [36]. Maihofner et al. [76] suggested that incongruence 
between changes in cortical and motor sensory representations may contribute to abnormal 
self perception and body schemas in CRPS. The effectiveness of graded motor imagery and 
mirror feedback studies in CRPS is based on the reconciliation of motor output and sensory 
feedback [79-81; 114].  
 
3.3  Psychological factors 
There have been some suggestions that CRPS is a manifestation of psychological 
dysfunction or malingering [112; 113]. Anxiety and depression are relatively common in 
CRPS [17; 23; 44; 45; 52] and may exacerbate pain [17-19; 40]. However, there is little 
evidence to suggest that these are the cause, rather than the consequence, of CRPS [16; 23; 
26; 52; 70; 78; 92; 110]. For such reasons, psychological dysfunction is generally 
recognised as secondary to CRPS [59]. It has been suggested that increased systemic levels 
of noradrenaline and adrenaline in CRPS may be related to psychological distress [53].   61 
Gray matter abnormalities in brain regions responsible for emotional-decision making may 
underlie observations of cognitive and emotional problems in CRPS [4; 46]. 
 
3.4  Conclusions from introductory chapters 1, 2 and 3 
CRPS symptoms reflect disturbances both in sensory, autonomic and motor systems 
which commonly spread outside the affected limb to encompass, in particular, the 
ipsilateral side of the body. Under normal circumstances pain is transmitted from the 
periphery to the brain via the dorsal horn of the spinal cord where a number of pain 
modulatory processes take place. Pain modulatory mechanisms such as DNIC, 
coeruleospinal and serotonergic pain modulation may be activated in response to a given 
noxious stimulus, and peripheral and central sensitization may facilitate the transmission of 
pain. In CRPS, an exaggerated inflammatory response and sympathetic activity may 
contribute to sensitization of peripheral and central neurons, resulting in cortical changes. A 
failure of inhibitory pain control could further contribute to this process. However, many 
speculations still underlie the interaction between these mechanisms. Although cortical 
changes have been suggested to underlie the hemilateral sensory deficit in CRPS, no 
research has, to the best of my knowledge, yet attempted to clarify what mechanisms 
produce these cortical changes and hence contribute to the spread of pain and sensory 
disturbances in CRPS. As the spread of disturbances is a particularly disabling feature of 
CRPS, this issue is addressed in this thesis.    62 
References 
 
[1] Alexander GM, van Rijn MA, van Hilten JJ, Perreault MJ, Schwartzman RJ. Changes in 
cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain 2005;116:213-9. 
[2] Alexander GM, Perreault MJ, Reichenberger ER, Schwartzman RJ. Changes in immune 
and glial markers in the CSF of patients with Complex Regional Pain Syndrome. Brain 
Behav Immun 2007;21:668-76. 
[3] Ali Z, Raja SN, Wesselmann U, Fuchs PN, Meyer RA, Campbell JN. Intradermal 
injection of norepinephrine evokes pain in patients with sympathetically maintained pain. 
Pain 2000;88:161-8. 
[4] Apkarian AV, Sosa Y, Krauss BR, Thomas PS, Fredrickson BE, Levy RE, Harden RN, 
Chialvo DR. Chronic pain patients are impaired on an emotional decision-making task. 
Pain 2004;108:129-36. 
[5] Baron R. Peripheral neuropathic pain: from mechanisms to symptoms. Clin J Pain 
2000;16:S12-S20. 
[6] Baron R, Schattschneider J, Binder A, Siebrecht D, Wasner G. Relation between 
sympathetic vasoconstrictor activity and pain and hyperalgesia in complex regional pain 
syndromes: a case-control study. Lancet 2002;359:1655-60. 
[7] Birklein F, Riedl B, Sieweke N, Weber M, Neundorfer B. Neurological findings in 
complex regional pain syndromes--analysis of 145 cases. Acta Neurol Scand 
2000;101:262-9. 
[8] Birklein F, Weber M, Ernst M, Riedl B, Neundorfer B, Handwerker HO. Experimental 
tissue acidosis leads to increased pain in complex regional pain syndrome (CRPS). Pain 
2000;87:227-34.   63 
[9] Birklein F, Weber M, Neundorfer B. Increased skin lactate in complex regional pain 
syndrome: evidence for tissue hypoxia? Neurology 2000;55:1213-5. 
[10] Birklein F, Kunzel W, Sieweke N. Despite clinical similarities there are significant 
differences between acute limb trauma and complex regional pain syndrome I (CRPS I). 
Pain 2001;93:165-71. 
[11] Birklein F, Schmelz M, Schifter S, Weber M. The important role of neuropeptides in 
complex regional pain syndrome. Neurology 2001;57:2179-84. 
[12] Birklein F. Complex regional pain syndrome. J Neurol 2005;252:131-8. 
[13] Birklein F, Schmelz M. Neuropeptides, neurogenic inflammation and complex 
regional pain syndrome (CRPS). Neurosci Lett 2008;437:199-202. 
[14] Blair SJ, Chinthagada M, Hoppenstehdt D, Kijowski R, Fareed J. Role of 
neuropeptides in pathogenesis of reflex sympathetic dystrophy. Acta Orthop Belg 
1998;64:448-51. 
[15] Brenner GJ. Neurophysiologic basis of pain. In: Ballantyne JC, editor(s). The 
Massachusettss General Hospital Handbook of Pain Management. Philadelphia: Lippincott 
Williams & Wilkins, 2006. pp. 3-27. 
[16] Bruehl S, Carlson CR. Predisposing psychological factors in the development of reflex 
sympathetic dystrophy. A review of the empirical evidence. Clin J Pain 1992;8:287-99. 
[17] Bruehl S, Husfeldt B, Lubenow TR, Nath H, Ivankovich AD. Psychological 
differences between reflex sympathetic dystrophy and non-RSD chronic pain patients. Pain 
1996;67:107-14. 
[18] Bruehl S, Chung OY, Burns JW. Differential effects of expressive anger regulation on 
chronic pain intensity in CRPS and non-CRPS limb pain patients. Pain 2003;104:647-54.   64 
[19] Bruehl S, Chung OY. Psychological and behavioral aspects of complex regional pain 
syndrome management. Clin J Pain 2006;22:430-7. 
[20] Calder JS, Holten I, McAllister RM. Evidence for immune system involvement in 
reflex sympathetic dystrophy. J Hand Surg [Br] 1998;23:147-50. 
[21] Casale R, Elam M. Normal sympathetic nerve activity in a reflex sympathetic 
dystrophy with marked skin vasoconstriction. J Auton Nerv Syst 1992;41:215-9. 
[22] Cepeda M, Lau J, Carr D. Defining the therapeutic role of local anesthetic sympathetic 
blockade in complex regional pain syndrome: a narrative and systematic review. Clin J Pain 
2002;18:216-33. 
[23] Ciccone DS, Bandilla EB, Wu W. Psychological dysfunction in patients with reflex 
sympathetic dystrophy. Pain 1997;71:323-33. 
[24] Cook AJ, Woolf CJ, Wall PD, McMahon SB. Dynamic receptive field plasticity in rat 
spinal cord dorsal horn following C-primary afferent input. Nature 1987;325:151-3. 
[25] de Mos M, Sturkenboom MC, Huygen FJ. Current understandings on complex 
regional pain syndrome. Pain Pract 2009;9:86-99. 
[26] DeGood DE, Cundiff GW, Adams LE, Shutty MS, Jr. A psychosocial and behavioral 
comparison of reflex sympathetic dystrophy, low back pain, and headache patients. Pain 
1993;54:317-22. 
[27] Del Valle L, Schwartzman RJ, Alexander G. Spinal cord histopathological alterations 
in a patient with longstanding complex regional pain syndrome. Brain Behav Immun 
2009;23:85-91. 
[28] Drummond PD, Finch PM, Smythe GA. Reflex sympathetic dystrophy: the 
significance of differing plasma catecholamine concentrations in affected and unaffected 
limbs. Brain 1991;114:2025-36.   65 
[29] Drummond PD, Skipworth S, Finch PM. alpha 1-adrenoceptors in normal and 
hyperalgesic human skin. Clin Sci 1996;91:73-7. 
[30] Drummond PD. Enhancement of thermal hyperalgesia by alpha-adrenoceptors in 
capsaicin-treated skin. J Auton Nerv Syst 1998;69:96-102. 
[31] Drummond PD. Nitroprusside inhibits thermal hyperalgesia induced by noradrenaline 
in capsaicin-treated skin. Pain 1999;80:405-12. 
[32] Drummond PD, Finch PM, Skipworth S, Blockey P. Pain increases during sympathetic 
arousal in patients with complex regional pain syndrome. Neurology 2001;57:1296-303. 
[33] Drummond PD. Involvement of the sympathetic nervous system in complex regional 
pain syndrome. Int J Low Extrem Wounds 2004;3:35-42. 
[34] Drummond PD, Finch PM. Persistence of pain induced by startle and forehead cooling 
after sympathetic blockade in patients with complex regional pain syndrome. J Neurol 
Neurosurg Psychiatry 2004;75:98-102. 
[35] Drummond PD, Finch PM. Sensory changes in the forehead of patients with complex 
regional pain syndrome. Pain 2006;123:83-9. 
[36] Eisenberg E, Chistyakov AV, Yudashkin M, Kaplan B, Hafner H, Feinsod M. 
Asymmetric impairment of cortical excitability in CRPS. Pain 2005;115:212-21. 
[37] Eisenberg E, Chistyakov AV, Yudashkin M, Kaplan B, Hafner H, Feinsod M. 
Evidence for cortical hyperexcitability of the affected limb representation area in CRPS: a 
psychophysical and transcranial magnetic stimulation study. Pain 2005;113:99-105. 
[38] Elam M, Olausson B, Skarphedinsson JO, Wallin BG. Does sympathetic nerve 
discharge affect the firing of polymodal C-fibre afferents in humans? Brain 1999;122:2237-
44.   66 
[39] Elam M, Macefield VG. Does sympathetic nerve discharge affect the firing of 
myelinated cutaneous afferents in humans? Auton Neurosci 2004;111:116-26. 
[40] Feldman SI, Downey G, Schaffer-Neitz R. Pain, negative mood, and perceived support 
in chronic pain patients: a daily diary study of people with reflex sympathetic dystrophy 
syndrome. J Consult Clin Psychol 1999;67:776-85. 
[41] Forderreuther S, Sailer U, Straube A. Impaired self-perception of the hand in complex 
regional pain syndrome (CRPS). Pain 2004;110:756-61. 
[42] Fuchs PN, Meyer RA, Raja SN. Heat, but not mechanical hyperalgesia, following 
adrenergic injections in normal human skin. Pain 2001;90:15-23. 
[43] Fukumoto M, Ushida T, Zinchuk VS, Yamamoto H, Yoshida S. Contralateral thalamic 
perfusion in patients with reflex sympathetic dystrophy syndrome. Lancet 1999;354:1790-
1. 
[44] Geertzen JH, de Bruijn H, de Bruijn-Kofman AT, Arendzen JH. Reflex sympathetic 
dystrophy: early treatment and psychological aspects. Arch Phys Med Rehabil 
1994;75:442-6. 
[45] Geertzen JH, de Bruijn-Kofman AT, de Bruijn HP, van de Wiel HB, Dijkstra PU. 
Stressful life events and psychological dysfunction in complex regional pain syndrome type 
I. Clin J Pain 1998;14:143-7. 
[46] Geha PY, Baliki MN, Harden RN, Bauer WR, Parrish TB, Apkarian AV. The brain in 
chronic CRPS pain: abnormal gray-white matter interactions in emotional and autonomic 
regions. Neuron 2008;60:570-81. 
[47] Gibbs GF, Drummond PD, Finch PM, Phillips JK. Unravelling the pathophysiology of 
complex regional pain syndrome: focus on sympathetically maintained pain. Clin Exp 
Pharmacol Physiol 2008;35:717-24.   67 
[48] Goldberg ME, Domsky R, Scaringe D, Hirsh R, Dotson J, Sharaf I, Torjman MC, 
Schwartzman RJ. Multi-day low dose ketamine infusion for the treatment of complex 
regional pain syndrome. Pain Physician 2005;8:175-9. 
[49] Gonzales R, Sherbourne CD, Goldyne ME, Levine JD. Noradrenaline-induced 
prostaglandin production by sympathetic postganglionic neurons is mediated by alpha 2-
adrenergic receptors. J Neurochem 1991;57:1145-50. 
[50] Groeneweg JG, Huygen FJ, Heijmans-Antonissen C, Niehof S, Zijlstra FJ. Increased 
endothelin-1 and diminished nitric oxide levels in blister fluids of patients with 
intermediate cold type complex regional pain syndrome type 1. BMC Musculoskelet 
Disord 2006;7:91. 
[51] Hagner S, Haberberger RV, Overkamp D, Hoffmann R, Voigt KH, McGregor GP. 
Expression and distribution of calcitonin receptor-like receptor in human hairy skin. 
Peptides 2002;23:109-16. 
[52] Harden RN, Bruehl S, Stanos S, Brander V, Chung OY, Saltz S, Adams A, Stulberg 
SD. Prospective examination of pain-related and psychological predictors of CRPS-like 
phenomena following total knee arthroplasty: a preliminary study. Pain 2003;106:393-400. 
[53] Harden RN, Rudin NJ, Bruehl S, Kee W, Parikh DK, Kooch J, Duc T, Gracely RH. 
Increased systemic catecholamines in complex regional pain syndrome and relationship to 
psychological factors: a pilot study. Anesth Analg 2004;99:1478-85. 
[54] Heerschap A, den Hollander JA, Reynen H, Goris RJ. Metabolic changes in reflex 
sympathetic dystrophy: a 31P NMR spectroscopy study. Muscle Nerve 1993;16:367-73. 
[55] Heijmans-Antonissen C, Wesseldijk F, Munnikes RJ, Huygen FJ, van der Meijden P, 
Hop WC, Hooijkaas H, Zijlstra FJ. Multiplex bead array assay for detection of 25 soluble   68 
cytokines in blister fluid of patients with complex regional pain syndrome type 1. 
Mediators Inflamm 2006;2006:28398. 
[56] Huge V, Lauchart M, Forderreuther S, Kaufhold W, Valet M, Azad SC, Beyer A, 
Magerl W. Interaction of hyperalgesia and sensory loss in complex regional pain syndrome 
type I (CRPS I). PLoS ONE 2008;3:e2742. 
[57] Jänig W, Koltzenburg M. What is the interaction between the sympathetic terminal 
and the primary afferent fiber? In: Basbaum AI,Besson JM, editor(s). Towards a New 
Pharmacotherapy of Pain. Chichester: Dahlem Workshop Reports, John Wiley & Sons, 
1991. pp. 331-52. 
[58] Jänig W, Baron R. Complex regional pain syndrome: mystery explained? Lancet 
Neurol 2003;2:687-97. 
[59] Jänig W, Baron R. Is CRPS I a neuropathic pain syndrome? Pain 2006;120:227-9. 
[60] Jorum E, Orstavik K, Schmidt R, Namer B, Carr RW, Kvarstein G, Hilliges M, 
Handwerker H, Torebjork E, Schmelz M. Catecholamine-induced excitation of nociceptors 
in sympathetically maintained pain. Pain 2007;127:296-301. 
[61] Juottonen K, Gockel M, Silen T, Hurri H, Hari R, Forss N. Altered central 
sensorimotor processing in patients with complex regional pain syndrome. Pain 
2002;98:315-23. 
[62] Kiefer RT, Rohr P, Ploppa A, Nohe B, Dieterich HJ, Grothusen J, Altemeyer KH, 
Unertl K, Schwartzman RJ. A pilot open-label study of the efficacy of subanesthetic 
isomeric S(+)-ketamine in refractory CRPS patients. Pain Med 2008;9:44-54. 
[63] Kim HK, Schattschneider J, Lee I, Chung K, Baron R, Chung JM. Prolonged 
maintenance of capsaicin-induced hyperalgesia by brief daily vibration stimuli. Pain 
2007;129:93-101.   69 
[64] Koban M, Leis S, Schultze-Mosgau S, Birklein F. Tissue hypoxia in complex regional 
pain syndrome. Pain 2003;104:149-57. 
[65] Krause P, Forderreuther S, Straube A. TMS motor cortical brain mapping in patients 
with complex regional pain syndrome type I. Clin Neurophysiol 2006;117:169-76. 
[66] Leitha T, Staudenherz A, Korpan M, Fialka V. Pattern recognition in five-phase bone 
scintigraphy: diagnostic patterns of reflex sympathetic dystrophy in adults. Eur J Nucl Med 
1996;23:256-62. 
[67] Lin Q, Zou X, Fang L, Willis WD. Sympathetic modulation of acute cutaneous flare 
induced by intradermal injection of capsaicin in anesthetized rats. J Neurophysiol 
2003;89:853-61. 
[68] Lipnicki DM, Drummond PD. Vascular and nociceptive effects of localized prolonged 
sympathetic blockade in human skin. Auton Neurosci 2001;88:86-93. 
[69] Livingstone JA, Atkins RM. Intravenous regional guanethidine blockade in the 
treatment of post-traumatic complex regional pain syndrome type 1 (algodystrophy) of the 
hand. J Bone Joint Surg Br 2002;84:380-6. 
[70] Lynch ME. Psychological aspects of reflex sympathetic dystrophy: a review of the 
adult and paediatric literature. Pain 1992;49:337-47. 
[71] Maihofner C, Handwerker HO, Neundorfer B, Birklein F. Patterns of cortical 
reorganization in complex regional pain syndrome. Neurology 2003;61:1707-15. 
[72] Maihofner C, Handwerker HO, Neundorfer B, Birklein F. Cortical reorganization 
during recovery from complex regional pain syndrome. Neurology 2004;63:693-701. 
[73] Maihofner C, Forster C, Birklein F, Neundorfer B, Handwerker HO. Brain processing 
during mechanical hyperalgesia in complex regional pain syndrome: a functional MRI 
study. Pain 2005;114:93-103.   70 
[74] Maihofner C, Handwerker HO, Neundorfer B, Birklein F. Mechanical hyperalgesia in 
complex regional pain syndrome: a role for TNF-alpha? Neurology 2005;65:311-3. 
[75] Maihofner C, Neundorfer B, Birklein F, Handwerker HO. Mislocalization of tactile 
stimulation in patients with complex regional pain syndrome. J Neurol 2006;253:772-9. 
[76] Maihofner C, Baron R, DeCol R, Binder A, Birklein F, Deuschl G, Handwerker HO, 
Schattschneider J. The motor system shows adaptive changes in complex regional pain 
syndrome. Brain 2007;130:2671-87. 
[77] McCabe CS, Haigh RC, Halligan PW, Blake DR. Referred sensations in patients with 
complex regional pain syndrome type 1. Rheumatology (Oxford) 2003;42:1067-73. 
[78] Monti DA, Herring CL, Schwartzman RJ, Marchese M. Personality assessment of 
patients with complex regional pain syndrome type I. Clin J Pain 1998;14:295-302. 
[79] Moseley GL. Why do people with complex regional pain syndrome take longer to 
recognize their affected hand? Neurology 2004;62:2182-6. 
[80] Moseley GL. Graded motor imagery is effective for long-standing complex regional 
pain syndrome: a randomised controlled trial. Pain 2004;108:192-8. 
[81] Moseley GL. Is successful rehabilitation of complex regional pain syndrome due to 
sustained attention to the affected limb? A randomised clinical trial. Pain 2005;114:54-61. 
[82] Niehof SP, Huygen FJ, van der Weerd RW, Westra M, Zijlstra FJ. Thermography 
imaging during static and controlled thermoregulation in complex regional pain syndrome 
type 1: diagnostic value and involvement of the central sympathetic system. Biomed Eng 
Online 2006;5:30. 
[83] Opree A, Kress M. Involvement of the proinflammatory cytokines tumor necrosis 
factor-alpha, IL-1 beta, and IL-6 but not IL-8 in the development of heat hyperalgesia:   71 
effects on heat-evoked calcitonin gene-related peptide release from rat skin. J Neurosci 
2000;20:6289-93. 
[84] Oyen WJ, Arntz IE, Claessens RM, Van der Meer JW, Corstens FH, Goris RJ. Reflex 
sympathetic dystrophy of the hand: an excessive inflammatory response? Pain 
1993;55:151-7. 
[85] Pleger B, Tegenthoff M, Schwenkreis P, Janssen F, Ragert P, Dinse HR, Volker B, 
Zenz M, Maier C. Mean sustained pain levels are linked to hemispherical side-to-side 
differences of primary somatosensory cortex in the complex regional pain syndrome I. Exp 
Brain Res 2004;155:115-9. 
[86] Pleger B, Tegenthoff M, Ragert P, Forster AF, Dinse HR, Schwenkreis P, Nicolas V, 
Maier C. Sensorimotor retuning [corrected] in complex regional pain syndrome parallels 
pain reduction. Ann Neurol 2005;57:425-9. 
[87] Pluteanu F, Ristoiu V, Flonta ML, Reid G. Alpha(1)-adrenoceptor-mediated 
depolarization and beta-mediated hyperpolarization in cultured rat dorsal root ganglion 
neurones. Neurosci Lett 2002;329:277-80. 
[88] Price DD, Long S, Wilsey B, Rafii A. Analysis of peak magnitude and duration of 
analgesia produced by local anesthetics injected into sympathetic ganglia of complex 
regional pain syndrome patients. Clin J Pain 1998;14:216-26. 
[89] Ramer MS, Thompson SW, McMahon SB. Causes and consequences of sympathetic 
basket formation in dorsal root ganglia. Pain 1999;Suppl 6:S111-20. 
[90] Ribbers GM, Oosterhuis WP, van Limbeek J, de Metz M. Reflex sympathetic 
dystrophy: is the immune system involved? Arch Phys Med Rehabil 1998;79:1549-52. 
[91] Ribbers GM, Geurts AC, Stam HJ, Mulder T. Pharmacologic treatment of complex 
regional pain syndrome I: a conceptual framework. Arch Phys Med Rehabil 2003;84:141-6.   72 
[92] Rommel O, Gehling M, Dertwinkel R, Witscher K, Zenz M, Malin JP, Janig W. 
Hemisensory impairment in patients with complex regional pain syndrome. Pain 
1999;80:95-101. 
[93] Rosen L, Ostergren J, Fagrell B, Stranden E. Skin microvascular circulation in the 
sympathetic dystrophies evaluated by videophotometric capillaroscopy and laser Doppler 
fluxmetry. Eur J Clin Invest 1988;18:305-8. 
[94] Ruocco I, Cuello AC, Ribeiro-Da-Silva A. Peripheral nerve injury leads to the 
establishment of a novel pattern of sympathetic fibre innervation in the rat skin. J Comp 
Neurol 2000;422:287-96. 
[95] Schattschneider J, Binder A, Siebrecht D, Wasner G, Baron R. Complex regional pain 
syndromes: the influence of cutaneous and deep somatic sympathetic innervation on pain. 
Clin J Pain 2006;22:240-4. 
[96] Schinkel C, Gaertner A, Zaspel J, Zedler S, Faist E, Schuermann M. Inflammatory 
mediators are altered in the acute phase of posttraumatic complex regional pain syndrome. 
Clin J Pain 2006;22:235-9. 
[97] Schlereth T, Dittmar JO, Seewald B, Birklein F. Peripheral amplification of sweating--
a role for calcitonin gene-related peptide. J Physiol 2006;576:823-32. 
[98] Schurmann M, Gradl G, Wizgal I, Tutic M, Moser C, Azad S, Beyer A. Clinical and 
physiologic evaluation of stellate ganglion blockade for complex regional pain syndrome 
type I. Clin J Pain 2001;17:94-100. 
[99] Schwenkreis P, Janssen F, Rommel O, Pleger B, Volker B, Hosbach I, Dertwinkel R, 
Maier C, Tegenthoff M. Bilateral motor cortex disinhibition in complex regional pain 
syndrome (CRPS) type I of the hand. Neurology 2003;61:515-9.   73 
[100] Seifert F, Kiefer G, DeCol R, Schmelz M, Maihofner C. Differential endogenous pain 
modulation in complex-regional pain syndrome. Brain 2009;132:788-800. 
[101] Shirani P, Salamone AR, Schulz PE, Edmondson EA. Ketamine treatment for 
intractable pain in a patient with severe refractory complex regional pain syndrome: a case 
report. Pain Physician 2008;11:339-42. 
[102] Sieweke N, Birklein F, Riedl B, Neundorfer B, Handwerker HO. Patterns of 
hyperalgesia in complex regional pain syndrome. Pain 1999;80:171-7. 
[103] Sinis N, Birbaumer N, Gustin S, Schwarz A, Bredanger S, Becker ST, Unertl K, 
Schaller HE, Haerle M. Memantine treatment of complex regional pain syndrome: a 
preliminary report of six cases. Clin J Pain 2007;23:237-43. 
[104] Steinhoff M, Stander S, Seeliger S, Ansel JC, Schmelz M, Luger T. Modern aspects 
of cutaneous neurogenic inflammation. Arch Dermatol 2003;139:1479-88. 
[105] Szolcsanyi J. Capsaicin-sensitive sensory nerve terminals with local and systemic 
efferent functions: facts and scopes of an unorthodox neuroregulatory mechanism. Prog 
Brain Res 1996;113:343-59. 
[106] Torebjork E, Wahren L, Wallin G, Hallin R, Koltzenburg M. Noradrenaline-evoked 
pain in neuralgia. Pain 1995;63:11-20. 
[107] Uceyler N, Eberle T, Rolke R, Birklein F, Sommer C. Differential expression patterns 
of cytokines in complex regional pain syndrome. Pain 2007;132:195-205. 
[108] van de Beek WJ, Remarque EJ, Westendorp RG, van Hilten JJ. Innate cytokine 
profile in patients with complex regional pain syndrome is normal. Pain 2001;91:259-61. 
[109] van der Laan L, ter Laak HJ, Gabreels-Festen A, Gabreels F, Goris RJ. Complex 
regional pain syndrome type I (RSD): pathology of skeletal muscle and peripheral nerve. 
Neurology 1998;51:20-5.   74 
[110] van der Laan L, van Spaendonck K, Horstink MW, Goris RJ. The Symptom 
Checklist-90 Revised questionnaire: no psychological profiles in complex regional pain 
syndrome-dystonia. J Pain Symptom Manage 1999;17:357-62. 
[111] Vartiainen NV, Kirveskari E, Forss N. Central processing of tactile and nociceptive 
stimuli in complex regional pain syndrome. Clin Neurophysiol 2008;119:2380-8. 
[112] Verdugo RJ, Ochoa JL. Reversal of hypoaesthesia by nerve block, or placebo: a 
psychologically mediated sign in chronic pseudoneuropathic pain patients. J Neurol 
Neurosurg Psychiatry 1998;65:196-203. 
[113] Verdugo RJ, Ochoa JL. Abnormal movements in complex regional pain syndrome: 
assessment of their nature. Muscle Nerve 2000;23:198-205. 
[114] Vladimir Tichelaar YI, Geertzen JH, Keizer D, Paul van Wilgen C. Mirror box 
therapy added to cognitive behavioural therapy in three chronic complex regional pain 
syndrome type I patients: a pilot study. Int J Rehabil Res 2007;30:181-8. 
[115] Wasner G, Heckmann K, Maier C, Baron R. Vascular abnormalities in acute reflex 
sympathetic dystrophy (CRPS I): complete inhibition of sympathetic nerve activity with 
recovery. Arch Neurol 1999;56:613-20. 
[116] Wasner G, Schattschneider J, Binder A, Baron R. Complex regional pain syndrome--
diagnostic, mechanisms, CNS involvement and therapy. Spinal Cord 2003;41:61-75. 
[117] Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological 
pain. Trends Neurosci 2001;24:450-5. 
[118] Watkins LR, Maier SF. Beyond neurons: evidence that immune and glial cells 
contribute to pathological pain states. Physiol Rev 2002;82:981-1011. 
[119] Weber M, Birklein F, Neundorfer B, Schmelz M. Facilitated neurogenic 
inflammation in complex regional pain syndrome. Pain 2001;91:251-7.   75 
[120] Wesseldijk F, Huygen FJ, Heijmans-Antonissen C, Niehof SP, Zijlstra FJ. Tumor 
necrosis factor-alpha and interleukin-6 are not correlated with the characteristics of 
Complex Regional Pain Syndrome type 1 in 66 patients. Eur J Pain 2008;12:716-21. 
[121] Yung Chung O, Bruehl SP. Complex Regional Pain Syndrome. Curr Treat Options 
Neurol 2003;5:499-511. 
 
   76 
CHAPTER 4 
APPROACH 
 
4.1  The studies 
To develop an understanding of the mechanisms involved in the hemilateral sensory 
disturbances of CRPS, it is important to determine whether a standard unilateral painful 
stimulus in healthy subjects has remote effects that differ between the stimulated and 
unstimulated sides of the body.  The aim of the first series of experiments (Study one) was 
to investigate the effect of experimental limb pain (cold-induced limb pain) on sensory 
changes to pressure-pain and sharpness on each side of the forehead in healthy volunteers. 
In particular, the aim was to establish whether such changes were symmetrical or 
asymmetrical. Measures of pressure-pain thresholds and sharpness were employed because 
hemilateral hyperalgesia in CRPS patients was most pronounced to these stimuli in a 
previous study [8].  
  In Study one, severe limb pain reduced forehead sensitivity to sharpness and 
pressure bilaterally with a greater ipsilateral reduction to pressure-pain, indicating the 
involvement of lateralized and diffuse pain inhibitory control mechanisms. The disruption 
of such mechanisms could thus be involved in the spread of sensory disturbances in CRPS. 
This hypothesis was investigated in healthy volunteers in Study two. In a previous study, 
increased forehead sensitivity to pressure-stimulation with a pointed probe was detected in 
the most nauseated subjects following optokinetic stimulation possibly due to a disruption 
of inhibitory pain control [5; 7]. Thus, the effect of optokinetic stimulation and subsequent 
cold-induced limb pain on sensitivity to pressure-pain and sharpness on each side of the 
forehead was investigated in healthy volunteers.   77 
As described in chapter 3, exaggerated neurogenic inflammation may contribute to 
pain in CRPS [1; 2; 11; 15]. The finding of a previous study that unilateral carageenan-
induced hindpaw inflammation in the rat produces thermal hyperalgesia both in the 
inflamed hindpaw and the non-inflamed forepaw, but not in the contralateral paws [14] 
prompted us to investigate the possibility of an association between limb inflammation and 
hemilateral hyperalgesia. Changes in sensitivity to sharpness and pressure-pain on each side 
of the forehead in healthy volunteers during topical treatment of the forearm with the 
inflammatory agent, capsaicin, was thus assessed in Study three.  
NMDA-receptors are up-regulated in inflamed human skin [13] and probably 
sensitize primary afferent nociceptors during inflammation and tissue injury [3; 9; 10]. 
Peripheral NMDA receptors could thus indirectly (by increasing the nociceptive input to 
the spinal cord thereby inducing central sensitization) contribute to the spread of pain 
outside the inflamed CRPS limb. In the fourth study, sensitivity to a range of sensory 
stimuli (touch, pinprick, thermal, pressure, brushing) in the affected limb, unaffected limb, 
and on each side of the forehead was investigated in patients with CRPS before and after 
the NMDA antagonist, topical ketamine, was applied to the affected or unaffected limb in a 
double-blind placebo-controlled trial.  
A lack of central inhibitory pain control could also contribute to the sensitization of 
central neurons in CRPS. A small number of studies in patients with CRPS have suggested 
that central inhibitory pain control is disrupted [4; 6; 12]. Whether the disruption of such 
mechanisms is lateralized was investigated in Study five and six. In a previous study, 
acoustic startle increased pain in the affected limb in the majority of CRPS patients 
whereas acoustic startle decreased capsaicin-induced thermal hyperalgesia of the forearm 
in healthy volunteers [4]. Study five assessed whether the CRPS response to startle differed 
between stimulation in the ear ipsilateral to the affected limb and the ear contralateral to the   78 
affected limb. Similarly, Study six investigated whether noxious cold stimulation of the 
affected limb versus noxious cold stimulation of the contralateral unaffected limb had 
differential influences on forehead sensitivity to pressure-pain and sharpness in CRPS 
patients. 
Finally, it is important to determine whether ipsilateral forehead hyperalgesia or 
hemilateral sensory disturbances occur in pain conditions other than CRPS. Thus Study 
seven assessed pressure-pain and sharpness sensations on each side of the forehead in 
chronic non-CRPS pain patients (neuropathic or nociceptive limb pain, back pain or acute 
herpes zoster/postherpetic neuralgia) and compared these results to those obtained in 
patients with CRPS.   79 
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Abstract 
 
The aim of this study was to investigate the effect of unilateral limb pain on sensitivity to 
pain on each side of the forehead.  In the first experiment, pressure-pain thresholds and 
sharpness sensations were assessed on each side of the forehead in 45 healthy volunteers 
before and after a 10°C cold pressor of the hand and in 18 controls who were not subjected 
to the cold pressor. In a second experiment, forehead sensitivity was assessed in 32 healthy 
volunteers before and after a 2°C cold pressor. The assessments were repeated without the 
cold pressor, and before and after six successive 4°C cold pressor tests. The 10°C cold 
pressor did not influence forehead sensitivity, whereas the 2°C cold pressor and the 4°C 
cold pressor tests resulted in bilateral analgesia to sharpness and pressure. The analgesia to 
pressure was greater in the ipsilateral forehead. Stress-induced analgesia and diffuse 
noxious inhibitory controls may have contributed to the analgesia to pressure-pain and 
sharpness sensations bilaterally after the most painful cold pressor tests. The locus 
coeruleus inhibits ipsilateral nociceptive activity in dorsal horn neurons during limb 
inflammation, and thus may have mediated the ipsilateral component of analgesia. Pain-
evoked changes in forehead sensitivity differed for sharpness and pressure, possibly due to 
separate thalamic or cortical representations of cutaneous and deep tissue sensibility. These 
findings suggest that several mechanisms act concurrently to influence pain sensitivity at 
sites distant from a primary site of painful stimulation.  
  
  83 
Introduction 
 
In complex regional pain syndrome (CRPS), pain and sensory disturbances often 
spread outside the area of initial injury, usually to regions on the ipsilateral side of the body 
(De Takats, 1937, 1943; Kozin et al., 1976a; Kozin et al., 1976b; Bentley and Hameroff, 
1980; Veldman et al., 1993; Veldman and Goris, 1996; Rommel et al., 1999; Maleki et al., 
2000; Rommel et al., 2001; Drummond and Finch, 2006).  In particular, hyperalgesia is 
detected in the ipsilateral forehead of most CRPS patients even when no subjective reports 
of pain or sensory disturbances are reported from this location (Drummond and Finch, 
2006).  
To fully appreciate such findings, it is important to determine whether a standard 
unilateral painful stimulus in healthy subjects has effects remote from the painful stimulus 
that differ between the stimulated and unstimulated sides of the body. Most studies have 
assessed and reported analgesic effects on the contralateral side of the body in response to 
cold-induced pain (Willer et al., 1984; Price and McHaffie, 1988; Kakigi, 1994; Witting et 
al., 1998; Leffler et al., 2002b) and tourniquet-induced ischemic pain (Kosek and Hansson, 
1997; Leffler et al., 2002a). To the best of our knowledge, bilateral effects of a standard 
unilateral painful stimulus have been assessed in healthy subjects in only one study 
(Tuveson et al., 2006). Analgesia to pressure and heat pain was similar in the left and right 
thighs after unilateral tourniquet-induced left arm pain in a relatively small sample of 18 
participants.  
The aim of the present report was to clarify lateralized effects of nociceptive 
stimulation. We wanted to determine whether a standard unilateral painful stimulus 
(immersion of the hand in ice-water) would alter pressure-pain or sharp sensations in the  
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forehead of a large sample of healthy subjects and, if so, to establish whether these changes 
were symmetrical or asymmetrical.  
 
Method 
 
Subjects 
The sample consisted of male and female university students aged between 17 and 
51 years. Participants suffering from medical conditions such as depression, epilepsy, 
gastric ulcers, ear problems, acute or chronic pain or any other medicated problems were 
excluded. Some of the subjects participated in both studies. Participants gave their informed 
consent for the procedures which were approved by the Murdoch University Human 
Research Ethics Committee. 
 
Procedures 
 
Testing was performed in a laboratory maintained at 20 ± 2ºC. 
 
Forehead sensitivity. To assess the participant’s forehead sensitivity, pain 
thresholds to firm pressure (PPT) and the degree of sharpness evoked by standard stimuli 
were measured on each side of the forehead. A spring loaded algometer with a rounded tip 
(1 cm in diameter) was used to apply pressure at intervals of 80 g to a maximum of 2.3 kg 
or until the participant felt pain. Sharpness was rated on both sides of the forehead in 
response to a single application of a firm nylon bristle (Filament 17, Senselab von Frey  
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Aesthesiometer, Somedic Sales AB, Sweden) on a scale from 0 (not sharp) to 10 (stabbing). 
Sufficient force was applied to bend the bristle for 1 second. 
 
Pain in the hand. The cold pressor (CP) was used to induce pain. The participant 
placed his or her hand in a cold water bath. The participant was asked to move the hand 
around in the water to avoid build-up of heat around the hand. The participant rated pain 
intensity verbally from 0 (no pain) to 10 (extremely severe pain) and also rated the distress 
associated with the pain in the hand from 0 (none) to 10 (extremely severe distress). 
 
Experiment 1: Effect of a 10°C cold pressor on forehead sensitivity. In 45 university 
students (14 males), forehead sensitivity was assessed before and after participants placed 
their hand into a cold water bath maintained at 10 ± 1ºC for 1 minute. Half of the 
participants immersed the dominant hand. Participants reported the pain and distress 
induced by the CP. These measurements were all repeated again 2 minutes later. A control 
group consisting of 7 male and 11 female students underwent equivalent assessments of the 
forehead without the CP to control for the effect of repeated forehead assessments. 
 
Experiment 2: Effect of a 2°C cold pressor and repeated 4°C cold pressors on 
forehead sensitivity. Forehead sensitivity was assessed in 32 subjects (13 males) before and 
after immersing their hand in a 2 ± 1ºC cold water bath for 1 minute. The dominant hand 
was immersed in half of the participants. The assessments were continued at 2 minute 
intervals for 12 minutes after the CP. Pain and distress ratings associated with the hand 
immersion were also obtained at these times. To control for effects of repeated forehead 
assessments, forehead sensitivity was also assessed at equivalent intervals without the CP.  
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Finally, forehead assessments were conducted before and after six successive 4 ± 1°C CPs 
each of 1 minute duration at 20 second intervals. Half of the participants immersed their 
dominant hand. During the 20 second intervals between each CP, participants were asked to 
rate the pain in the immersed hand and associated distress. The three procedures (a 2°C 
cold pressor, repeated 4°C cold pressors, and repeated forehead assessments without a cold 
pressor) were all performed during a single visit. They occurred in random order with 
sufficient time (median time 15 min, range 10 – 20 min) between them for forehead ratings 
and pain and distress to return to baseline. 
 
Statistical analyses. Student’s t-tests were used to assess side differences in 
forehead sensitivity to pressure and sharpness prior to testing. The degree and asymmetry 
of forehead sensitivity (ipsilateral versus contralateral) across time and conditions was 
investigated with analysis of variance for PPT and sharpness ratings. Analysis of variance 
was also performed for changes in pain intensity and distress across time. Hierarchical 
linear regression analyses were conducted to assess associations between pain experience 
(pain intensity, distress), demographics (age, gender) and forehead sensitivity outcome after 
the CPs, after controlling for forehead sensitivity at baseline. This was done both for 
general forehead sensitivity and forehead asymmetry to pressure and sharpness. However, 
the results of these analyses are not reported as they failed to clarify effects of the CP on 
forehead sensitivity. Finally, differences in pain and distress ratings between the 10°C CP 
and the 2°C CP were determined using Student’s t-tests. Pearson’s correlations assessed 
any associations between pain and distress ratings and PPT and sharpness ratings in the 
pooled data from the 10°C CP and the 2°C CP groups. Data are reported as the mean ± 
standard error of the mean.  
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Results 
 
Experiment 1: Effect of a 10°C cold pressor on forehead sensitivity 
Symmetry of forehead sensations in healthy subjects. Prior to testing, absolute 
differences in PPTs between the right and left sides of the forehead in the CP group were 
80 g or less in the majority of participants (67%) (range 0 - 800 g). No difference was 
found in 42% of participants. Only 7% (3 participants) had a difference larger than 250 g. 
PPTs did not differ significantly between the right and left sides [Mright = 675 ± 30 g, Mleft = 
652 ± 33 g, t(44) = 0.80, not significant]. Absolute differences in sharpness ratings between 
the right and left sides of the forehead ranged from 0 to 5 prior to testing with the majority 
(69%) having a difference of 1 or less. No side differences were found in 31% of 
participants. Sharpness ratings did not differ significantly between the two sides of the 
forehead [Mright = 3.2 ± 0.2, Mleft = 3.3 ± 0.3, t(44) = 0.21, not significant]. 
In the control group, absolute differences in PPTs between the right and left sides of 
the forehead were 80 g or less in most participants (89%) (range 0 - 160 g). Fifty percent 
displayed no difference. Differences in sharpness ratings in this group ranged from 0 to 2 
with the majority (89%) reporting a difference of 1 or less. In 56%, no difference in 
sharpness sensitivity was reported. The right and left sides of the forehead did not differ 
significantly in response to pressure [Mright = 738 ± 46 g, Mleft = 724 ± 47 g, t(16) = 0.90, 
not significant] or sharpness [Mright = 2.3 ± 0.3, Mleft = 2.1 ± 0.3, t(16) = 1.29, not 
significant].  
 
Change in forehead sensations after the CP. Participants in the CP group 
experienced moderate pain from the CP (M = 5.3 ± 0.4) which they found mildly  
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distressing (M = 2.8 ± 0.4). Two minutes after limb immersion, both pain (M = 0.7 ± 0.2) 
and distress (M = 0.3 ± 0.1) were almost gone.  
As shown in Fig. 1, both the CP group and the control group became more sensitive 
to pressure with each assessment [p < 0.05] and no ipsilateral predominance appeared 
[main effect for Time F(2,59) = 10.04, p < 0.001]. Sharpness ratings remained unchanged 
for both groups across forehead assessments (Fig. 2). However, for unknown reasons, the 
CP group (M = 3.22 ± 0.21) was, in general, more sensitive to sharpness than the control 
group (M = 2.24 ± 0.34) [main effect for Group F(1,60) = 6.16, p < 0.05]. 
 
Experiment 2: Effect of a 2°C cold pressor and repeated 4°C cold pressors on forehead 
sensitivity  
Symmetry of forehead sensations. Prior to testing, absolute differences in PPTs 
between the right and left sides of the forehead were again 80 g or less in the majority of 
participants (91%) (range 0 - 160 g). No difference was found in 53% of participants. PPTs 
did not differ significantly between the two sides of the forehead [Mright = 726 ± 33 g, Mleft 
= 705 ± 32 g, t(30) = 1.86, not significant]. Absolute differences in sharpness ratings 
between the right and left sides of the forehead were 1 or less in most participants (91%) 
(range 0 - 2). No side difference was found in 50% of participants. Sharpness ratings did 
not differ significantly between the two sides of the forehead [Mright = 2.3 ± 0.2, Mleft = 2.1 
± 0.2, t(30) = 1.56, not significant].  
 
Change in forehead sensations after the 2°C CP. As shown in Fig. 3, participants 
experienced intense pain from the CP which caused them moderate distress. The pain 
decreased significantly from one assessment to the next [p < 0.001] to almost no pain 6  
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minutes after the CP [main effect for Time F(6,25) = 82.66, p < 0.001]. Distress similarly 
decreased between consecutive assessments [p < 0.05] and was almost gone 6 minutes after 
the CP [main effect for Time F(4,27) = 31.35, p < 0.001]. 
PPTs decreased with the second measurement in the control session [t(30) = 3.91, p 
< 0.001] whereas PPTs increased significantly after the CP [t(30) = -2.11, p < 0.05] with 
significantly higher PPTs on the ipsilateral forehead than contralaterally [t(30) = 2.69, p < 
0.05] [Condition x Time x Side interaction F(7,24) = 2.79, p < 0.05] (Fig. 4). Sharpness 
responses decreased gradually after the CP with significant differences to baseline at 6 min 
[t(30) = 2.97, p < 0.01] and 12 min post CP [t(30) = 2.13, p < 0.05], but remained stable in 
the control session [Condition x Time interaction F(7,24) = 3.23, p < 0.05]. No side 
differences in forehead sensitivity were observed for sharpness (Fig. 5).  
 
Change in forehead sensations after the repeated 4°C CPs. Participants experienced 
intense pain from the repeated cold-water immersions (Fig. 6). The initial pain increased 
with the second immersion [p < 0.05] after which the pain remained relatively stable [main 
effect for Time F(5,26) = 3.12, p < 0.05]. Participants were moderately distressed about the 
pain (Fig. 6). Their level of distress did not change with repeated immersions [main effect 
for Time F(5,26) = 2.48, not significant].   
As Fig. 7 illustrates, PPTs increased both ipsilaterally [t(30) = 3.56, p < 0.001] and 
contralaterally [t(30) = 2.54, p < 0.05] after the CPs with significantly higher PPTs on the 
ipsilateral forehead than contralaterally [t(30) = 3.66, p < 0.001] [Side x Time interaction 
F(1,30) = 5.56, p < 0.05]. Sharpness ratings decreased to the same extent on both sides of 
the forehead [main effect for Time F(1,30) = 8.01, p < 0.01]. 
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Are the differing forehead sensitivity responses from the 10°C CP to the 2°C CP related to 
pain intensity and distress? 
The CP was perceived as significantly more painful by the 2°C CP group (M = 7.7 
± 0.3) than the 10°C CP group (M = 5.3 ± 0.4) [t(74) = 4.63, p < 0.001]. Higher pain ratings 
were associated with an increase in PPT [r = 0.24, p < 0.05] and with a decrease in 
sharpness ratings of the forehead [r = -0.28, p < 0.05] after the CP. However, pain ratings 
were unrelated to the development of asymmetry in PPT [r = 0.04, not significant] or 
sharpness [r = -0.03, not significant] between the two sides of the forehead from before to 
after the CP. Distress ratings from the pain were also significantly higher in the 2°C CP 
group (M = 6.10 ± 0.53) than the 10°C CP group (M = 2.8 ± 0.36) [t(74) = 5.35, p < 0.001]. 
Higher distress ratings were associated with an increase in PPT [r = 0.25, p < 0.05] after the 
CP. However, there was no association with sharpness [r = -0.12, not significant].  
 
Discussion 
 
In most CRPS patients, PPTs  in the forehead are 250 – 1,500 g lower ipsilateral 
than contralateral to the affected limb (Drummond and Finch, 2006). In the current 
experiments, differences in sensitivity between the left and right sides of the forehead in the 
majority of healthy pain-free participants were small (80 g or less) or non-existent. This 
also applied for sharpness sensations. It thus appears unusual for healthy individuals to 
display the asymmetrical forehead sensitivity associated with CRPS.  
We investigated whether a unilateral standard painful stimulus in healthy subjects 
evoked remote effects that differed between the ipsilateral and contralateral sides of the 
forehead. Inducing moderate limb pain with a 10°C CP did not affect forehead sensitivity.  
  91 
However, severe limb pain and repeated cold water immersions resulted in bilateral and, 
particularly, ipsilateral forehead analgesia to pressure. No ipsilateral predominance was 
seen for the development of analgesia to sharpness. These findings contrast with ipsilateral 
forehead hyperalgesia in CRPS (Drummond and Finch, 2006), but correspond to some 
extent with bilateral analgesia during tourniquet-induced ischemic pain in healthy subjects 
(Tuveson et al., 2006).  
During normal pain transmission, signals from nociceptive fibers enter the dorsal 
horn (Light and Perl, 1979a, 1979b) where they are facilitated or inhibited by pain-
modulating mechanisms such as ‘gate control’ (Melzack and Wall, 1965; Basbaum and 
Fields, 1978), stress-induced hyper- or analgesia (Willer et al., 1981; Quintero et al., 2003), 
diffuse noxious inhibitory controls (DNIC) (Morton et al., 1987; Villanueva and Le Bars, 
1995), or coeruleospinal pain modulation (Proudfit and Clark, 1991; Sluka and Westlund, 
1992). In ‘gate control’, inhibitory influences resulting from large-fiber activity (non-
noxious input) compete with excitatory influences from small-fiber activity (noxious input) 
to determine pain perception locally (Basbaum and Fields, 1978). As forehead analgesia 
developed remotely in the present study, mechanisms other than ‘gate control’ presumably 
mediated the response.  
Acute noxious and non-noxious stress attenuates pain behaviour in animals 
(Chesher and Chan, 1977; Gamaro et al., 1998) and produces generalized anti-nociception 
in humans (Willer et al., 1981; Bandura et al., 1988).  Such effects are mediated by 
endogenous opiate and non-opiate mechanisms (Spiaggia et al., 1979; Watkins and Mayer, 
1982; Tierney et al., 1991). In the present study, the pain from the 2°C CP and the repeated 
CPs were perceived as moderately distressing. It is thus likely that stress-induced analgesia 
contributed to the bilateral forehead analgesia. Indeed, endogenous opioids have been  
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found to be partly involved in the analgesia following cold water-induced limb pain 
(Jungkunz et al., 1983; Robertson et al., 2008). In the present study, higher distress ratings 
were associated with greater forehead analgesia to pressure but not sharpness. 
DNIC is also likely to have played a role in the forehead analgesia. The principal 
feature of DNIC is that painful stimuli diminish or mask pain in a distant part of the body 
(Villanueva and Le Bars, 1995). In line with the present study, thermal stimuli, particularly 
noxious cold (Willer et al., 1984; Arendt-Nielsen and Gotliebsen, 1992; Plaghki et al., 
1994; Watanabe et al., 1996; Witting et al., 1998; Leffler et al., 2002b; Bouhassira et al., 
2003; Lariviere et al., 2007), have been found to activate DNIC in healthy volunteers and 
inhibit pain elsewhere, as has a range of other stimuli (e.g. mechanical, electrical, ischemic) 
(Pertovaara et al., 1982; Willer et al., 1984; Price and McHaffie, 1988; Kosek and Hansson, 
1997; Bouhassira et al., 2003). Such counter-stimulation appears to inhibit wide dynamic 
range neurons in the dorsal horn (Le Bars et al., 1979a; Morton et al., 1987) and in the 
trigeminal nucleus caudalis (Dickenson et al., 1980; Murase and Kawakita, 2000) via a 
supraspinal loop (Le Bars et al., 1979b; Cadden et al., 1983; Morton et al., 1987). Bilateral 
DNIC effects, detected by recordings from spinal and trigeminal convergent neurons, have 
been reported in rat studies involving immersion of paws, tail and muscle in hot water 
(Bouhassira et al., 1990; Bouhassira et al., 1992). DNIC also appears to act bilaterally in 
response to noxious conditioning stimuli in humans (Tuveson et al., 2006). Thus, the severe 
and prolonged limb immersions in the present study probably activated DNIC as well as 
stress-induced analgesia, resulting in bilateral forehead analgesia to pressure and sharpness.  
In line with previous studies which found that the intensity of the stimulus is 
associated with the strength of the resultant DNIC (Willer et al., 1984; Villanueva and Le 
Bars, 1985; Fujii et al., 2006), the 10
oC CP apparently did not activate DNIC. Whether the  
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amount of nociceptive discharge or perceived pain determines the extent of DNIC, or 
whether pain is even necessary for the induction of DNIC, is controversial (Lautenbacher et 
al., 2002; Le Bars, 2002; Baad-Hansen et al., 2005; Pud et al., 2005; Granot et al., 2008). In 
the present experiments, higher limb pain ratings were associated with a greater reduction 
in sensitivity to forehead pressure and sharpness.  
The analgesic response to pressure was greater in the ipsilateral forehead. The 
mechanism of this effect is unclear, but may have involved coeruleospinal pain modulation. 
The nucleus locus coeruleus (LC), located in the dorsolateral pons, induces anti-nociception 
when stimulated electrically or chemically (Margalit and Segal, 1979; Jones and Gebhart, 
1986a; West et al., 1993). Activation of the LC is thought to inhibit nociceptive activity in 
dorsal horn (Jones and Gebhart, 1986b) and trigeminal subnucleus caudalis neurons 
(Tsuruoka et al., 2003c) via noradrenergic projections (Westlund et al., 1983; Fritschy and 
Grzanna, 1990) that act on α2-adrenoceptors (Jones and Gebhart, 1986a, 1986b). Although 
the LC projects bilaterally to the dorsal horn (Clark et al., 1991; Clark and Proudfit, 1992; 
Sluka and Westlund, 1992), activity in LC projections increases in the ipsilateral dorsal 
horn but not contralaterally during unilateral hindpaw inflammation (Tsuruoka and Willis, 
1996a, 1996b; Tsuruoka et al., 1999; Tsuruoka et al., 2003b). The finding of a bilateral 
increase in Fos expression in the LC during unilateral hindpaw inflammation suggests that 
the ipsilateral activation emanates bilaterally, but perhaps travels through the dorsolateral 
funiculus ipsilaterally (Tsuruoka et al., 2003a). This is still a contentious issue, however. 
Importantly, the LC appears to project to all segmental levels of the spinal cord. 
Injection of anterograde transport of Phaseolus vulgaris leucoagglutinin (PHA-L) in the LC 
resulted in consistent labeling in cervical, thoracic and lumbar segments of the spinal cord 
(Proudfit and Clark, 1991). Consistent with this, Tsuruoka et al. (2004) measured the  
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thermal response threshold on all four paws of the rat during unilateral hindpaw 
inflammation and found shorter paw withdrawal latencies for the inflamed hindpaw in rats 
with bilateral LC lesions than in sham operated rats. This was also observed in the non-
inflamed, but hyperalgesic, ipsilateral forepaw but not in the contralateral hind- or forepaw. 
Such studies suggest that the coeruleospinal modulation system plays a role in suppressing 
inflammation-induced hyperexcitability of nociceptive dorsal horn neurons that extend 
through the propriospinal pathways, although it may not completely deter such activity. 
Importantly, electrical stimulation of primary afferent A-delta fibers produces excitation of 
descending noradrenergic neurons from the LC, resulting in an increase in the level of 
noradrenaline in the dorsal horn (Hitoto et al., 1998). The increase was seen ipsilaterally 
but not contralaterally after carageenan inflammation of the hindpaw (Tsuruoka et al., 
1999). It is thus likely that the finding of ipsilateral analgesia in the present study reflects 
ipsilateral coeruleospinal pain modulation, perhaps acting in concert with stress-induced 
analgesia and DNIC. Pain intensity did not appear to be the determining factor for this 
component of the analgesia as we failed to find any association between pain ratings and 
forehead asymmetry. 
Interestingly, the ipsilateral analgesia occurred for pressure but not sharpness. 
Dissociations between such sensations were also found in patients with central post-stroke 
pain (Mailis and Bennett, 2002) and in CRPS patients (Drummond and Finch, 2006) who 
often display a loss of cutaneous sensation but a persistence or increase in deep-pressure 
pain. Pressure also induces pain more so than cutaneous stimulation in patients with 
thalamic lesions (Riddoch, 1938). These findings suggest that different central mechanisms 
account for painful cutaneous versus deep-pressure sensations. Consistent with this, 
cutaneous nociceptors appear to project predominantly to laminas I and II of the dorsal horn  
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(Willis and Coggeshall, 1991) whereas muscle afferents innervate laminas I and V (Craig et 
al., 1988; Mense and Craig, 1988; Ohtori et al., 2000). Furthermore, pain of superficial 
origin evokes neural activity in different brain sites than pain of deeper origin (Henderson 
et al., 2006).  
Some limitations apply to this study as it was performed in a predominantly young, 
educated, female population. Nonetheless, women were studied across every stage of the 
menstrual cycle rendering this an unlikely influence, and gender and age were unrelated to 
the development of analgesia. The present findings demonstrate that limb pain in healthy 
participants induces bilateral analgesia to mechanical stimulation and ipsilateral analgesia 
to pressure in the forehead, suggesting the involvement of stress-induced analgesia, DNIC 
and perhaps ipsilateral coeruleospinal pain-controlling mechanisms. Thus, disruption of 
these mechanisms may contribute to ipsilateral forehead hyperalgesia in CRPS.  
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Fig. 1. PPT for sides of the forehead ipsilateral and contralateral to the CP in the CP group and equivalent sides of the forehead in the control 
group. PPTs decreased significantly in both groups after the CP. Error bars represent standard errors and the arrow represents the CP in the 
CP group. 
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Fig. 2. Sharpness ratings for sides of the forehead ipsilateral and contralateral to the CP in the CP group and equivalent sides of the forehead 
in the control group. Sharpness ratings were unchanged across measurements for both groups. The CP group was significantly more 
sensitive to sharpness than the control group. Error bars represent standard errors and the arrow represents the CP in the CP group. 
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Fig. 3. Hand pain and distress ratings for 12 minutes after the 2 °C. Error bars represent standard errors and the arrow represents the CP. 
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Fig. 4. PPT before and for 12 minutes after the 2 °C CP  and equivalent time intervals in the control session for sides of the forehead 
ipsilateral and contralateral to the immersed hand. PPTs decreased with the second measurement in the control session, but increased 
significantly after the CP (* p < 0.05). PPTs after the CP were significantly greater ipsilaterally than contralaterally (* p < 0.05). Error bars 
indicate standard errors and the arrow represents the CP in the CP condition.  
 
Control  Session
-2 0 2 4 6 8 10 12
500
600
700
800
900
Ipsilateral
Contralateral
Time (min)
T
h
r
e
s
h
o
l
d
 
(
g
)
2C  CP Session
-2 0 2 4 6 8 10 12
500
600
700
800
900
*
Time (min)
T
h
r
e
s
h
o
l
d
 
(
g
) 
 
110  
 
 
 
 
 
 
 
 
 
Fig. 5. Sharpness ratings before and for 12 minutes after the 2 °C CP  and equivalent time intervals in the control session for sides of the 
forehead ipsilateral and contralateral to the immersed hand. Sharpness ratings were unchanged in the control session, but had decreased 
significantly 6 min and 12 min after the CP. Error bars indicate standard errors and the arrow represents the CP in the CP condition. 
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Fig. 6. Hand pain and distress ratings after each 4 °C immersion. Error bars represent standard errors.  
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Fig. 7. PPT and sharpness ratings before and after the repeated CPs for sides of the forehead ipsilateral and contralateral to the immersed 
hand. Sensitivity to pressure and sharpness decreased bilaterally. PPTs were greater ipsilaterally than contralaterally after the CPs (** p < 
0.01). Error bars indicate standard errors and the arrow represents the repeated CPs.  
 
 
Pressure-pain Threshold
-2 0
500
600
700
800
900
Ipsilateral
Contralateral
**
Time (min)
T
h
r
e
s
h
o
l
d
 
(
g
)
Sharpness Rating
-2 0
0
1
2
3
4
Time (min)
S
h
a
r
p
n
e
s
s
 
(
0
-
1
0
)  113 
CHAPTER 6 
EFFECT OF LIMB PAIN AND MOTION SICKNESS ON 
SCALP TENDERNESS 
 
Lone Knudsen, Peter D. Drummond 
School of Psychology, Murdoch University, Perth, Western Australia 
 
 
Address for correspondence: 
Lone Knudsen 
School of Psychology 
Murdoch University 
South Street 
Murdoch 6150 
Western Australia 
 
Ph: 61-8-93606911 
Fax: 61-8-93606492 
Email: L.Knudsen@murdoch.edu.au 
 
 
Pages: 29 
Tables: 2 
Figures: 4 
 
Key words: diffuse noxious inhibitory controls, stress-induced analgesia, cold pressor, 
motion sickness, complex regional pain syndrome, hyperalgesia 
   114 
Abstract 
 
A disruption of central pain control may be involved in the development of scalp tenderness 
during motion sickness. The aim of this study was to investigate the effect of limb pain on 
sensitivity to noxious stimulation on each side of the forehead during motion sickness. 
Eighty-five healthy volunteers were subjected to a cold pressor task of the hand on two 
occasions. On one of these occasions, the cold pressor was preceded by optokinetic 
stimulation to induce symptoms of motions sickness. Pressure-pain thresholds and ratings 
of sharpness to a firm bristle were obtained from each side of the forehead before and after 
each stimulus. On its own, the CP decreased forehead sensitivity to sharpness and opposed 
an increase in sensitivity to pressure-pain in pain sensitive individuals, suggesting 
involvement of diffuse noxious inhibitory controls (DNIC) and stress-induced analgesia 
(SIA). During residual motion sickness, forehead sensitivity to pressure and sharpness 
increased, but decreased following the CP. These findings suggest that DNIC and SIA 
remained intact during residual motion sickness. Forehead sensitivity to sharpness and 
pressure varied independently, possibly due to the recruitment of separate central deep 
versus cutaneous tissue sensibility pathways.   115 
Introduction 
 
In complex regional pain syndrome (CRPS), pain and sensory disturbances may 
spread from the painful limb to other areas of the body [33; 43; 44]. Both sides of the body 
may be affected [20; 48], but most marked is a spread of sensitivity ipsilaterally [15]. 
Drummond and Finch [15] found that sensitivity to sharpness from a firm bristle in the 
affected limb of most CRPS patients was associated with similar sensations in the 
ipsilateral forehead, and that pressure-pain thresholds were between 250 g to 1,500 g lower 
in the ipsilateral forehead than contralaterally, consistent with an ipsilateral spread of 
hyperalgesia. Whether this spread is a specific pathological sign of CRPS, as the 
investigators speculated, is unknown. If so, it may provide for a possible diagnostic tool. 
We recently investigated whether a standard unilateral painful stimulus in healthy 
subjects has effects remote from the site of stimulation that mimic the pattern seen in CRPS 
[25]. While a 10°C cold water immersion had no effect on forehead sensitivity, a single 2°C 
immersion and six repeated 4°C immersions resulted in bilateral analgesia in the forehead 
both for sharpness ratings to a firm bristle and pressure-pain thresholds. In addition, 
analgesia to pressure-pain was greater ipsilaterally than contralaterally. These findings 
contrast with the ipsilateral forehead hyperalgesia in CRPS. In fact, such findings suggest 
that diffuse noxious inhibitory controls (DNIC), acting on wide dynamic range neurons in 
the dorsal horn upon nociceptive stimulation [55], inhibited sensitivity in the forehead, 
perhaps in concert with stress-induced analgesia (SIA) [46; 49; 57] and coeruleospinal pain 
modulation [50-54]. In the latter mechanism, noradrenergic projections from the locus 
coeruleus act on α2- adrenoceptors proximally as well as distally in the ipsilateral dorsal   116 
horn during unilateral limb inflammation, and could thus account for ipsilateral forehead 
analgesia during intensely painful cold pressor tests.  
Interestingly, central pain control mechanisms such as DNIC and SIA seem to be 
disrupted in CRPS as painful forehead cooling and startle with a loud tone increase rather 
than reduce limb pain [10; 13]. Recently Seifert et al.[45] reported a slower decline in pain 
ratings during repetitive noxious electrical stimulation of both the affected and unaffected 
limb in CRPS patients compared to controls consistent with reduced inhibitory pain control. 
Perhaps it is a lack of such pain modulation which accounts for the spread of pain in CRPS.   
The present experiment investigated whether limb pain accentuates scalp tenderness 
associated with residual motion sickness induced by optokinetic stimulation (OKS) in 
healthy people. OKS has been shown to induce mechanical hyperalgesia in the forehead of 
nauseated subjects [11], leading to speculation that activation of certain brainstem nuclei 
during motion sickness disrupts pain inhibitory mechanisms such as DNIC or SIA [14]. If 
this provides an adequate model for mimicking the lack of central pain control in CRPS 
patients, and if this lack of control is responsible for the ipsilateral forehead hyperalgesia, 
cold-induced pain in the hand should aggravate mechanical hyperalgesia in the ipsilateral 
forehead during residual motion sickness. 
 
Materials and Methods 
 
Subjects 
Participants were 85 young and mature age university students (26 males) ranging 
in age from 17 to 59 years (median age 22). Participants with psychiatric problems or 
medical problems including acute or chronic pain or vestibular problems were excluded, as 
were medicated participants. The study was approved by the Murdoch University Human   117 
Research Ethics Committee. Participants gave their informed consent to participate; they 
were informed that they might experience motion sickness from optokinetic stimulation and 
pain from the cold pressor, but they were not otherwise aware of the specific purpose or 
expected findings of the study.  
 
Procedures 
Forehead sensitivity. A spring loaded algometer with a rounded tip (1 cm in 
diameter) was used to assess pressure-pain thresholds (PPT) on each side of the forehead. 
Pressure was applied at intervals of 80 g to a maximum of 2.3 kg or until the participant 
reported pain [25]. Sharpness was rated in response to a single application of a firm nylon 
bristle (Filament 17, Senselab von Frey Aesthesiometer, Somedic Sales AB, Sweden) on 
each side of the forehead on a scale from 0 (not sharp) to 10 (stabbing). Enough force was 
applied to bend the bristle for 1 s [25]. 
 
Pain in the hand. The cold pressor (CP) was used to induce pain. The participant 
immersed his or her hand in a cold water bath maintained at 10 ± 1 ºC for 1 min [25]. The 
dominant hand was immersed in half of the participants and the non-dominant hand in the 
other half. The participant moved the hand around in the water to avoid build-up of heat 
around the hand. Pain intensity was rated verbally from 0 (no pain) to 10 (extremely severe 
pain) and distress associated with the pain in the hand was rated from 0 (none) to 10 
(extremely severe). 
 
Optokinetic stimulation. To induce symptoms of motion sickness, the participant sat 
on a stationary chair with his or her head and shoulders inside an illuminated drum 50 cm 
in diameter, 70 cm in height and painted internally with 24 pairs of vertical black and white   118 
stripes each 3.3 cm wide [11]. The drum revolved 10 times per minute for 10 min or until 
participants could no longer tolerate the sensations evoked by optokinetic stimulation. To 
enhance the illusion of movement, the participant was asked to look at a distant point rather 
than watch the stripes move past. The mismatch between the visual illusion of movement 
and contrasting vestibular and proprioceptive cues induced motion sickness. Symptoms of 
motion sickness (dizziness, nausea and headache) were rated by the participant from 0 
(none) to 10 (extremely severe).  
 
Trial sequence. Sessions took place in a laboratory maintained at 20 ± 2 ºC. 
Sensitivity to mechanical stimulation on each side of the forehead and motion sickness 
symptoms were assessed both before and after OKS. The participant then placed his or her 
hand into the cold water for 1 min. Straight after removing the hand and 2 min later, the 
participant reported the pain and distress associated with the hand immersion along with 
motion sickness symptoms, and forehead sensitivity assessments were repeated. During a 
separate session randomly performed at least 3 days (median 7 days, range 3-8) prior to or 
after the OKS session, the cold pressor and associated assessments were repeated without 
OKS (henceforth termed the “isolated” cold pressor).  
 
Statistical analyses. Student’s t-tests were used to assess side differences in 
forehead sensitivity to pressure and sharpness prior to testing. Changes in dizziness, nausea 
and headache to OKS (before OKS, after OKS, after the CP, 2 min after the CP) were 
investigated with analyses of variance as were changes in pain and distress to the CP (after 
the CP, 2 min after the CP) in the residual motion sickness versus no motion sickness 
conditions. The Huynh-Feldt epsilon was used to correct for violations of sphericity. 
Analyses of variance were also used to assess changes in the degree and asymmetry of   119 
forehead sensitivity (ipsilateral versus contralateral) to sharp and pressure sensations from 
before OKS to after OKS as well as to assess changes in forehead sensitivity from before 
the CP to after and 2 min after the CP in the two conditions (with and without residual 
motion sickness). Planned comparisons, analyses of variance or student’s t-tests were used 
as appropriate to explore significant findings. Pearson’s correlations assessed associations 
between changes in forehead sensitivity to pressure and sharpness and motion sickness 
symptoms. Data are reported as the mean ± standard error of the mean. 
 
Results 
 
Symmetry of forehead sensations in healthy subjects 
Prior to testing, the majority of participants displayed absolute PPT differences 
between the right and left sides of the forehead of 80 g or less (69%) (range 0 - 800 g). 
There was no difference in 34% of participants. Eight participants (9%) had a difference 
larger than 250 g (i.e. at a level similar to that of the majority of CRPS patients). Overall, 
forehead sensitivity to pressure-pain did not differ significantly between the right and left 
sides [Mright = 710.35 ± 23.60 g, Mleft = 698.12 ± 25.23 g, t(84) = 0.63, not significant]. 
Sharpness ratings also did not differ significantly between the two forehead sides prior to 
testing [Mright = 3.03 ± 0.17, Mleft = 3.04 ± 0.19, t(84) = 0.09, not significant]. The absolute 
difference in sharpness ratings between the sides of the forehead was a rating of 1 or less in 
the majority of participants (81%) (range 0 - 5). Sharpness was identical on both sides of 
the forehead in 45% of the participants.  
 
 
   120 
Development of motion sickness after OKS 
Eleven participants asked for the drum to be stopped during rotation [mean time for 
this group = 5.18 ± 0.61 min]. The other 74 participants stayed in the drum for the entire 10 
minute period. Participants reported the development of dizziness, nausea and headache 
after OKS [p < 0.001 for all symptoms]. The symptoms decreased after immersion of the 
hand in the water [p < 0.001 for all symptoms] and decreased further 2 minutes later [p < 
0.001 for dizziness and nausea and p < 0.01 for headache] (Fig. 1) [main effect for Time for 
dizziness F(2.22,186.75) = 197.02, p < 0.001, nausea F(2.05,171.94) = 104.48, p < 0.001) 
and headache F(2.25,189.12) = 31.24, p < 0.001]. Two minutes after the CP, the symptoms 
were still slightly higher than at baseline [p < 0.01 for dizziness, p < 0.001 for nausea and 
headache].  
 
Pain and Distress 
Participants, in general, experienced moderate pain from the isolated CP (M = 5.21 
± 0.28). They found it mildly distressing (M = 2.59 ± 0.25). However, while some 
participants perceived no or very little pain from the CP, others reported much more severe 
pain. As pain is generally considered important for DNIC and was previously associated 
with the degree of forehead analgesia following a CP task [25], we allocated participants to 
two groups based on their pain score during the isolated CP: those with a mean pain score 
of 3 or less (M = 1.83 ± 0.26, range 0 - 3) who were regarded as pain insensitive (n = 23) 
and those with a pain score of more than 3 (M = 6.46 ± 0.21, range 3.5 - 10) (pain sensitive, 
n = 62). Sex, age, and mean PPT before testing were similar in the two groups (Table 1). 
However, the pain sensitive group reported greater sharpness sensations in the forehead 
prior to the experiment than the pain insensitive group [main effect for Group F(1,83) =   121 
5.94, p < 0.05. The length of time spent in the drum and intensity of motion sickness 
induced by OKS were similar in the two groups. 
  The CP (during and without residual motion sickness) consistently induced more 
pain in the pain sensitive than the pain insensitive group [main effect for Group F(1,83) = 
88.05, p < 0.001] (Fig. 2). The pain induced by the CP virtually resolved  in both groups 2 
min after the CP regardless of whether it was preceded by OKS [main effect for Time 
F(1,83) = 362.40, p < 0.001]. This decrease was greater in the pain sensitive group than the 
pain insensitive group [t(83) = 9.09, p < 0.001] [Time x Group interaction F(1,83) = 82.66, 
p< 0.001] possibly because the CPs induced more pain in this group in the first place.  
Interestingly, the pain sensitive group reported a similar amount of pain from the 
CP in the presence or absence of residual motion sickness [t(61) = 0.59, not significant] 
whereas motion sickness increased cold-induced pain in the pain insensitive group [t(22) = 
3.18, p < 0.01] [Condition x Time x Group interaction F(1,83) = 5.51, p < 0.05] (Fig. 2).  
The CP tests also produced consistently more distress in the pain sensitive than the 
pain insensitive group irrespective of residual motion sickness [main effect for Group 
F(1,83) = 29.70, p < 0.001] (Fig. 2). Distress induced by the CP decreased in both groups 2 
min after the CP both in the presence and absence of residual motion sickness [main effect 
for Time F(1,83) = 86.00, p < 0.001]. As with pain, the decrease in distress was greater in 
the pain sensitive than the pain insensitive group [t(83) = 5.55, p < 0.001] [Time x Group 
interaction F(1,83) = 30.81, p < 0.001] probably because distress initially was greater in 
this group.  
 
Scalp tenderness after OKS 
Forehead sensitivity to pressure-pain increased after OKS [main effect for Time 
F(1,84) = 47.34, p < 0.001] (Fig. 3). This occurred in both pain groups alike and to a   122 
similar extent on both sides of the forehead. This was also the case for sharpness [main 
effect for Time F(1,84) = 31.79, p < 0.001] (Fig. 4). Again the response did not differ 
between the two sides of the forehead or between the pain groups.  
The development of scalp tenderness to pressure-pain and sharpness was associated 
with nausea (Table 2). In addition, the development of scalp tenderness to pressure-pain 
was associated with the development of dizziness, and scalp tenderness to sharpness was 
associated with headache.  
 
Changes in forehead sensations after the CP during and without residual motion sickness 
Changes in forehead sensitivity to pressure-pain after the CP tests are shown in 
Figure 3. A significant condition by time by group interaction emerged for PPTs [F(2,166) 
= 3.17, p < 0.05]. Post hoc analyses of variance revealed that the pain insensitive group 
became more sensitive to pressure-pain immediately after the isolated CP [p < 0.001] [main 
effect for Time (before, after and 2 min after the CP) F(2,44) = 5.74, p < 0.01]. In the pain 
sensitive group, this increase in sensitivity did not occur until 2 min after the isolated CP [p 
< 0.05] [main effect for Time (before, after and 2 min after the CP) F(2, 122) = 3.52, p < 
0.05]. In contrast, during residual motion sickness, both groups became less sensitive to 
pressure-pain immediately after the CP [main effect for Time in the pain insensitive group 
(before and after the CP) F(1,22) = 3.65, p = 0.07] [main effect for Time in the pain 
sensitive group (before and after the CP) F(1,61) = 4.22, p < 0.05]. Participants were, in 
general, more sensitive to pressure-pain during residual motion sickness (M = 596.36 ± 
18.29) than during CP stimulation alone (M = 653.74 ± 22.91) [main effect for Condition 
F(1,83) = 14.34, p < 0.001]. 
As shown in Figure 4, ratings of forehead sharpness also differed between the two 
pain groups across the time course of the experiment [Condition x Time x Group   123 
interaction, F(2,166) = 4.33, p < 0.05]. In post hoc analyses of variance, ratings of 
sharpness remained unchanged in the pain insensitive group [main effect for Time (before, 
after and 2 min after the CP) F(2,44) = 1.40, not significant] whereas sharpness ratings 
decreased significantly in the pain sensitive group 2 min after the isolated CP [p < 0.01] 
[main effect for Time (before, after and 2 min after the CP) F(2,122) = 4.84, p < 0.01]. 
During residual motion sickness, forehead sensitivity to sharpness decreased immediately 
after the CP in the pain sensitive group [p < 0.001], followed by a further decrease 2 min 
later [p < 0.01] [main effect for Time (before, after and 2 min after the CP) F(2,122) = 
21.13, p < 0.001]. A decrease was also reported by the pain insensitive group albeit not 
until 2 min after the CP [p < 0.001] [main effect for Time (before, after and 2 min after the 
CP) F(2,44) = 10.84, p < 0.001]. No side differences to sharpness emerged at any time in 
either group or condition.  
 
Discussion 
   
  This study confirmed previous observations  that healthy people generally show 
little difference in sensitivity between the two sides of the forehead to pressure or sharpness 
[25]. In contrast, the majority of CRPS patients display ipsilateral forehead hyperalgesia 
[15]. Nonetheless, 9% of participants displayed differences to a similar extent as CRPS 
patients. 
  As central pain control appears to be disrupted in CRPS [10; 45], we wanted to 
assess whether disrupting pain control in healthy volunteers during residual motion 
sickness would result in a spread of sensitivity from a standard painful stimulus to the 
ipsilateral forehead. Scalp tenderness developed during residual motion sickness. 
Nevertheless, limb pain produced by cold water immersion did not induce ipsilateral   124 
forehead hyperalgesia. Instead, bilateral forehead analgesia both to pressure-pain and 
sharpness emerged after the CP, in particular in subjects who reported moderate to severe 
pain from the hand immersion. 
 
Remote analgesia to limb pain during residual motion sickness: evidence of diffuse noxious 
inhibitory controls (DNIC) and stress-induced analgesia (SIA)  
DNIC operates on the counter-irritation principle whereby one noxious stimulus 
inhibits another irrespective of body location [55]. The neurons that mediate DNIC 
originate in the subnucleus reticularis dorsalis of the caudal medulla [3] and inhibit wide 
dynamic range neurons in the trigeminal nucleus caudalis [8; 36] and dorsal horn [29; 35] 
via a supraspinal loop [28]. The DNIC effect has been reported following various 
conditioning stimuli (e.g. mechanical, electrical, ischemic) [4; 26; 38; 40; 59], in particular 
noxious cold [1; 4; 27; 30; 39; 56; 59; 61].  
The isolated CP may have activated DNIC, albeit weakly, in subjects who found the 
CP moderately or intensely painful. In participants who found the CP only mildly painful or 
not at all painful, forehead responses were similar to those during repeated forehead 
assessments (i.e., immediately decreased PPTs and unchanged sharpness sensations) [25].  
In contrast, the isolated CP decreased forehead sensitivity to sharpness and inhibited an 
immediate decrease in PPT in pain sensitive participants. As the pain sensitive group also 
experienced significantly greater distress from the CP than the pain insensitive group, SIA 
[2; 5; 17; 58] may have added to this inhibitory forehead response. Short term stress 
appears to activate non-opioid analgesia whereas longer term stress activates opioid 
analgesia [9; 31]. As the CP test lasted only 1 min, analgesia was probably mediated by a 
non-opioid mechanism in the present case.    125 
Contrary to expectations, the pain modulatory mechanisms of DNIC and SIA 
appeared to remain intact during residual motion sickness. The inhibitory response in the 
pain sensitive group was stronger, not weaker, during residual motion sickness in that 
forehead sensitivity both to pressure-pain and sharpness decreased immediately after the 
CP. The inhibitory effect probably was stronger during residual motion sickness than the 
CP alone because it was associated with a concurrent return of forehead sensitivity to 
baseline (after an increase following OKS) as motion sickness resolved.  
The isolated CP failed to inhibit pain sensitivity in the forehead in the group who 
perceived no or very little pain from the CP. This lack of inhibition was unrelated to age, 
gender or forehead sensitivity to pressure-pain prior to the study as these were similar in the 
two groups. However, sharpness ratings were lower in the pain insensitive group prior to 
testing, suggesting a higher degree of general pain tolerance in this group. Biological 
differences or better coping skills in pain insensitive than pain sensitive people may 
account for this difference [7; 18; 21]. Interestingly, the central release of endogenous 
opioids during cold water limb immersions was greater in pain insensitive individuals than 
pain sensitive individuals [42]. Perhaps such characteristics prevented the development of 
pain and distress from reaching a level sufficient to activate DNIC or SIA.  
 
Greater limb pain during residual motion sickness: disruption of tonic opioid release? 
Curiously, the pain insensitive group reported greater pain from the cold pressor 
during residual motion sickness than without. There is some evidence to support the 
existence of a tonically active opioid system in healthy individuals [16; 24]. For example, 
during sustained sadness, opioid activity decreases in the rostral anterior cingulate region in 
non-depressed controls [24]. It is tempting to speculate that motion sickness disrupted this 
system in pain-insensitive participants. Future research is needed to confirm this.   126 
Residual motion sickness and scalp tenderness 
Motion sickness results from a sensory mismatch between visual, vestibular and 
proprioceptive inputs [47]. During OKS, the mismatch between sitting still versus the 
perception of movement results in symptoms characteristic of motion sickness i.e. 
dizziness, nausea and headache [11; 22]. In the present study, OKS was employed to induce 
symptoms of motion sickness because this was found previously to increase forehead 
sensitivity to pressure applied with a pointed probe, at least in nauseated subjects [11]. The 
present study confirmed such findings of scalp tenderness both to blunt pressure and 
sharpness in association with symptoms of motion sickness. Consistent with previous 
findings, nausea was the symptom most consistently associated with the development of 
scalp tenderness. In addition, headache was weakly related to the development of scalp 
tenderness to sharpness, and dizziness to the development of scalp tenderness to pressure-
pain. Dizziness, nausea and headache are also characteristic of migraine [12], implying that 
scalp tenderness develops in conjunction with or in response to symptoms of migraine. 
Interestingly, susceptibility to motion sickness is greater than normal in migraine sufferers 
[23], and nausea is more likely to develop in response to OKS in migraine sufferers than 
controls [11].  
Drummond [14] speculated that failure of an inhibitory mechanism to suppress 
symptoms such as dizziness, nausea and headache increases vulnerability both to motion 
sickness and migraine. In the present study, DNIC and, perhaps non-opiate SIA, appeared 
to remain functional during residual motion sickness. The increase in cold-induced pain 
during residual motion sickness in the pain insensitive group suggests that motion sickness 
may instead be associated with disruption of a tonically active opioid system [16; 42]
 or 
with a direct increase in the excitability of central nociceptive circuits. 
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Dissociation between pressure and sharpness 
Sensitivity to pressure-pain and sharpness varied independently in the current study. 
Similar dissociation was observed previously to noxious cold water limb immersion in 
healthy subjects [25]. These sensations are also dissociated in CRPS [15] and in patients 
with thalamic lesions or central post-stroke pain [32; 41], who often display a loss of 
cutaneous sensation but a persistence or hypersensitivity to deep-pressure. Separate sensory 
pathways may thus be responsible for cutaneous versus deep-pressure sensations. Evidence 
that cutanenous nociceptors predominantly innervate laminas I and II of the dorsal horn 
[60] whereas nociceptors from deeper tissues project to laminas I and V [6; 34; 37] is 
consistent with this idea. Furthermore, superficial pain induces neural activity in different 
brain regions than pain of deeper origin [19].  
 
Limitations and conclusion 
Some limitations apply to the present study as it was performed during residual 
motion sickness, due to the impracticality of conducting forehead assessments during drum 
rotation. Replicating the study using other means of motion sickness induction, to allow for 
concurrent forehead assessments, may clarify any differences between peak and residual 
motion sickness. Nonetheless, this study confirmed previous findings of scalp tenderness 
both to pressure and sharpness during residual motion sickness. The mechanism underlying 
this hyperalgesia did not appear to involve disruption of DNIC or SIA. Cold water limb 
immersion failed to produce ipsilateral forehead hyperalgesia during residual motion 
sickness and can thus be ruled out as an appropriate model for the spread of ipsilateral 
hyperalgesia in CRPS.  
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Table 1  
Sex,  age,  mean  PPT  and  mean  sharpness  ratings  before  testing,  time  in  the  drum  and 
motion sickness symptoms in the pain insensitive and pain sensitive groups 
  Pain Insensitive  Pain Sensitive 
Males (n) 
Females (n) 
Age (years) ± SEM 
PPT (g) 
Sharpness (0 – 10)* 
Time in drum (min) 
Dizziness (0-10) 
Nausea (0-10) 
Headache (0-10) 
6 
17 
24.39 ± 1.49 
738.26 ± 43.19 
2.37 ± 0.32 
9.40 ± 0.34 
4.37 ± 0.55 
3.35 ± 0.57 
1.65 ± 0.42 
20 
42 
24.61 ± 1.09 
691.61 ± 26.30 
3.28 ± 0.20 
9.37 ± 0.23 
5.26 ± 0.26 
4.65 ± 0.37 
2.23 ± 0.30 
 
Sharpness was greater in the pain sensitive than pain insensitive group (* p < 0.05). No 
differences between the left and right sides of the forehead existed in either group. 
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Table 2 
Pearson’s correlations between changes in forehead sensitivity after OKS and the development of motion sickness 
 
 
 
 
 
*p < 0.05; **p < 0.01 
 
 
Change in mean forehead sensitivity after OKS  Change in motion sickness symptoms 
  Dizziness  Nausea  Headache 
PPT  -0.23*  -0.23*  -0.06 
Sharpness   0.10  0.28**  0.26* 137 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Motion sickness symptoms before and after OKS and the subsequent CP. All 
symptoms increased significantly after OKS (*** p < 0.001 all symptoms), followed by a 
significant decrease in severity immediately after the CP (*** p < 0.001 all symptoms). 
Error bars indicate standard errors.
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Fig. 2. Hand pain and distress ratings in the pain insensitive and the pain sensitive groups for 2 minutes after the CP during residual motion 
sickness and without. The pain insensitive group experienced more pain from the CP during residual motion sickness than without OKS (* p 
< 0.01) whereas no difference was detected in the pain sensitive group. Pain and distress had almost disappeared 2 minutes after the CP in 
both groups irrespective of motion sickness. Error bars represent standard errors.  
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Fig. 3. PPTs at times before and after the CP during and without residual motion sickness for the pain insensitive and pain sensitive groups. 
PPTs decreased in the pain insensitive group after the isolated CP (*** p < 0.001). This decrease was delayed in the pain sensitive group 
until 2 minutes after the CP (*p < 0.05). After OKS, PPTs decreased in both groups (*** p < 0.001). However, when the CP was 
subsequently induced, PPTs increased bilaterally (# p = 0.07; * p < 0.05). Errors bars represent standard errors. 
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Fig. 4. Sharpness ratings at times before and after the CP during and without residual motion sickness for the pain insensitive and pain 
sensitive groups. Sensitivity to sharpness decreased 2 min after the isolated CP in the pain sensitive group (** p < 0.01) but no change was 
seen in the pain insensitive group. After the OKS, sharpness ratings increased in both groups (*** p < 0.001), but decreased immediately 
after the CP in the pain sensitive group (*** p < 0.001) with a further decrease 2 min later (** p < 0.01). During residual motion sickness, 
the CP induced a reduction in sharpness ratings in the forehead in the pain insensitive group 2 min after the CP (*** p< 0.001). Error bars 
represent standard errors. 
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CHAPTER 7 
LIMB INFLAMMATION PRODUCES ANALGESIA TO 
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Abstract 
 
This study aimed to investigate the remote effects of topical capsaicin, an inflammatory 
agent, applied to the forearm on pain sensitivity in each side of the forehead in 17 healthy 
volunteers. Pressure-pain thresholds and sharpness sensations were assessed on each side of 
the forehead before and during 48 hours of capsaicin treatment. Heat was applied to the 
treated area to rekindle pain at times of assessment. Tests of sensation were also performed 
in the treated forearm and the contralateral forearm before and after 48 hours of treatment. 
Hyperalgesia to sharpness, but not pressure-pain, developed in the treated area whereas 
sensations remained stable in the contralateral forearm. Sharpness ratings decreased 
bilaterally in the forehead 6 hours after treatment, and an ipsilateral analgesia to pressure-
pain developed when the treated area was heated after 48 hours of treatment. No 
contralateral changes were observed for pressure-pain. Diffuse noxious inhibitory controls 
and stress-induced analgesia may account for the bilateral decrease in forehead analgesia to 
sharpness, whereas the ipsilateral forehead analgesia to pressure-pain may arise due to 
activation of coeruleospinal pain control. These findings suggest that pain modulation 
involves unilaterally extending mechanisms in addition to local and generalized controls. 
The dissociated changes to sharpness and pressure-pain indicate distinct cutaneous and 
deep central pain pathways.    144 
Introduction 
 
The present understanding of the perception of pain is that it is the end result of a 
number of inhibitory and facilitatory influences on nociceptive neurotransmission in the 
central nervous system. Some well-known mechanisms that may be activated in response to 
a painful stimulus are the gate-control response (Melzack and Wall, 1965; Basbaum and 
Fields, 1978), diffuse noxious inhibitory controls (Morton et al., 1987; Villanueva and Le 
Bars, 1995), stress-induced analgesia (Willer et al., 1981) and stress-induced hyperalgesia 
(Quintero et al., 2003). Also the locus coeruleus (LC) nuclei have been implicated in 
descending inhibitory control (Jones, 1991; Zhang et al., 1997). Apart from the gate-control 
effect which is concerned with pain perception locally, the remaining mechanisms are 
generally thought to exert widespread inhibitory or facilitatory influences.  
Findings are now beginning to emerge to challenge this concept of widespread 
inhibition and facilitation. In rats, unilateral carageenan inflammation of the hindpaw 
induced hyperalgesia, not just in the injected hindpaw, but also in the ipsilateral non-
inflamed forepaw four hours after the carageenan injection (Tsuruoka et al., 2004). This 
was not seen in the contralateral paws. Interestingly, the hyperalgesia in both the inflamed 
hindpaw and the ipsilateral forepaw was more severe in rats with bilateral LC lesions than 
in sham-operated rats, suggesting that an inhibitory influence, emanating from the LC, 
extended ipsilaterally.  
In humans, the effect of noxious stimulation on contralateral pain sensitivity has 
been studied over a range of stimulus modalities (e.g. thermal, electrical, ischemic) (Willer 
et al., 1984; Price and McHaffie, 1988; Kosek and Hansson, 1997) including brief 
inflammatory pain (Witting et al., 2000; Graven-Nielsen et al., 2002; de Tommaso et al., 
2007; Shenker et al., 2008; Gibson et al., 2009). However, to the best of our knowledge, the   145 
remote effect of a noxious stimulus on bilateral sensitivity to pain has been assessed in only 
two human studies. Unilateral tourniquet-induced left arm pain resulted in analgesia to 
pressure and heat which was similar in the left and right thigh in a sample of 18 participants 
(Tuveson et al., 2006). In a larger sample of participants, we reported bilateral analgesia to 
a sharp stimulus that was similar in the ipsilateral and contralateral forehead following 
cold-induced arm pain (Knudsen and Drummond, 2009). Analgesia to pressure-pain was 
also detected bilaterally in the forehead; however, this was more marked on the ipsilateral 
side suggesting that an inhibitory mechanism, perhaps coeruleospinal control, extended 
ipsilaterally. This finding was at odds with studies in rats that demonstrated hyperalgesia in 
the ipsilateral forepaw after hindpaw injection of the inflammatory agent carageenan 
(Tsuruoka et al., 2004), possibly because of differences in the stimulus modality (noxious 
cold versus inflammation) or duration of pain. 
In the present study, sensory testing was performed on each side of the forehead in 
healthy humans during prolonged (48 hour) treatment of the forearm with topical capsaicin, 
an inflammatory agent. The aim was to investigate the remote effects of unilateral 
inflammatory limb pain at ipsilateral and contralateral sites in healthy humans. 
 
Methods 
 
Subjects 
Seventeen healthy university students (3 males) with a median age of 27 years 
(range 18-41 years) participated in the study. Participants were excluded if they suffered 
from any medical problems including pain. Each participant provided written informed 
consent for the procedures, which were approved by the Murdoch University Human 
Research Ethics Committee.    146 
 
Procedures 
  Inflammatory hyperalgesia of the forearm. After cleaning the skin with alcohol, two 
13.5 cm
2 areas of the volar forearm were treated with the topical application of capsaicin 
cream (10% capsaicin dissolved in ethoxydiglycol and incorporated into a base of acetyl 
alcohol, stearic acid and fatty acid ester). The two areas were separated by 5 ± 2 cm with 
the lower area approximately 5 ± 2 cm from the wrist. The forearm on the non-dominant 
side of the body was treated in 50% of cases and the dominant forearm in the remaining 
cases. The capsaicin treatment was covered in bandages and left in place for 24 hours. The 
area of treatment was marked and a new amount of capsaicin was applied to the same 
cleaned skin for another 24 hours. A 45ºC heat pack was placed on the treated areas (on top 
of the bandages) to rekindle pain at times of sensory assessments. Heating capsaicin treated 
areas reliably rekindles capsaicin-induced sensitivity (Koltzenburg et al., 1992; Dirks et al., 
2003). Participants rated the pain intensity on a scale from 0 (no pain) to 10 (extremely 
severe pain) and also rated the distress associated with the pain in the forearm from 0 (no 
distress) to 10 (extremely severe distress).  
 
Sensory assessments. Pain thresholds to firm pressure (PPT) and the extent of 
sharpness produced by a firm nylon bristle were assessed in the two areas of capsaicin 
application and in the equivalent areas of the contralateral forearm as well as on each side 
of the forehead. Pressure was applied gradually at intervals of 200 g using a spring loaded 
algometer with a rounded tip (1 cm in diameter). This was done to a maximum of 2.3 kg or 
until the participant felt pain. The mean value in each forearm was assumed as the PPT for 
that arm. In the forehead, pressure was applied at 80 g increments (Knudsen and 
Drummond, 2009). In participants who did not experience pain at 2.3 kg in the forearm, a   147 
pressure-pain threshold of 2.3 kg was assumed. Sharpness was rated on a scale from 0 (not 
sharp) to 10 (stabbing) in response to a single application of the bristle (Filament 17, 
Senselab von Frey Aesthesiometer, Somedic Sales AB, Sweden). Sufficient force was 
applied to bend the bristle for 1 s (Knudsen and Drummond, 2009). Again the values 
obtained from the two sites in each forearm were averaged. The order of assessments was 
randomised between subjects to exclude order or time effects, but was kept constant within 
each subject to ensure that any change in sensitivity was not due to a change in the order of 
assessments. 
 
Trial sequence. Participants were examined five times over a 48 hour period. In the 
morning of day one, sensory assessments were conducted at all sites before the first 
capsaicin application. In the afternoon (median time after application 6 hours, range 5.5-8 
hours), sensory assessments were repeated in the forehead before and during heat 
stimulation. Participants reported the maximum pain and associated distress experienced 
since the previous session in addition to pain and distress levels before and during heat 
stimulation. These procedures were repeated the following morning (median time after 
application 24 hours, range 23-25.5 hours) before the capsaicin was re-applied, and were 
performed again in the afternoon (median time after application 30 hours, range 29.5-32 
hours). These procedures were also conducted in the morning of day three (median time 
after application 48 hours, range 46-49.5 hours) after which the capsaicin was removed and 
a final assessment of sensitivity was performed at all sites in the arm and forehead.  
 
Statistical analysis. Student’s t-tests were used to assess side differences in forehead 
sensitivity to pressure-pain and sharpness prior to testing as well as to assess differences in 
pain and distress responses between the two capsaicin applications. The extent of pain and   148 
distress from the capsaicin and heat stimulation were investigated in Heating (before and 
during heating of the capsaicin-treated skin) x Time (the five assessments) analyses of 
variance. Side (treated forearm, untreated forearm) x Time (before capsaicin, after removal 
of capsaicin) analyses of variance for PPT and sharpness ratings assessed the development 
of hyperalgesia in the treated forearm. The influence of heating the capsaicin-treated skin 
on forehead sensations was investigated in Side (ipsilateral or contralateral to the capsaicin 
application) x Time (the five repeated measures) x Heating (before and during heating of 
the capsaicin-treated skin) analyses of variance for PPT and sharpness ratings. The Huynh-
Feldt epsilon was used to correct for violations of sphericity. Changes across time points 
were investigated with simple contrasts, and student’s t-tests or analyses of variance were 
used as appropriate for post hoc analyses. In addition, Pearson’s correlations were 
performed between pain, distress ratings, sensations in the capsaicin-treated forearm 
(compared with the contralateral forearm) and changes in forehead sensitivity from before 
to after 48 hours of capsaicin treatment, to investigate whether the changes in forehead 
sensitivity were related to the pain intensity, distress and hyperalgesia caused by the 
capsaicin. Data are reported as the mean ± standard error of the mean. 
 
Results 
 
Symmetry of forehead sensations prior to capsaicin treatment 
The absolute difference between the right and left side of the forehead to pressure-
pain upon commencement of the experiment was 80 g or less in the majority of participants 
(88%) (range 0-200 g). There was no difference in 36% of participants. In the group as a 
whole, PPTs did not differ between the two sides [Mright = 637.60 ± 31.84 g, Mleft = 652.00 
± 30.64 g, t(24) = 0.86, not significant]. The absolute difference in sharp sensations   149 
between the right and left side of the forehead was a rating of 1 or less in 96% of 
participants (range 0-4) with 52% reporting no difference in sensitivity to sharpness. The 
difference was not statistically significant [Mright = 2.34 ± 0.40, Mleft = 2.71 ± 0.38, t(24) = 
1.91, not significant]. 
 
Pain and distress from the capsaicin 
  A burning pain marked by a red flare developed in all participants. The most severe 
pain was reported by participants after the first application of capsaicin (M = 7.53 ± 0.46) 
with slightly less severe pain after the second application (M = 6.65 ± 0.62) [t(16) = 2.11, p 
< 0.05]. However, the two applications produced similar distress [Mfirst = 5.09 ± 0.73, 
Msecond = 4.38 ± 0.83, t(16) = 1.54, not significant]. The pain peaked 5-6 hours after each 
application [Mfirst = 6.01 ± 1.72 hours, Msecond = 4.62 ± 1.26 hours, t(16) = 0.70, not 
significant]. 
 
The pain immediately before each assessment was significantly lower (M = 2.63 ± 
0.64) than the most severe pain reported (Mfirst and second application = 7.09 ± 0.50) [t(16) = 8.31, 
p < 0.001]. Nonetheless, the heat stimulation successfully rekindled the pain (M = 6.47 ± 
0.42) [main effect for Heating F(1,16) = 95.10, p < 0.001] to a level similar to the most 
severe pain. Interestingly, a significant interaction between time and heating [F(3,48) = 
4.85, p < 0.01] revealed that the heat was less successful at rekindling pain after 48 hours of 
capsaicin than during previous sessions [p < 0.01] (Fig. 1). No difference in the pain 
immediately before heat stimulation was observed across sessions (Fig. 1).  
Distress ratings were also lower before each session (M = 1.86 ± 0.64) compared to 
when the pain was most severe (Mfirst and second application = 4.74 ± 0.74) [t(16) = 5.02, p < 
0.001]. However, heat stimulation similarly rekindled distress (M = 4.30 ± 0.72) [main   150 
effect for Heating F(1,16) = 38.51, p < 0.001] to a level equivalent to when the pain was 
worst. Again a significant interaction between time and heating [F(1.95,31.20) = 6.39, p < 
0.01] revealed that the heat was less successful at inducing distress after 48 hours of 
capsaicin compared to previous sessions [p < 0.01] (Fig. 1). The distress during 
assessments without heat stimulation was similar across all sessions (Fig. 1). 
 
Primary hyperalgesia following capsaicin 
  As shown in Figure 2, PPTs were similar in the two forearms [main effect for Side 
F(1,16) = 0.67, not significant] and were unchanged in both forearms from before to after 
removal of the capsaicin 48 hours later [main effect for Time F(1,16) = 1.07, not 
significant, Time x Side interaction F(1,16) = 3.37, not significant]. Sharpness ratings were 
also similar in the two forearms before capsaicin treatment, but increased in the treated 
forearm [t(16) = 2.83, p < 0.05], and not in the untreated forearm, after removal of the 
capsaicin (Fig. 2) [Time x Side interaction F(1,16) = 9.85, p < 0.01]. This resulted in a 
greater sensitivity to sharpness in the treated than the untreated forearm at this time [t(16) = 
3.54, p < 0.01], consistent with the development of primary hyperalgesia to punctate stimuli 
(Kilo et al., 1994).  
 
Change in forehead sensations to the capsaicin 
  As shown in Figure 3, heating the capsaicin-treated skin altered forehead sensitivity 
to pressure-pain [Side x Time x Heating interaction F(4,64) = 4.07, p < 0.01]. Investigation 
of this interaction revealed that PPTs were unchanged across sessions when sensory 
assessments were performed without the application of heat (main effect for Time F(4,64) 
= 1.71, not significant], although a trend of an increase in PPTs was apparent. This was the 
case for both sides of the forehead [Time x Side interaction F(4,64) = 1.44, not significant].   151 
However, when the pain was rekindled by heat, a significant interaction between time and 
side tested emerged [F(4,64) = 5.86, p < 0.001]. After 48 hours of capsaicin, participants 
reported a significant increase in PPTs in the ipsilateral forehead compared to baseline [p < 
0.01] [main effect for Time (ipsilateral forehead) F(4,64) = 5.49, p < 0.01]. This resulted in 
significantly higher PPTs in the ipsilateral forehead compared with the contralateral 
forehead at this time [t(16) = 3.28, p < 0.01]. PPTs did not change significantly in the 
contralateral side of the forehead [main effect for Time F(4,64) = 0.82, not significant].  
Sharpness sensations decreased in the forehead after 6 hours of capsaicin [p < 0.01] 
and remained at this level for the duration of the study [main effect for Time F(1.96,31.32) 
= 9.11, p < 0.01] (Fig. 4). This occurred irrespective of heat stimulation [Heating x Time 
interaction F(4,64) = 0.69, not significant] and to the same extent on both sides of the 
forehead [Heating x Time x Side interaction F(2.03,32.45) = 0.53, not significant]. 
Sharpness sensations were similar during assessments with and without heat stimulation 
[main effect for Heating F(1,16) = 2.22, not significant].  
 
Were changes in forehead sensitivity related to pain intensity, distress and hyperalgesia? 
Individual changes in forehead sensitivity to pressure-pain from before to after 48 
hours of capsaicin generally appeared to be unrelated to pain, distress or sensations in the 
capsaicin-treated forearm (Table 1). On the other hand, the development of bilateral 
analgesia to sharpness, which persisted after 48 hours of capsaicin treatment, appeared to 
be related to greater pain and distress irrespective of heat stimulation.  
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Discussion 
 
The aim of this study was to investigate the remote effects of unilateral 
inflammatory limb pain at ipsilateral and contralateral sites in healthy humans. We detected 
bilateral forehead analgesia to sharpness and ipsilateral forehead analgesia to pressure-pain. 
Capsaicin causes an inflammatory response by releasing vasoactive peptides such as 
substance P and calcitonin gene-related peptide (CGRP) from the peripheral endings of 
primary afferent fibers (Holzer, 1988; Maggi and Meli, 1988; Saria et al., 1988). It initially 
excites (Kenins, 1982; Szolcsanyi, 1988) and sensitizes C nociceptors (Szolcsanyi, 1977; 
Baumann et al., 1991). Consistent with inflammation, a red flare (Carpenter and Lynn, 
1981; Culp et al., 1989; Mohammadian et al., 1998), burning pain and primary hyperalgesia 
to punctate (sharp) stimulation (Kilo et al., 1994) developed in the capsaicin-treated 
forearm. However, hyperalgesia to pressure-pain was absent in the treated area after 48 
hours of treatment, possibly because the capsaicin did not penetrate to nociceptors in deeper 
tissue or because of C-fiber desensitization to the capsaicin treatment (Lynn, 1990; Pini et 
al., 1990; Nagy et al., 1993). In support of the second possibility, hyperalgesia to heat 
decreased across the period of capsaicin treatment. Capsaicin-induced sensitivity to heat is 
mediated by sensitization of C fiber mechano-heat nociceptors (Konietzny and Hensel, 
1983; LaMotte et al., 1992), and C fibers mediate capsaicin-induced pressure hyperalgesia 
(Culp et al., 1989). Only one participant failed to report pain below maximum pressure at 
the treated site thus tolerance levels above maximum pressure is unlikely to have masked a 
decrease in pressure-pain thresholds at this site. Interestingly, hyperalgesia to sharp stimuli 
persisted despite signs of desensitization to heat possibly because Aʴ fibers signal 
sharpness hyperalgesia with only a minor contribution from C fibers (Ali et al., 2000;   153 
Fitzek et al., 2001) or because hyperalgesia to sharpness was maintained by central 
sensitization (Kilo et al., 1994). 
When triggered by nociceptive stimuli, DNIC inhibit the activity of wide dynamic 
range neurons in the dorsal horn (Le Bars et al., 1979a; Morton et al., 1987) and in the 
trigeminal nucleus caudalis (Dickenson et al., 1980; Murase and Kawakita, 2000) via a 
supraspinal loop (Le Bars et al., 1979b; Cadden et al., 1983) evident by a reduction in pain 
sensitivity remote from the inciting stimulus. This effect was demonstrated to a range of 
conditioning stimuli (e.g., thermal, mechanical, electrical and ischemic) (Pertovaara et al., 
1982; Willer et al., 1984; Price and McHaffie, 1988; Kosek and Hansson, 1997; Bouhassira 
et al., 2003; Tuveson et al., 2006; Knudsen and Drummond, 2009) including capsaicin-
induced pain (de Tommaso et al., 2007; Gibson et al., 2009). The inhibitory action of DNIC 
is widespread rather than localised. In rats, bilateral DNIC effects were recorded from wide 
dynamic range neurons in the spinal cord and trigeminal nucleus caudalis following hot 
water immersion of tail, muscle and paws (Bouhassira et al., 1990; Bouhassira et al., 1992). 
In humans, analgesia developed bilaterally to pressure in the thighs during tourniquet-
induced arm pain (Tuveson et al., 2006) and to sharp sensations in the forehead during 
cold-induced hand pain (Knudsen and Drummond, 2009). Thus, DNIC probably accounted 
for the bilateral forehead analgesia to sharp stimuli in the present study.  
Whether the extent of DNIC is related to the intensity of pain induced by the 
conditioning stimulus is uncertain (Lautenbacher et al., 2002; Le Bars, 2002; Baad-Hansen 
et al., 2005; Pud et al., 2005; Granot et al., 2008). However, general agreement exists that 
the intensity of the conditioning stimulus, albeit not necessarily the perceived intensity, is 
important in determining the DNIC outcome. The present study lends support for a 
relationship between the extent of DNIC and perceived pain as forehead analgesia to   154 
sharpness was greater in those experiencing more pain. This is consistent with a previous 
study by our group (Knudsen and Drummond, 2009). 
Stress-induced analgesia (SIA) may also have contributed to the bilateral forehead 
analgesia to sharpness. The well-documented generalised inhibitory effects of stress and 
anxiety (Chesher and Chan, 1977; Willer et al., 1981; Bandura et al., 1988; Gamaro et al., 
1998) are mediated both by non-opioid and opioid mechanisms (Spiaggia et al., 1979; 
Watkins and Mayer, 1982; Tierney et al., 1991). Distress was associated with greater 
forehead analgesia to sharpness in the present study, providing support for an involvement 
of SIA in concert with DNIC. In a previous study in our laboratory, these two mechanisms 
also appeared to operate jointly following cold-induced limb pain, which caused  bilateral 
forehead analgesia both to pressure and sharpness in association with pain and distress 
(Knudsen and Drummond, 2009).  
Curiously, sensitivity to sharpness was not reduced in the contralateral forearm. 
Both contralateral hyperalgesia (Shenker et al., 2008) and contralateral analgesia (Graven-
Nielsen et al., 2002; Gibson et al., 2009) were previously reported in response to capsaicin. 
Perhaps the lack of change in sensitivity to sharpness in the contralateral forearm reflects a 
competitive balance between excitatory and inhibitory processes. Many neurons in lamina 
VII of the spinal cord respond to noxious stimulation from either side of the body 
(Basbaum and Jessell, 2000), providing a possible location for a convergence between 
excitatory signals from the treated and contralateral forearm. 
Ipsilateral forehead analgesia to pressure-pain developed in the present study. A 
similar response developed acutely during cold-induced limb pain (Knudsen and 
Drummond, 2009). The mechanism underlying this analgesic response is uncertain, but 
might involve coeruleospinal pain modulation (Knudsen and Drummond, 2009). The locus 
coeruleus (LC) inhibits nociceptive activity in dorsal horn neurons (Jones and Gebhart,   155 
1986b) via bilateral noradrenergic projections (Westlund et al., 1983; Fritschy and Grzanna, 
1990; Clark et al., 1991; Clark and Proudfit, 1992; Sluka and Westlund, 1992) to all 
segmental levels of the spinal cord (Proudfit and Clark, 1991). It does so via actions at ʱ2-
adrenoceptors (Jones and Gebhart, 1986a; 1986b). During unilateral hindpaw inflammation 
of rats, noradrenaline was released in the ipsilateral dorsal horn but not contralaterally 
(Tsuruoka et al., 1999). Tsuruoka et al. (2004) found shorter paw withdrawal latencies to 
heat not only in the inflamed hindpaw but also in the non-inflamed but hyperalgesic 
forepaw of rats with bilateral LC lesions compared to sham operated rats. As this was not 
observed in the contralateral hind- or forepaw, coeruleospinal pain modulation appeared to 
inhibit hyperexcitable nociceptive dorsal horn neuron activity ipsilaterally. Hence, this 
mechanism may have contributed to the development of ipsilateral forehead analgesia to 
pressure-pain in human studies, both during inflammation and to cold-induced pain 
(Knudsen and Drummond, 2009).  
Why an ipsilateral spread of hyperalgesia developed during intramuscular 
carageenan-induced hindpaw inflammation in the rat (Tsuruoka et al., 2004), but not during 
topical capsaicin treatment in humans, is unclear. The two chemicals appear to exert their 
effects via similar mechanisms (activation and sensitization of C fibers) (Kocher et al., 
1987; Baumann et al., 1991). Both an excitatory and a less dominant anti-nociceptive 
component were present during carageenan-induced hindpaw inflammation (Tsuruoka et 
al., 2004). It is tempting to speculate that the inhibitory component outweighed the 
facilitatory component during capsaicin-induced inflammation in the present study.  
Alternatively, the difference might lie in the tissue affected (predominantly muscle 
in the rat studies and skin in the human studies). Indeed, an accumulating body of evidence 
suggests that pain from muscle and skin are processed differently. Intramuscular capsaicin 
injections induce a greater area of referred pain than intradermal capsaicin in healthy   156 
humans (Witting et al., 2000) and brief low frequency input from C fibers in the muscle are 
more effective at producing a prolonged increase in the excitability of the flexion reflex 
(central sensitization) than cutaneous C fibers (Wall and Woolf, 1984). In some clinical 
populations (thalamic lesions, central post-stroke pain, complex regional pain syndrome), a 
loss of cutaneous sensation co-exists with the persistence or increase in pain to deep 
pressure (Riddoch, 1938; Mailis and Bennett, 2002; Drummond and Finch, 2006). 
Nociceptors from cutaneous tissue primarily innervate laminas I and II (Willis and 
Coggeshall, 1991) whereas muscle afferents predominantly project to laminas I and V 
(Craig et al., 1988; Mense and Craig, 1988; Ohtori et al., 2000). Moreover, different areas 
in the brain appear to be activated in response to cutaneous pain versus pain of deeper 
origin (Henderson et al., 2006). The dissociation between sharpness and pressure-pain 
sensations to conditioning stimuli in the present and a previous study (Knudsen and 
Drummond, 2009) provides further support for different central processing of skin and deep 
tissue sensibility.  
Interestingly, some discrepancies appeared between the remote effects of 
inflammatory pain (the present study) and cold-induced pain in our previous study 
(Knudsen and Drummond, 2009). During cold-induced limb pain, pressure-pain sensitivity 
in the forehead decreased bilaterally, although the ipsilateral reduction was greater than the 
contralateral reduction (Knudsen and Drummond, 2009). The reason for the lack of the 
bilateral component to pressure-pain in the present study may lie in the sensitization of C 
fibers during capsaicin treatment (Baumann et al., 1991) which increases the input of C 
fibers to the dorsal horn. Repeated or persistent C fiber input to the dorsal horn has been 
associated with central sensitization – an enhanced response in dorsal horn neurons to 
normal input (Wall and Woolf, 1984; Woolf and Wall, 1986). This mechanism may 
underlie referred pain (Graven-Nielsen et al., 2002). Perhaps an enhanced response of   157 
dorsal horn neurons to input from C fibers competed with inhibitory mechanisms at remote 
sites, resulting in a lack of change in sensitivity to pressure-pain remotely for most of the 
study. When C fiber desensitization began peripherally in the treated area, input to the 
spinal cord (and perhaps the sensitization of central dorsal horn neurons) may have 
decreased enough to shift the equilibrium toward analgesia in the ipsilateral forehead. 
Clearly more research is needed to investigate this possibility. 
The time course of the forehead changes also varied greatly between the two studies 
(minutes in the cold pressor study and hours in the present study). The size or depth of the 
tissue affected (the entire hand in the cold pressor versus a small area of skin on the 
forearm in the capsaicin study) could underlie such differences. 
The present study was performed in a young, educated and predominantly female 
population and thus may not be entirely representative of the general population. 
Nonetheless, the results replicate findings of activation of bilateral and ipsilateral pain 
inhibitory mechanisms following painful conditioning or inflammatory stimuli (Tsuruoka et 
al., 2004; Tuveson et al., 2006; Knudsen and Drummond, 2009). DNIC and SIA probably 
accounted for the development of bilateral analgesia to sharpness, whereas coeruleospinal 
pain modulation may have been involved in the ipsilateral analgesia to pressure-pain. These 
findings lend support to an increasing body of research that suggests that pain modulation 
involves unilaterally extending mechanisms in addition to local and generalized controls. 
Patients with complex regional pain syndrome experience hyperalgesia in the affected limb 
which often extends to the ipsilateral forehead (Drummond and Finch, 2006). Further 
elucidation of the inhibitory and facilitatory mechanisms that modulate ipsilateral pain 
processing may help to clarify the pathophysiology of this poorly understood condition.  
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Table 1 
Pearson’s correlations between pain, distress and hyperalgesia in the capsaicin-treated forearm (compared with the contralateral forearm) at 
48 hours of capsaicin treatment and changes in forehead sensations (mean, asymmetry between the side ipsilateral and contralateral to 
treatment) from before to after 48 hours of capsaicin treatment 
 
# p < 0.09; * p < 0.05; ** p < 0.01 
  Changes in forehead sensations 
  Pressure-pain     Sharpness 
  No heat  Heat    No heat  Heat 
Treated forearm  Mean  Asymmetry  Mean  Asymmetry     Mean  Asymmetry  Mean  Asymmetry 
Pain  0.07  -0.45
#  0.07  0.12     -0.43
#  0.09  -0.50**  0.23 
Distress  0.15  -0.35  0.09  0.02    -0.50*  0.09  -0.57
*  0.14 
 
                   
Pressure hyperalgesia  -0.17  0.23  -0.02  -0.18    -0.32  -0.22  -0.13  -0.21 
Sharpness hyperalgesia  - 0.18   -0.02   -0.09  -0.01      0.39  -0.14  0.25  -0.18  
168
 
 
 
 
 
 
 
 
 
 
Fig.1. Forearm pain and distress ratings for 48 hours during capsaicin stimulation and at times of heat stimulation. Heat was less successful 
at rekindling pain and distress after 48 hours of treatment compared to previous sessions (** p < 0.01). Error bars represent standard errors 
and the arrow represents the initial application of capsaicin. 
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Fig. 2. PPTs and sharpness ratings for the capsaicin-treated and untreated forearm before and after 48 hours of capsaicin. PPTs did not 
change in either forearm whereas sharpness ratings increased in the treated (* p < 0.05) but not the untreated forearm resulting in greater 
sensitivity to sharpness in the treated than the untreated forearm (** p < 0.01). Error bars represent standard errors. 
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Fig. 3. PPTs for sides of the forehead ipsilateral and contralateral to the capsaicin-treated forearm before and for 48 hours during treatment 
and during times of heat stimulation. PPTs increased significantly in the ipsilateral forehead after 48 hours of treatment (** p < 0.01) 
resulting in greater PPTs in the ipsilateral than contralateral forehead (** p < 0.01). Error bars represent standard errors and the arrow 
represents the initial application of capsaicin. 
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Fig. 4. Sharpness ratings for sides of the forehead ipsilateral and contralateral to the capsaicin-treated forearm before and for 48 hours during 
treatment and during heat stimulation.  Sharpness ratings decreased bilaterally after 6 hours of treatment (** p < 0.01) and remained at this 
level for the duration of the study. Error bars represent standard errors and the arrow represents the initial application of capsaicin. 
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Abstract 
 
A double-blind placebo-controlled crossover trial was used to determine the effects of 
topical ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, on sensory 
disturbances in 20 patients with complex regional pain syndrome (CRPS). On two 
occasions separated by at least one week, sensory tests to light touch, pressure, punctate 
stimulation, light brushing and thermal stimuli were performed in the symptomatic and 
contralateral limb and on each side of the forehead before and 30 minutes after 10% 
ketamine cream was applied to the symptomatic or healthy limb. Venous blood for 
plasma estimations of ketamine and norketamine was obtained one hour after 
application of the creams. Ketamine applied to the symptomatic limb inhibited allodynia 
to light brushing and hyperalgesia to punctate stimulation. Systemic effects of the 
ketamine are unlikely to account for this as plasma levels were below detectable limits. 
As touch thresholds were unchanged, NMDA receptors may contribute to sensory 
disturbances in CRPS via actions at cutaneous nociceptors. Allodynia and hyperalgesia 
were detected in the ipsilateral forehead to a range of stimuli (brushing, pressure, 
punctate stimulation, cold, heat, warmth). In several patients, ketamine treatment of the 
symptomatic limb inhibited allodynia to brushing the ipsilateral forehead, suggesting 
that the mechanism that mediates allodynia in the symptomatic limb contributed to 
allodynia at more remote sites. The present study shows promise for the use of topical 
ketamine as opposed to parenteral and oral forms which often result in undesirable side 
effects.    174 
Introduction 
 
Complex regional pain syndrome (CRPS) can develop after apparently trivial 
injury and is often associated with widespread sensory disturbances [21, 64, 77]. 
Unfortunately, the treatment of neuropathic pain states, including CRPS, remains a 
significant challenge [19]. Moreover, many of the commonly used orally administered 
drugs can cause significant central side effects such as somnolence and cognitive 
impairment with loss of patient compliance [30; 33]. A number of topical applications 
have been tried for neuropathic pain states, targeting peripheral receptor systems and 
pain mediators, but with mixed success [16; 17; 36; 39; 40; 41; 47; 48; 53; 59; 79; 84; 
89; 94; 97]. 
Glutamatergic mechanisms are widely involved in excitatory neurotransmission, 
including nociception [7; 68; 88]. Of particular importance is the involvement of N-
methyl-D-aspartate (NMDA) receptors in chronic pain states, including CRPS. As all 
major groups of glutamate receptor are found on nerve fibres in peripheral tissues [10], it 
would appear logical to attempt local peripheral block of NMDA receptors to reduce 
allodynia in CRPS.  The general anaesthetic agent ketamine [18], and its major 
metabolite norketamine, have a significant non-competitive blocking action on NMDA 
receptors [1; 24]. Subanaesthetic dosage of ketamine provides worthwhile analgesia both 
in acute, postoperative and chronic pain states [4]. Trials of the use of ketamine in the 
treatment of neuropathic pain states have largely revolved around its intravenous 
administration [2; 3; 5; 11; 25-27; 29; 34; 37; 42; 49-51; 54; 69; 71; 80; 82; 93] but 
intramuscular [35] and subcutaneous infusions have also been tried [25; 67; 70]. 
Alternative routes of administration have included epidural [85], intrathecal [96], 
placement adjacent to the sympathetic chain [83], oral [15; 31; 75; 91] and topical 
application [12; 32; 41; 57; 60; 61; 73; 74; 81; 90]. Several randomised, double-blind,   175 
placebo-controlled studies have reported on the reduction of allodynia following 
intravenous administration of ketamine [7; 25; 28; 29; 65] but literature on the topical 
use of ketamine is particularly sparse, mostly comprising case studies. To our 
knowledge, only one group has reported the effects of topical ketamine on pain and 
hyperalgesia in a double-blind, placebo-controlled trial. In this study neither ketamine 
1% nor amitriptyline 2%, either separately or combined, were effective in patients with 
neuropathic pain, possibly because drug concentrations were suboptimal [60].  
Topical administration aims to deposit drugs with localised activity in the outer 
layers of skin, thus minimizing systemic absorption and reducing unwanted central side 
effects [78]. For ketamine, these include vivid dreaming, dysphoria and alteration of 
cognition. The aim of the current study was to investigate the sensory effects of topical 
ketamine 10% in CRPS, particularly on allodynia. A double-blind placebo-controlled 
trial was used with simultaneous plasma estimations of ketamine and its principal 
metabolite. Sensory effects were investigated in the CRPS-affected limb and also in the 
forehead, to determine if the effects of ketamine were restricted to the site of application 
or whether topical ketamine also impeded the hemilateral sensory disturbances 
associated with CRPS [21]. 
 
Materials and Methods 
 
Participants 
Twenty sequential patients with features of CRPS (6 males, 14 females), 
attending a small private pain medicine centre, were studied. Each patient met the 
diagnostic criteria for CRPS [43] and the majority (17) met the more stringent criteria by 
Harden et al. [38]. Twelve had developed CRPS in an upper limb and eight in a lower 
limb. CRPS had developed after fractures (5 patients), soft tissue injury, or sprain (6 
patients), surgery or needle insertion (3 patients). Four patients had developed pain   176 
following infection, clotting, electric shock or anaphylactic reaction. In all, eighteen 
patients were classified CRPS Type 1 and two patients were classified CRPS Type 2 
following direct injuries to an ulnar nerve. The pain had persisted for 2 months to 19.2 
years (median duration 18 months). Sensory, autonomic and motor disturbances were 
reported by patients and noted during the initial physical examination (Table 1). Sensory 
disturbances to punctate stimulation and brushing in the symptomatic and healthy limbs 
were determined using the standard tests of sensation described below. The temperature 
of the first phalanx of each toe was determined in lower limb CRPS patients, whilst the 
equivalent was obtained in the fingers of patients with upper limb pain, using an infrared 
skin thermometer (Tempett IR Thermometer, Somedic Sales AB, Sweden) after the 
patient had rested quietly for at least 20 minutes in a room maintained at 20 ± 2°C. The 
Murdoch University Human Research Ethics Committee approved the study and written 
informed consent was obtained from each participant. 
 
Sensory testing 
All assessments were performed by the same examiner (LK) on the most 
hyperalgesic dorsal aspect of the symptomatic limb (lateral or medial hand or foot), as 
determined at the initial examination. Testing was performed at only one site in each 
limb to limit the duration of testing and thus decrease any effects of fatigue. If 
hyperalgesia did not differ between the lateral and medial sites, the lateral site was 
selected. The equivalent site was tested in the contralateral limb. Sensory testing was 
also conducted on each side of the forehead to determine remote effects of the ketamine. 
 
Light touch. Threshold to touch was estimated by using thin Von Frey filaments 
(Senselab Aesthesiometer, Somedic Sales AB, Sweden). With closed eyes, patients 
indicated the site of stimulation on the symptomatic or healthy limb, once a sensation   177 
was detected. The assessment started with mid-range filaments and thicker or thinner 
filaments were applied as required, until the detection threshold was established for each 
site. When detection was missed on at least two of three touches, this was determined to 
be at a level below the threshold for light touch. Participants were required to make 
similar distinctions for each side of the forehead. 
 
Pressure-pain thresholds. Pressure-pain thresholds (PPT) were assessed with a 
rounded-tip (1 cm diameter) spring-loaded algometer [22]. Force was applied to each 
limb in increments of 200 gm to a maximum of 2.3 kg or until pain was reported. In the 
forehead, force was applied in 80 gm increments on each side. Some patients did not 
perceive pain at 2.3 kg. For these participants, a value of 2.3 kg was recorded as the 
pressure-pain threshold. 
 
Punctate stimulation. Sharpness was rated at each site in response to a single 
application of a firm nylon bristle (Filament 17, Senselab von Frey Aesthesiometer, 
Somedic Sales AB, Sweden), which was tolerated by all patients. Ratings were given on 
a scale from 0 (not sharp) to 10 (stabbing). Sufficient force was applied to bend the 
bristle for 1 second. Wind-up to punctuate stimulation was investigated with three 
repeated applications of the bristle at 1-second intervals. The sharpness from the final 
application was recorded. 
 
Sensations evoked by light brushing. Light stroking with a small brush (3-4 
strokes backwards and forwards) was rated at each site as a normal or abnormal 
sensation. When the brushing evoked an abnormal sensation, participants gave a 
qualitative description of that sensation. Sensations with an element of pain (e.g., sharp, 
scratching, or uncomfortable sensations) were categorised as allodynia. Because of their   178 
disparate quality, patients were not asked to rate the intensity of these sensations. Dull or 
numb sensations to brushing were also noted by two patients (Table 1) but were not 
regarded as allodynia. 
 
Thermal thresholds. A thermal stimulator with a 2 cm diameter circular 
stimulating area operating on the Peltier principle was used to determine thermal 
thresholds. The contact probe was applied at a thermoneutral starting temperature of 
32°C. The probe temperature was increased or decreased at a rate of 0.5 °C/sec to a 
maximum of 50°C or a minimum of 5°C. The following stimuli were presented 
sequentially: decreasing probe temperature until a cold sensation was detected; 
increasing probe temperature until a warm sensation was detected; decreasing probe 
temperature to the cold pain threshold; and increasing probe temperature to the heat pain 
threshold. For determination of cold and warm sensory thresholds, the subject was 
instructed to report as soon as a change of temperature was detected. For cold pain and 
heat pain thresholds, the subject was instructed to signal the first instance of pain. Some 
subjects did not detect cold pain sensations at 5°C; for these a value of 5°C was assumed 
as the cold pain threshold. Similarly, a heat pain threshold of 50°C was recorded for 
those who did not perceive heat pain at 50°C. Stimulation was rotated between each site 
until all sites had been tested two to four times (two assessments were considered 
sufficient if differences between presentations were equal to or less than 0.2°C). The 
average of the values for each sensation was considered to be the detection threshold for 
that sensation. 
 
Topical ketamine and placebo. Absorption of topical agents can be influenced by 
vehicle composition [13]. Pluronic lecithin organogel (PLO), a microemulsion-based 
gel, was used in the composition of the cream to assist penetration of the stratum   179 
corneum of the skin. It is a stable compound that shows no harmful effects when applied 
for prolonged periods [20; 46; 95].  The racemic form of ketamine hydrochloride 10% in 
PLO was used in the ketamine cream (Professional Compounding Centers of America, 
9901 South Wilcrest, Houston, Texas, USA). The placebo contained the same PLO 
vehicle but without the addition of ketamine or any other active ingredient. The two 
creams were physically indistinguishable to patients and experimenters alike. A 
subgroup of patients (N = 5) attempted to identify the active cream following the trial 
but did so at a rate no better than chance. The 10% concentration of ketamine was 
chosen on the basis of pilot tests. For each patient, the active and placebo creams were 
randomly labelled A or B by the compounding pharmacist. Throughout the trial, access 
to the randomisation codes was available only to the pharmacist. One of the 
investigators (LK) applied 0.5 ml of either A or B cream to the symptomatic limb while 
0.5 ml of the other cream was applied to the healthy limb. The amount of cream was 
restricted to minimise any systemic effects but was usually enough to cover the area of 
testing on the dorsum of the hand or foot as well as the neighbouring medial or lateral 
side of the appendage.  
 
Blood samples. Venous blood was drawn 1 hour after the application of both  
 
topical agents for the first 10 patients during their initial trial. The blood was  
 
centrifuged for 10 minutes and the plasma was subsequently stored at -20°C until it  
 
was analysed for concentrations of ketamine and its main metabolite, norketamine  
 
[8]. 
 
 
Assay of ketamine and norketamine by high performance liquid 
chromatography. Plasma (1 ml) was spiked with ephedrine as an internal standard, 
alkalinised with NaOH, and extracted with t-butyl methyl ether. The organic phase was 
back extracted into 0.05M HCl and aliquots of the HCl phase were injected onto the   180 
HPLC column. Separation was performed on a Merck Chromolith
® Performance 
column (100 mm x 4.6 mm id) using a mobile phase of 6% v/v acetonitrile in 50 mM 
K2HPO4 adjusted to pH 2.5 with H3PO4.  The mobile phase was pumped at 2.5 mL/min 
and analytes were detected by their UV absorbance at 210nm.  Calibration curves 
ranging from 1-20 µg/l were linear for both norketamine and ketamine.  Intra-day (n=5) 
and inter-day (n=25) relative standard deviations for both ketamine and norketamine, 
measured at 5 g/L, 50 g/L and 200 g/L ranged between 14.3% and 4.2%.  The limit 
of quantitation was 1 µg/l for both analytes. The limits of detection were 0.5 µg/l and 
0.7 µg/l for norketamine and ketamine, respectively. 
 
Trial sequence. Participants underwent two separate sensory assessments with 
application of the topical creams, separated by at least one week (median 1 week, range 
7 days to 23 days) to allow for the metabolic removal of any active ingredients from the 
skin. The sensory assessments were performed before and 30 minutes after the 
application of the topical creams. This timing was determined after pilot testing. To rule 
out systematic effects of testing, the order of the assessments was randomised between 
participants. However, the order of the assessments was kept constant within each 
participant to ensure that the active and placebo conditions were identical. 
 
Statistical approach 
Although some of the score distributions did not fit a normal bell-shaped curve, 
logarithmic transformations did not necessarily improve the score distribution 
significantly and generally did not strengthen statistical effects. Therefore, where 
appropriate, a nonparametric statistical approach was employed. Before the creams were 
applied, differences in pain and sensory thresholds between the symptomatic and healthy 
limbs were investigated with Wilcoxon’s matched-pairs signed-ranks test. As analysis of   181 
variance generally is robust to violations of normality, effects of ketamine on limb pain 
were investigated in Drug (ketamine versus placebo) x Side (symptomatic versus healthy 
side) x Pre-Post (the change from before to after the application of the creams) analyses 
of variance. The effect of most interest was the Drug x Side x Pre-Post interaction, as it 
tested whether ketamine applied to the symptomatic limb inhibited sensory disturbances 
in that limb. More generally, the Drug x Pre-Post interaction tested whether ketamine 
inhibited painful sensations locally when applied to either limb. Wilcoxon’s test was 
employed to investigate significant interactions. For clarity, effects of ketamine on 
sensory disturbances in the forehead were investigated in separate analyses. The 
association between sensory disturbances in the symptomatic limb and sensory 
disturbances in the ipsilateral forehead was investigated with Spearman’s correlation 
coefficient. 
 
Results 
 
Effect of topical ketamine on sensory disturbances in the symptomatic limb 
Before the creams were applied, sensory disturbances in the symptomatic limb 
included allodynia to brushing and hyperalgesia to punctate stimulation and pressure 
(Table 2). In addition, the touch threshold, assessed with von Frey hairs, was greater in 
the symptomatic than healthy limb.  
Pain in the symptomatic limb averaged 4.9 + 0.5 on a 0-10 scale (moderately 
painful), and did not change after the application of the ketamine cream or placebo. Nor 
did the touch threshold change significantly. Nevertheless, the ketamine cream inhibited 
allodynia to lightly brushing the symptomatic limb [Drug x Side x Pre-Post interaction 
F(1,19) = 4.41, p = 0.049] (Figure 1). Ketamine also inhibited pain evoked by pricking 
the skin three times with a firm von Frey bristle [Drug x Pre-Post interaction F(1,15) =   182 
10.6, p = 0.005]. The inhibitory effect was greatest when ketamine was applied to the 
symptomatic limb, but ketamine applied to the healthy limb also inhibited pin-prick 
sensations slightly in that limb (Figure 2). Results were similar after the skin was 
pricked once [Drug x Pre-Post interaction F(1,15) = 3.63, p = 0.076]. 
The pressure-pain threshold increased in the symptomatic limb after ketamine or 
placebo cream was applied to the symptomatic limb [Side x Pre-Post interaction F(1,19) 
= 5.33, p = 0.032] (Figure 3), and the warmth threshold increased in both limbs when the 
creams were applied [from 36.1 + 0.9 
oC to 37.2 + 0.9 
oC, Pre-Post main effect F(1,18) = 
4.56, p = 0.047]. However, the cool, cold-pain and heat-pain thresholds did not change. 
 
Effect of topical ketamine on sensory disturbances in the forehead 
Allodynia to brushing and hyperalgesia to punctate stimulation, pressure, cold 
and heat were detected on the symptomatic side of the forehead before the creams were 
applied to the limbs (Table 3). In addition, sensitivity to warmth was greater on the 
symptomatic side of the forehead than on the non-symptomatic side. As shown in Table 
4, sensory disturbances in the forehead were associated with heightened tactile 
sensitivity in the symptomatic limb, and with hyperalgesia to punctate and thermal 
stimuli. 
In two patients, hypoesthetic sensations were evoked by lightly brushing the 
symptomatic limb but not the healthy limb, both before and after the ketamine and 
placebo creams were applied. In one of these patients, brushing the forehead also evoked 
a similar sensation on the symptomatic side before ketamine was applied to the 
symptomatic limb; this sensation persisted after the cream was applied. In the other 18 
patients, brushing the limbs and forehead provoked either a normal sensation or 
allodynia. The ketamine cream inhibited allodynia to lightly brushing the forehead   183 
[Drug x Pre-Post interaction F(1,19) = 4.75, p = 0.042]. The inhibitory effect was greater 
when ketamine than placebo was applied to the symptomatic limb (Figure 4). 
Sensitivity to cool and warm sensations decreased slightly on both sides of the 
forehead after the creams were applied. In particular, the cool detection threshold 
decreased from 29.7 + 0.3 
oC to 29.1 + 0.5 
oC [Pre-Post main effect F(1,18) = 4.52, p = 
0.048], whereas the warmth detection threshold increased from 34.9 + 0.5 
oC to 35.3 + 
0.5 
oC [Pre-Post main effect F(1,18) = 5.22, p = 0.035]. Conversely, the heat pain 
threshold decreased from 39.7 + 0.6 
oC to 39.1 + 0.7 
oC [Pre-Post main effect F(1,18) = 
4.79, p = 0.042].  The other sensory thresholds remained unchanged. 
 
Detection threshold for Ketamine and Norketamine 
Neither ketamine nor norketamine could be detected in any of the plasma 
 
samples from the first 10 patients assessed in the trial. Therefore, assays were 
discontinued for the remainder of the study. The threshold for detection was 
0.7 g/l for ketamine and 0.5 g/l for norketamine. 
 
Discussion 
 
The primary aim of this study was to determine whether topical ketamine 
inhibited sensory disturbances in the symptomatic limb of patients with CRPS. We 
found evidence of this for allodynia and punctate hyperalgesia. The effect was greatest 
in the symptomatic limb, but ketamine applied to the healthy limb also slightly inhibited 
sharp sensations in that limb. This appeared to involve a local mechanism because 
ketamine applied to the healthy limb had no effect on allodynia or punctate hyperalgesia 
in the symptomatic limb.   184 
Allodynia to brushing the skin and punctate hyperalgesia to sharp stimulation is 
mediated by sensitized spinal noiciceptive and wide dynamic range neurons that receive 
input from nociceptive A-delta fibres and non-nociceptive A-beta fibres [55; 56]. 
However, our findings suggest that a peripheral mechanism involving NMDA receptors 
also contributed to these sensory disturbances in our CRPS patients. This mechanism 
appeared to involve nociceptors because touch thresholds remained unchanged after the 
topical ketamine treatment. It did not seem to entail a systemic mechanism, because 
ketamine applied to the healthy limb was ineffective. Moreover, plasma levels of 
ketamine and its active metabolite, norketamine, were below the limits of detection after 
the creams were applied. Plasma levels of ketamine above 150 g/l have previously 
been shown to cause pain threshold elevation [9; 92]. In our study the threshold for 
detection of ketamine was substantially lower, at 0.7 g/l. 
NMDA- and related ionotropic glutamate receptors are present on peripheral 
primary afferent neurons in the hairy and glabrous skin of rats [44] and in the hairy skin 
of humans [52]. These glutamate receptor populations are up-regulated in inflamed 
human skin [86] and appear to be involved in sensitizing primary afferent nociceptors 
during inflammation and tissue injury [6, 23, 45]. As NMDA increases the excitability 
of thermal nociceptors in animal models of inflammation, [23], we expected that the 
NMDA antagonist ketamine would inhibit thermal hyperalgesia in our CRPS patients. 
However, the cold-pain and heat-pain thresholds remained unchanged, implying that 
NMDA receptor blockade after the topical ketamine treatment was insufficient to 
decrease the activity of thermal nociceptors within the timeframe of the experiment. A 
higher concentration of ketamine and a longer delay before testing (to permit greater 
entry of ketamine into the skin) could be employed to investigate this possibility. 
Sensitivity to warmth decreased in both limbs when the creams were applied, and 
sensitivity to cool and warm sensations decreased in the forehead. Conversely,   185 
sensitivity to heat pain increased on both sides of the forehead after the ketamine cream 
was applied to either limb. These changes are more likely to reflect a reduction in 
perceptual acuity due to fatigue or effects of repeated testing than a systemic effect of 
ketamine, because neither ketamine nor norketamine were detected in plasma samples 
after the creams were applied. The pressure-pain threshold increased in the symptomatic 
limb irrespective of whether ketamine cream or placebo was applied to the symptomatic 
limb, possibly for similar reasons. 
CRPS is associated with hemisensory disturbances that extend to the face [21; 
76; 77; 87]. Rommel et al. [77] reported that sensory impairment to light touch, heat-
pain, cool and warmth extended hemilaterally to the face in 30% of patients, whereas 
facial sensation was symmetrical in patients with sensory impairment limited to the 
affected limb. Although hypoalgesia in the symptomatic limb was associated with 
hypoalgesia on the symptomatic side of the forehead in a few of our patients, in most 
cases allodynia to brushing and hyperalgesia to pressure, punctate stimulation, cold and 
heat were detected on the symptomatic side of the forehead. In addition, this site was 
generally more sensitive to warmth than contralaterally. In a previous study of sensory 
disturbances in CRPS, we detected hyperalgesia to deep pressure on the symptomatic 
side of the forehead in the majority of patients; in addition, hyperalgesia to punctate 
stimulation extended ipsilaterally to the forehead in patients with punctate hyperalgesia 
in the symptomatic limb [21]. For unknown reasons, a greater range of sensory 
modalities was disrupted on the symptomatic side of the forehead in the present cohort 
of patients; this might have been a sampling effect or possibly was due to greater 
precision of measurement as measures were averaged across two sessions in the present 
study. In general, hyperalgesia in the symptomatic limb was associated with 
hyperalgesia on the symptomatic side of the forehead, implying mediation by a similar   186 
mechanism (e.g., sensitization of spinal or supraspinal nociceptive neurons or disruption 
of central pain modulating processes). 
Curiously, in a few patients ketamine cream applied to the symptomatic limb 
inhibited allodynia to lightly brushing the forehead. As this was a double-blind placebo-
controlled trial and the effect was limited to allodynia, we are confident that this was not 
due to expectancy or social desirability biases. Clearly, the finding needs to be 
confirmed in a larger sample of patients. However, it is tempting to speculate that the 
mechanism that mediated allodynia in the symptomatic limb also contributed to 
allodynia at more remote sites. For example, disruption of central pain modulating 
processes might not only increase the excitability of sensitized spinal nociceptors but 
might also sensitize supraspinal nociceptive neurons that receive convergent hemilateral 
input (e.g., in the thalamus or somatosensory cortex). Cortical processing of input from 
the symptomatic limb is disrupted in CRPS [58; 62; 63; 72], with heightened cortical 
responses to noxious stimuli and shrinkage of representation of the symptomatic limb in 
the somatosensory cortex. This cortical reorganization might account for referred pain in 
CRPS [66], and might also explain why a reduction of allodynia in the symptomatic 
limb after the topical ketamine treatment was sometimes accompanied by a reduction of 
allodynia on the symptomatic side of the forehead. 
The strengths of this study include the double-blind placebo-controlled crossover 
design, confirmation that ketamine did not enter the bloodstream in detectable 
concentrations, and the psychophysical assessment of multiple sensory modalities. 
However, as only one concentration of ketamine was employed, only a single dose was 
administered, and effects of ketamine were assessed at only one time point, further 
controlled studies are needed to determine whether the therapeutic effects of ketamine in 
CRPS are limited to dynamic allodynia and punctate hyperalgesia or also include other 
forms of hyperalgesia.   187 
Parenteral and oral forms of ketamine have shown some promise for treating the 
burning pain and exquisite skin hypersensitivity of CRPS and other chronic pain states 
associated with nerve injury [42]. However, administration by these routes is limited by 
central side effects such as hallucinations and nightmares. Frequent abuse of ketamine 
can even cause long term memory impairment [14]. In open studies of topical ketamine, 
therapeutic effects appeared to strengthen with repeated applications [12; 32; 61; 74; 
90]. As topical ketamine is simple and inexpensive to use, and systemic absorption 
appears to be minimal, further exploration of the therapeutic potential of topical NMDA 
blockers in CRPS would be welcome. 
In conclusion, topical ketamine does not lead to pain reduction in patients with 
CRPS but does cause a reduction in allodynia, a most unpleasant aspect of this 
condition. Future treatment protocols could be expanded, to use topical ketamine for 
patients who manifest allodynia, as an adjunct to sensory-motor retraining programs and 
other more traditional forms of treatment. 
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Table 1 
Sensory, vasomotor/sudomotor, and motor/trophic disturbances in CRPS patients 
   Limb 
Pain 
duration    Sensory      Vasomotor/Sudomotor     Motor/trophic 
    (months)    Hyperalgesia  Allodynia    Temp.  ΔT   Dyschromia  Hyper-    Tremor  Dystonia  Hair  Nail  Skin 
                    sensation  (°C)      hidrosis            growth   growth   changes   
1. F, 59  RU  24    hyperalgesia  allodynia    cold   0.46  flushed/cyanotic  sweats    resting   dystonia    fast   
2. F, 35  RU  19    hyperalgesia  allodynia    hot/cold  0.40    sweats    intention     more  fast  scaly 
3. F, 51  RL  125    hyperalgesia  allodynia    hot/cold  -0.26  flushed/cyanotic  sweats        less  fast  scaly 
4. M, 45  LL  6    hyperalgesia  allodynia      0.18  cyanotic  sweats             
5. F, 54  LU  27    hyperalgesia  allodynia    cold   -0.04    sweats    resting        pale 
6. M , 20  RL  2    hyperalgesia  allodynia    cold   -1.34  flushed/cyanotic  sweats    resting    less  fast  scaly 
7. F, 27  RL  17    hyperalgesia  allodynia    cold   -2.96  flushed/cyanotic      resting         yellow 
8. F, 37  LL  3    hyperalgesia  allodynia    cold  -3.82  pale/flushed/cyanotic  sweats    resting      slow  mottled 
9. F, 44  LU  26    hyperalgesia  allodynia    cold   -0.36  pale/flushed  sweats          fast   
10. M, 50  RU  230    hyperalgesia  allodynia    hot   -1.14  flushed  sweats    resting    less  dystrophy  glossy 
11. M, 48  LU  23    hyperalgesia  allodynia    cold  -0.37  flushed      resting      fast/brittle  scaly 
12. F, 35  RU  10    hyperalgesia  allodynia    cold   0.44  flushed/cyanotic  sweats    resting    less  slow  glossy 
13. F, 38  RU  57    hyperalgesia  allodynia    cold   0.04  flushed/cyanotic  sweats    intention      brittle  pigmented 
14. F, 20  LU  2    hyperalgesia  allodynia    hot/cold   0.60  flushed  sweats    resting  dystonia       
15. M, 51  RU  129    hyperalgesia  allodynia    cold   0.46  pale/flushed  sweats    resting        cracks 
16. M, 23  LU  6    hyperalgesia  allodynia    cold  -0.02  flushed  sweats    intention    more  fast  scaly  
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17. F, 31  RU  13    hyperalgesia  allodynia    hot/cold   0.36    sweats    resting        pigmented 
18. F, 51  RL  10    hyperalgesia  allodynia    hot  1.00  flushed  sweats        less  fast  scaly 
19. F, 41  LU  118    hyperalgesia  allodynia    hot   0.84  flushed/cyanotic  sweats    resting     
slow, 
brittle   
20. F, 36  LL  11    hyperalgesia  allodynia     cold   -3.00  flushed/cyanotic           dystonia        scaly 
 
Symptom history as reported by patients. Signs of disturbances noted during the initial physical examination are italicized in bold. Limb LU, left upper 
extremity; RU, right upper extremity; LL, left lower extremity; RL, right lower extremity. Sensory disturbances reported by patients included 
hyperalgesia, allodynia and numbness. Numbness was reported by all but two patients (Nos. 4 and 10). Sensory disturbances noted during an initial 
physical examination included hyperalgesia to punctuate stimulation with a firm bristle (a sharpness rating (0-10) of at least 2 higher in the affected 
than the unaffected limb indicated hyperalgesia) and allodynia to brushing the skin with a light brush (an uncomfortable or painful sensation indicated 
allodynia). Two patients reported a numb sensation to the brushing (Nos. 9 and 11). Vasomotor and sudomotor disturbances reported by patients were 
asymmetrical temperature sensations, dyschromia and hyperhidrosis. Patients reported whether they perceived their limb to be cold or hot. Four 
patients reported that the limb would at times appear cold and other times hot. ∆T, temperature asymmetry between the affected and unaffected limb as 
averaged for the first phalanx of each toe (lower limb patients) or each finger (upper limb patients). Negative values indicate that the affected limb was 
cooler than the unaffected limb. Swelling was reported by all patients. A decreased range of movement was observed and reported by all patients. Other 
motor disturbances reported by patients included weakness (all patients), tremor and dystonia. Trophic changes (hair, nails, skin) varied greatly 
between patients.   
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Table 2 
Sensory thresholds and allodynia in the symptomatic and healthy limbs before ketamine 
and placebo creams were applied to the symptomatic limb 
  Mean ± S.E.  Wilcoxon’s Z 
  Symptomatic  Healthy   
Touch (von Frey units)  10.3 ± 0.9  8.8 ± 0.4  1.99 * 
Pressure (grams)  321 ± 82  1101 ± 116  3.92 *** 
Brushing (% with allodynia)  85%  10%  3.04 ** 
Sharpness (one application)  5.0 ± 0.7  3.5 ± 0.4  1.92 
Sharpness (three applications)  5.7 ± 0.7  3.7 ± 0.4  2.20 * 
Cool threshold (
oC)  26.2 ± 1.4  27.9 ± 0.9  1.09 
Warmth threshold (
oC)  36.6 ± 1.5  36.2 ± 0.6  .04 
Cold-pain threshold (
oC)  19.0 ± 2.3  16.0 ± 1.5  1.33 
Heat-pain threshold (
oC)  39.9 ± 0.9  41.7 ± 0.6  1.91 
 
* p < 0.05; ** p < 0.01; *** p < 0.001 
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Table 3 
Sensory thresholds and allodynia in the forehead ipsilateral and contralateral to the 
symptomatic limb before ketamine and placebo creams were applied to the symptomatic 
limb 
  Mean ± S.E.  Wilcoxon’s Z 
  Ipsilateral side  Contralateral side   
Touch (von Frey units)  5.0 ± 0.7  4.6 ± 0.6  0.49 
Pressure (grams)  398 ± 44  524 ± 33  3.38 *** 
Brushing (% with allodynia)  60%  5%  3.40 *** 
Sharpness (one application)  5.1 ± 0.5  3.7 ± 0.5  2.07 * 
Sharpness (three applications)  4.9 ± 0.5  3.9 ± 0.5  1.94 
Cool threshold (
oC)  30.3 ± 0.2  29.5 ± 0.5  1.69 
Warmth threshold (
oC)  34.4 ± 0.4  35.8 ± 0.6  2.66 ** 
Cold-pain threshold (
oC)  24.7 ± 1.3  22.5 ± 1.3  2.98 ** 
Heat-pain threshold (
oC)  38.7 ± 0.7  40.8 ± 0.6  2.70 ** 
 
* p < 0.05; ** p < 0.01; *** p < 0.001  
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Table 4 
Association (Spearman’s rank-order correlation coefficient) between sensory disturbances in the symptomatic limb and asymmetry of sensations in the 
forehead 
* p  <0.05; ** p < 0.01; *** p < 0.001
  Sensations in the symptomatic limb (compared with the healthy limb) 
Ipsilateral versus 
contralateral side of the 
forehead 
Loss of touch  Pressure 
hyperalgesia 
Allodynia to 
brushing 
Sharp – 1 
rating 
Sharp – 3 
rating 
Reduced cool 
sensitivity 
Reduced 
warm 
sensitivity 
Cold 
hyperalgesia 
Heat 
hyperalgesia 
Loss of touch  .286  .006  .029  -.052  -.073  -.187  -.224  .118  -.043 
Pressure hyperalgesia  -.483*  .206  .220  .710***  .751***  .447  .351  .593**  .408 
Allodynia to brushing  -.390  .167  .094  .278  .329  .244  .313  .420  .379 
Sharp – 1 rating  -.669***  .258  -.021  .643**  .584**  .616**  .631**  .744***  .707*** 
Sharp – 3 rating  -.574*  .147  .085  .482*  .409  .614**  .718***  .808***  .745*** 
Reduced cool sensitivity  -.107  .037  .114  -.030  -.033  .240  .191  .311  .426 
Reduced warm 
sensitivity 
-.312  .294  .043  .254  .272  .395  .426  .242  .337 
Cold hyperalgesia  -.349  .363  .363  .521*  .530*  .284  .239  .679***  .681*** 
Heat hyperalgesia  -.608**  .336  .108  .467*  .451  .595**  .642**  .660***  .672**  
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Fig. 1. Proportion of patients with allodynia (+ S.E.) to lightly brushing the symptomatic and healthy limbs before and after the application of 10% 
ketamine cream and placebo. Allodynia in the symptomatic limb decreased significantly after the ketamine cream was applied (* p < 0.01, Wilcoxon’s 
test).  
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Fig. 2. Sharpness ratings (+ S.E.) to punctate stimulation with a firm von Frey bristle before and after the application of 10% ketamine cream and 
placebo to the symptomatic and healthy limbs of patients who reported that the bristle induced a sharp sensation in the symptomatic limb (i.e., the 
rating was greater than 0 before the cream was applied). When the bristle was applied three times at intervals of approximately 1 second (N = 16), 
sharpness ratings decreased after the ketamine cream was applied to the symptomatic limb (# p < 0.1, Wilcoxon’s test). Sharpness ratings to a single 
application of the bristle (N = 16) also decreased after the ketamine cream was applied to the healthy limb (# p < 0.1, Wilcoxon’s test).  
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Fig. 3. Pressure-pain thresholds (+ S.E.) in the symptomatic and healthy limbs before and after the application of 10% ketamine cream and placebo. 
The pressure-pain threshold increased in the symptomatic limb after the ketamine cream was applied either to the symptomatic or healthy limb (* p < 
0.05, Wilcoxon’s test).  
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Fig. 4. Proportion of patients with allodynia (+ S.E.) to lightly brushing the forehead ipsilateral or contralateral to the symptomatic limb before and after 
the application of 10% ketamine cream or placebo to the symptomatic limb. Allodynia on the ipsilateral side of the forehead decreased after the 
ketamine cream was applied to the symptomatic limb (# p < 0.1, Wilcoxon’s test) but did not change after the placebo cream was applied to the 
symptomatic limb.  
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Abstract 
 
Patients with complex regional pain syndrome (CRPS) often demonstrate hemilateral 
sensory disturbances and brain imaging changes in the contralateral sensory and motor 
cortices. This might indicate unilateral disturbances in nociceptive pathways. Unlike 
healthy controls, CRPS pain is aggravated, not inhibited, by startle with a loud tone. This is 
consistent with dysfunction of central inhibitory pain control. To determine whether such 
dysfunction is predominantly unilateral, we investigated whether the response was more 
pronounced during startle in the ipsilateral than the contralateral ear. Twenty-eight CRPS 
patients rated limb pain from 0 (no pain) to 10 (extremely severe pain) at 5 s intervals 
before and for 30 s after startle with a loud tone in each ear, and also rated auditory 
discomfort. Startle aggravated limb pain in 21 patients (75%), had no effect in six patients 
and inhibited limb pain in one patient. The pain increase was greater to ipsilateral than 
contralateral startle. Patients with increased pain during startle reported greater auditory 
discomfort than non-responders, particularly to ipsilateral startle. These findings suggest 
neuronal hyperexcitability both in the sensory and auditory system in cortical or subcortical 
areas that process sensations from the CRPS-affected side of the body. 
  
 
 
211 
Introduction 
 
The causalgic pain of complex regional pain syndrome (CRPS) is highly sensitive 
to acoustic stimuli and emotional excitement [13; 28; 39]. Although sensory-sympathetic 
coupling in the CRPS-affected limb may contribute to this, startle stimuli can still evoke 
limb pain after peripheral sympathetic blockade [14]. Thus, additional mechanisms appear 
to be involved. 
CRPS is associated with heightened activity in the cortical nociceptive networks 
that process signals from the CRPS-affected limb [35; 37; 41]. Moreover, pain and sensory 
disturbances often spread beyond the limb, usually in a hemilateral distribution [15; 42; 
48]. Together, such findings imply disruption of pain modulation at sites of somatosensory 
convergence within the central nervous system – for example, in the medullary reticular 
formation, thalamus or cerebral cortex. In the current study, a startle stimulus (a loud tone) 
was presented sequentially on the affected and unaffected side of patients with CRPS. We 
hypothesized that stimuli presented on the CRPS-affected side would evoke greater 
increases in limb pain than contralateral stimuli, due to ipsilateral excitatory influences on 
sensitized nociceptive networks. 
 
Method 
 
Participants 
The sample consisted of 5 men and 23 women aged between 15 and 59 years (mean 
age 41.4 years) attending a pain medicine clinic. All patients met the IASP criteria for 
CRPS I (26 patients) or CRPS II (2 patients), and all but one met the more stringent criteria 
of Harden and colleagues [21]. Patients with hearing difficulties were excluded from the  
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study. Fourteen patients suffered from upper limb pain and 14 from lower limb pain. CRPS 
had begun after a fracture (10 patients), soft-tissue injuries such as sprains, tendonitis, 
bursitis or dislocation (7 patients), surgery (3 patients), nerve lesion (2 patients) or infection 
(2 patients). Another four patients had developed CRPS following an injection, electric 
shock, anaphylactic reaction or a non-occlusive blood clot. Pain had persisted between 2 
months and 19.2 years (median 3.4 years). Twenty-two patients took analgesics, 
anticonvulsants and/or anti-depressants and 6 patients were medication-free. Patients 
continued routine medication during the trial due to ethical and practical concerns relating 
to discontinuation of medication. Sensory, autonomic and motor disturbances were reported 
by patients and noted during a physical examination by a medically-trained pain specialist, 
and sensory disturbances in the CRPS-affected limb were investigated further using 
psychophysical procedures (Table 1). Each participant gave their written informed consent 
for the procedures which had been approved by the local ethics committee. 
 
Procedures 
Sensory disturbances in the symptomatic limb and the forehead.  Pressure-pain 
thresholds (PPT) and the intensity of sharpness evoked by a firm nylon bristle [29] were 
measured in the symptomatic limb and the contralateral healthy limb and on each side of 
the forehead. To obtain PPTs, a spring-loaded algometer with a rounded tip (1 cm in 
diameter) was applied in 200 g steps on each limb and in 80 g steps on each side of the 
forehead to a maximum of 2.3 kg or until the participant reported pain. Sharpness was rated 
on a scale from 0 (not sharp) to 10 (stabbing) in response to a single application of a bristle 
(Filament 17, Senselab von Frey Aesthesiometer, Somedic Sales AB, Sweden), which was 
applied with enough force to bend it for 1 s .  
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Startle. A loud tone (100 Hz, 102 dBA, 0.5 s duration) was delivered through 
headphones to one ear. To investigate the effect of the tone on pain in the symptomatic 
limb, ratings of pain intensity were obtained on a scale from 0 (no pain) to 10 (extremely 
severe pain) [13]. Participants then rated auditory discomfort induced by the tone on a scale 
from 0 (not unpleasant) to 10 (extremely unpleasant). 
 
Sweating and blood flow. Changes in sweating and blood flow in response to the 
startle stimuli were assessed in the final 11 patients studied (7 with upper limb pain and 4 
with lower limb pain). To measure electrodermal activity (which reflects sweating), two 
silver-silver chloride Beckman cup electrodes (0.8 cm diameter) were filled with 
conducting paste and attached to the CRPS-affected and contralateral healthy limb [13]. In 
upper limb patients, the electrodes were placed on the middle phalanx of the index and third 
finger (palmar surface) whilst they were attached to the second and third toe in lower limb 
patients (plantar surface). The maximum increase in electrodermal activity 10 s after the 
startle stimulus was measured in both limbs. Changes in digital blood flow were monitored 
using pulse transducers (photoplethysmographs, Grass Instruments Company, Quincy, MA) 
attached with Velcro straps to a finger (upper limb patients) or a toe (lower limb patients) 
of the symptomatic and healthy limbs [13]. The blood flow response to startle was defined 
as the mean pulse amplitude for 10 s after startle, expressed as a proportion of the mean 
pulse amplitude for 10 s prior to startle. 
 
Trials. After PPTs and sharpness were measured in the limbs and forehead, the loud 
tone was presented four times in the following sequence: to the first ear (then wait 2 
minutes); second ear (wait 5 minutes); second ear again (wait 2 minutes); first ear. The first 
startle stimulus was presented on the CRPS-affected side in 50% of participants. Pain in the  
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CRPS-affected limb was rated every 5 s for 15 s before and for 30 s after each tone. 
Patients were warned about the appearance of the tone to reduce any painful effects of 
sudden movement. After the pain ratings had been completed, patients rated auditory 
discomfort.  
    
Statistical analysis. Due to violations of normality, Wilcoxon’s matched-pairs 
signed-ranks tests were used to assess differences in sensitivity to pressure-pain and 
sharpness between the affected and unaffected limbs, and between the ipsilateral and 
contralateral sides of the forehead. Wilcoxon’s tests were also employed to assess the 
difference in auditory discomfort to ipsilateral versus contralateral startle. The mean pain 
intensity for 15 s before ipsilateral startle and for 15 s before contralateral startle was 
calculated, and ratings were averaged across stimuli presented to the same ear for each 
subsequent time point. A 2 (ipsilateral startle, contralateral startle) x 8 (consecutive time-
points) repeated measures analysis of variance assessed changes in pain in the CRPS-
affected limb to startle stimuli in the contralateral versus ipsilateral ear. The Huynh-Feldt 
epsilon was used to correct for violations of sphericity (i.e., when scores at one set of times 
were more closely related than scores at another set of times). Changes in electrodermal 
activity and digital blood flow after the startle stimuli were investigated in similar analyses. 
Although the normality assumption was not met for some of the variables included in these 
analyses, analysis of variance generally is robust to such violations and, unlike non-
parametric approaches, permits investigation of interaction between factors. Individual 
differences in the intensity and asymmetry of startle-hyperalgesia (from before to after the 
tone) were investigated in relation to age, pain intensity, pain duration, ipsilateral forehead 
hyperalgesia, hyperalgesia in the symptomatic limb and auditory discomfort with 
Spearman’s rank-order correlation coefficient. A similar analysis was conducted to  
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determine associations between auditory discomfort and age, pain intensity, pain duration, 
forehead hyperalgesia, ipsilateral forehead hyperalgesia and hyperalgesia in the affected 
limb. Data is presented as the mean ± standard error of the mean. 
 
Results 
 
Sensory disturbances in the symptomatic limb 
PPTs were lower in the symptomatic limb than the healthy limb (464 ± 105 g versus 
1257 ± 105 g) [Wilcoxon’s Z = -4.23, p < 0.001], consistent with hyperalgesia to pressure-
pain. Similarly, sharpness ratings generally were greater in the symptomatic limb (mean 
rating 4.36 ± 0.63) than the healthy limb (mean rating 2.59 ± 0.41) [Wilcoxon’s Z = -2.29, 
p < 0.05], indicating punctate hyperalgesia.  
 
Sensory disturbances in the forehead 
In the group as a whole, PPTs in the forehead were significantly lower on the 
CRPS-affected side than contralaterally (551 ± 59 g versus 654 ± 58 g) [Wilcoxon’s Z = -
1.97, p < 0.05]. Sharpness sensations to the bristle did not differ between the ipsilateral and 
contralateral sides of the forehead in the group as a whole [mean ratings 4.04 ± 0.53 and 
3.02 ± 0.46 respectively, Wilcoxon’s Z = -1.61, not significant]. However, asymmetry of 
sharpness sensations in the limbs was associated with asymmetry of sharpness and 
pressure-pain sensations in the forehead (Table 2), consistent with a spread of sensory 
disturbances from the CRPS-affected limb to the ipsilateral forehead. 
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Startle response 
Auditory discomfort was greater when the tone was presented on the CRPS-affected 
side than contralaterally [mean discomfort 5.80 ± 0.51 versus 4.96 ± 0.48, Wilcoxon’s Z = 
2.42, p < 0.05]. Most (21) patients reported that limb pain increased after the startle stimuli; 
however, six patients reported no change and one other reported that limb pain decreased 
(Fig. 1).  In the startle-responsive group, limb pain increased immediately and remained 
elevated for at least 30 s [main effect for Time F(2.46,49.25) = 9.66, p < 0.001]. The 
immediate increase was most pronounced when the tone was presented on the CRPS-
affected side [mean increase 1.23 ± 0.21 to ipsilateral stimuli versus 0.68 ± 0.16 to 
contralateral stimuli, Wilcoxon’s Z = -3.16, p < 0.01] and pain remained greater during 
ipsilateral than contralateral startle for the entire 30 s post startle [Time x Startle Side 
interaction F(3.83,76.59) = 5.58, p < 0.001]. 
Differences between startle-responders and non-responders were investigated with 
Wilcoxon’s test and Fisher’s exact test for small samples (Table 3). Startle-responders were 
characterized by greater generalized forehead hyperalgesia to pressure-pain and sharpness 
and greater ipsilateral forehead hyperalgesia to sharpness, greater pain in the CRPS-
affected limb and greater auditory discomfort from the tone. During their initial physical 
examination, only one of the six non-responders (17%) reported that limb pain increased 
when they were anxious, angry or distressed or after being startled or frightened. In 
contrast, 81% of the startle-responders reported that such stimuli aggravated their pain.  
The number of patients on medication was similar in the two groups (Table 3). 
Greater hyperalgesia to startle on the CRPS-affected side was associated with 
greater auditory discomfort on the CRPS-affected side (Table 4). In addition, greater 
auditory discomfort on the affected side was associated with greater hyperalgesia to 
pressure on the ipsilateral side of the forehead (Table 5), and greater auditory discomfort, in  
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general, was associated with greater limb pain and with greater bilateral punctate 
hyperalgesia in the forehead (Table 5).  
 
Sweating and blood flow 
In the 11 patients included in this part of the study, electrodermal activity (sweating) 
increased to the same extent in both limbs after the startle stimuli, irrespective of the side 
stimulated (mean increase 3.94 ± 1.0 µS). Eight of the 11 patients reported increased pain 
to startle, whereas three patients were startle non-responders. When the three non-
responsive patients were removed from the analysis, the electrodermal response was greater 
in the healthy than symptomatic limb, irrespective of whether the tone was presented on the 
CRPS-affected side or contralaterally [mean increase 4.8 ± 1.7 µS versus 3.0 ± 1.1 µS, 
main effect for Limb F(1,7) = 6.22, p < 0.05].  
Digital blood flow did not change in either limb after startle in either ear (mean 
decrease 1 ± 8%). These results did not change after excluding the non-responders. 
 
Discussion 
 
Auditory startle stimuli evoked greater increases in limb pain and auditory 
discomfort when presented on the CRPS-affected side than when presented contralaterally. 
As startle stimuli inhibit nociceptive sensations in healthy controls [13], these findings 
suggest that mechanisms that normally inhibit activity in nociceptive networks are 
compromised in patients with CRPS. They further imply that processing of signals from 
multiple sensory modalities is disrupted hemilaterally. 
In a recent study, pain ratings to repetitive noxious electrical stimulation of the 
hands decreased more slowly in CRPS patients than controls (consistent with impaired  
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inhibitory pain modulation), whereas the area of pinprick hyperalgesia increased to a 
greater extent in the CRPS-affected limb than the contralateral healthy limb (consistent 
with an ipsilateral enhancement of facilitatory pain modulation) [46]. Such disturbances 
probably mediated allodynia and mechanical hyperalgesia in the CRPS-affected limb of our 
patients, and might also have contributed to sensory disturbances that spread beyond the 
CRPS-affected limb to the forehead.  
Such disturbances might also have mediated the hyperalgesia and auditory 
discomfort evoked by startle stimuli. In a study of 40 patients with CRPS-related dystonia, 
15 (38%) reported hyperacusis to bilateral ear stimulation [10]. The hyperacusis was 
attributed to central sensitization as it was associated with allodynia and/or hyperalgesia in 
the symptomatic limb. Although this finding was not replicated in our study, auditory 
discomfort was associated with greater limb pain and with hyperalgesia in the forehead. 
Perhaps a lack of inhibitory control promotes uncontrolled sensitization or unmasks 
facilitatory mechanisms, particularly in pathways subserving the CRPS-affected limb [18; 
25; 36; 40; 45; 53].  
The source of the auditory-nociceptive interaction in CRPS is uncertain. One 
possibility is the cochlear nucleus (CN), which is the first link in the neural pathway 
underlying the acoustic startle response [56] and the lone site in the central auditory system 
that exclusively receives unilateral input from the adjacent ipsilateral ear [12]. Importantly, 
supraspinal sites involved in the descending control of pain such as the locus coeruleus 
(LC) [17; 31; 43] and the raphe nuclei [49] project to the CN. The LC is active during 
acoustic startle [20], possibly via dorsal CN activation of the lateral paragigantocellular 
nucleus in the reticular formation which provides excitatory input to the LC [26]. 
Alternatively, output from the amygdala and periaqueductal gray during startle [58] might 
activate the LC. The LC plays a dual role in neuronal modulation, producing both  
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facilitation and inhibition in the dorsal horn and the CN via α1-adrenoceptors and α2-
adrenoceptors respectively [8; 17; 22; 24; 31; 43]. Thus, a shift in the inhibitory-facilitatory 
balance of LC control might facilitate nociceptive traffic in the dorsal horn and auditory 
signals in the CN.  
The LC is active in the ipsilateral, but not the contralateral dorsal horn during 
unilateral hindpaw inflammation [50-52], thus providing a possible neuroanatomical 
substrate for the lateralized deficits in pain control observed in our patients. Whereas spinal 
input to the thalamus is contralateral, spinobulbar projections are bilateral [2; 9]. Thus, 
ipsilateral spinobulbar nociceptive projections from the dorsal horn and trigeminal nuclei 
could intersect with CN and LC pathways in the brainstem and midbrain, potentially 
establishing an ipsilateral facilitatory loop. Serotonergic projections from raphe nuclei also 
have both excitatory and inhibitory effects on CN [16]
 and dorsal horn neurons [59] and 
could account for a more generalized facilitation of somatosensory and auditory activity 
during startle. This could also explain the association between migraine and CRPS [11], 
which share symptoms such as hyperalgesia and phonophobia [34; 38; 55].  
Another potential mechanism underlying hyperacusis in CRPS includes 
convergence of auditory input onto sensitized thalamic nuclei [10]. Reports of auditory 
discomfort to auditory stimulation in CRPS in the present and a previous study [10] may 
also indicate involvement of the limbic system [10], as startle stimuli generally evoke 
momentary fright. It is worth noting that both noradrenergic LC and serotonergic raphe 
nuclei innervate the thalamus [1; 57]
 and the limbic system [19; 23], and could thus up- or 
down-regulate nociceptive signals and emotional responses in parallel. Finally, cochlear 
disturbances might contribute to loudness recruitment on the CRPS-affected side. Although 
possible, this seems unlikely as pure tone audiogram thresholds and speech reception 
thresholds were within the normal range in CRPS patients with hyperacusis in a previous  
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study [10]. Furthermore, none of the patients in the present study reported a history of 
hearing problems. 
The nociceptive effect of startle may also have a peripheral component, mediated by 
adrenergic excitation of sensitized nociceptors [14]. Although sweating increased in both 
limbs to startle, the response was greater in the contralateral healthy limb than the 
symptomatic limb implying sudomotor dysfunction in the CRPS-affected limb [5; 6; 15; 
27; 30; 47; 54]. As increased sweating in the symptomatic limb appears to be associated 
with adrenergic supersensitivity [7], the lesser degree of sweating in this limb does not 
support peripheral adrenergic mediation of startle-hyperalgesia. Moreover, vasoconstrictor 
responses to startle (normally mediated by adrenergic vasomotor neurons) were minimal. 
Visual inspection of the response curves indicated that vasoconstriction preceded the startle 
stimulus in most cases, perhaps due to the warning given prior to startle. Attenuated 
vasoconstrictor reflexes in the limbs of CRPS patients, particularly on the symptomatic 
side, may also reflect a central disturbance in sympathetic vasomotor control [3; 4; 32; 33; 
44].  
Forehead hyperalgesia, auditory discomfort and pain in the affected limb were 
greater in the 21 patients with increased pain during startle than in six non-responsive 
patients. These findings suggest an association between startle-hyperalgesia and other 
sources of pain in CRPS. Nevertheless, dynamic allodynia, which is thought to reflect 
central sensitization, was detected in the symptomatic limb of all but one of the six non-
responsive patients. Whether failure of pain modulation mechanisms differentiates startle-
responders from non-responders requires further investigation. 
A potential limitation of this study is that limb pain may have increased during 
startle due to movement. However, this does not account for greater increases in pain and 
auditory discomfort to startle stimuli on the CRPS-affected side. Similarly, pain  
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medication, although a potential influence, would be expected to suppress rather than 
enhance responses to startle. A further limitation is that the assessment technique relied on 
patient-reported pain ratings, which are sensitive to subjective influences. However, this is 
unlikely to have played a major role as patients were unaware of the purpose of the study.  
In conclusion, our findings suggest that modulation of activity in nociceptive 
networks is compromised in the majority of patients with CRPS, predominantly in central 
pathways that serve the CRPS-affected side of the body. Activity in pathways that converge 
upon this sensitized system (e.g., from the somatosensory supply of ipsilateral body sites, 
the cochlear nucleus, or locus coeruleus) may intensify nociceptive sensations in the CRPS-
affected limb and evoke discomfort to stimulation on the CRPS-affected side of the body.  
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  Table 1 
Sensory, vasomotor/sudomotor and motor/trophic disturbances in CRPS patients 
   Limb  Pain duration    Sensory      Vasomotor/sudomotor     Motor/trophic 
    (months)    Hyperalgesia  Allodynia    Temp.  Dyschromia  Hyper-    Tremor  Dystonia  Hair  Nail  Skin 
                   sensation     hidrosis           growth  growth  changes 
Startle-responders 
1. F, 59  RU  28    hyperalgesia  allodynia    cold   flushed/cyanotic  sweats    resting  dystonia    fast   
3. F, 52  RL  139    hyperalgesia  allodynia    hot/cold  flushed/cyanotic  sweats        less  fast  scaly 
4. M, 46  LL  24    hyperalgesia  allodynia      cyanotic  sweats             
6. M , 21  RL  16    hyperalgesia  allodynia    cold   flushed/cyanotic  sweats    resting    less  fast  scaly 
9. F, 45  LU  36    hyperalgesia  allodynia    cold   pale/flushed  sweats          fast   
11. M, 48  LU  24    hyperalgesia  allodynia    cold  flushed      resting      fast/brittle  scaly 
12. F, 35  RU  8    hyperalgesia  allodynia    cold   flushed/cyanotic  sweats    resting    less  slow  glossy 
13. F, 39  RU  74.5    hyperalgesia  allodynia    cold   flushed/cyanotic  sweats    intention      brittle  pigmented 
19. F, 41  LU  127    hyperalgesia  allodynia    hot   flushed/cyanotic  sweats    resting      slow, brittle   
20. F, 36  LL  11    hyperalgesia  allodynia    cold   flushed/cyanotic        dystonia      scaly 
21. F, 52  RL  202    hyperalgesia  allodynia    hot/cold  flushed/cyanotic  sweats    resting      fast  mottled 
22. F, 49  RL  47    hyperalgesia  allodynia    cold  flushed/cyanotic  sweats    resting      fast   
23. F, 33  RU  81    hyperalgesia  allodynia    hot        resting    more      
231  
24. F, 15  RL  13    hyperalgesia  allodynia    hot   flushed/cyanotic  sweats    resting        grey 
25. F, 22  RL  18    hyperalgesia  allodynia    hot/cold  flushed/cyanotic  sweats    resting        glossy 
26. F, 43  RU  4.5    hyperalgesia  allodynia    cold  cyanotic            slow  scaly 
27. F, 44  LU  55      allodynia    cold  flushed/cyanotic  sweats    intention      fast  scaly 
31. F, 59  LL  86    hyperalgesia  allodynia      flushed/cyanotic  sweats    resting      slow  glossy 
32. F, 49  LL  107    hyperalgesia  allodynia    cold  flushed      resting    less  fast   
33. F, 46  LU  46    hyperalgesia  allodynia    hot  flushed/cyanotic  sweats    resting  dystonia  less  slow   
34. F, 53  RL  5.5    hyperalgesia  allodynia     cold  flushed/cyanotic  sweats                 glossy 
Non-responders 
2. F, 36  RU  35    hyperalgesia  allodynia    hot/cold    sweats    intention    more  fast  scaly 
7. F, 29  RL  27    hyperalgesia  allodynia    cold   flushed/cyanotic      resting        yellow 
10. M, 50  RU  230    hyperalgesia  allodynia    hot/cold  flushed  sweats    resting    less  dystrophy  glossy 
14. F, 20  LU  2    hyperalgesia  allodynia    hot/cold   flushed  sweats    resting  dystonia       
28. M, 48  RL  90    hyperalgesia  allodynia    cold  flushed/cyanotic  sweats    resting    less    scaly 
30. F, 55  RL  96    hyperalgesia  allodynia    hot  cyanotic  sweats          sensitive  glossy/scaly 
Pain-reduction patient 
29. F, 34  RU  106    hyperalgesia  allodynia    cold  flushed/cyanotic      intention        scaly 
 
Symptom history as reported by patients. Signs of disturbances noted during the physical examination are italicized in bold. A blank space indicates a   
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lack of that particular symptom. Limb LU, left upper extremity; RU, right upper extremity; LL, left lower extremity; RL, right lower extremity. Sensory 
disturbances reported by patients included hyperalgesia, allodynia and numbness. Numbness was reported by all but seven patients (Nos. 4, 10, 23, 24, 
25, 32, 34). The extent of hyperalgesia (to punctate stimulation) and allodynia (to brushing) in the symptomatic and the contralateral healthy limb was 
assessed during the physical examination. Sharpness was rated in response to a single application of a firm nylon bristle (Filament 17, Senselab von 
Frey Aesthesiometer, Somedic Sales AB, Sweden) on a scale from 0 (not sharp) to 10 (stabbing). The bristle was applied with sufficient force to bend 
it for 1 s. Punctate hyperalgesia was defined as a sharpness rating at least 2 higher on a 0-10 scale in the affected than the unaffected limb. Patients 
rated the sensation to 3-4 light backwards-forwards strokes with a small brush as a normal or abnormal sensation. Descriptions of the brushing as 
uncomfortable, scratching or painful were regarded as allodynia. Three patients reported a numb sensation to the brushing (Nos. 9, 11, 24). Vasomotor 
and sudomotor disturbances reported by patients were asymmetrical temperature sensations, dyschromia and hyperhidrosis. Limb temperature was also 
obtained from both the symptomatic and the equivalent healthy limb. This was done after the patient had rested quietly for at least 20 minutes in a 
room maintained at 20 ± 2°C. The temperature of the first phalanx of each toe was determined in lower limb CRPS patients, whilst the equivalent was 
obtained in the fingers of patients with upper limb pain, using an infrared skin thermometer (Tempett IR Thermometer, Somedic Sales AB, Sweden). A 
temperature difference greater than 1°C was regarded as asymmetrical (e.g., a hot or cold limb) and is italicized in bold. Swelling was reported by all 
patients except one (No. 10). A decreased range of movement was observed and reported by all but two patients (Nos. 23 and 28). Other motor 
disturbances reported by patients included weakness (all but patient no. 34), tremor and dystonia. Trophic changes (hair, nails, skin) varied greatly 
between patients.  
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Table 2 
Association (Spearman’s rank-order correlation coefficient) between sensory disturbances in the affected limb and asymmetry of sensations 
in the forehead 
 
 
 
 
 
 
 
 
 
 
 
 
** p < 0.01; *** p < 0.001 
 
   Sensations in the affected limb (compared with the unaffected limb) 
Ipsilateral side of the forehead (compared 
with the contralateral side)  Pressure hyperalgesia  Punctate hyperalgesia 
Pressure hyperalgesia  0.18  -0.48** 
Punctate hyperalgesia  -0.04  0.60***  
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Table 3 
 Demographic and sensory characteristics in startle-responders and non-responders 
 
aFisher’s exact test.
 bWilcoxon test.    
 
Startle-responders 
(N = 21) 
Non-responders 
(N = 6)  p 
Females   86%  67%  0.30 
a 
Age (years)  42.24 ± 2.59  39.67 ± 5.55  0.77 
b 
Pain intensity (0-10)  5.38 ± 0.37  3.10 ± 0.89  0.02 
b 
Pain duration (months)  49.17 ± 8.99  80 ± 33.55  0.52 
b 
       
Forehead hyperalgesia (overall mean)       
PPT (g)  530 ± 40  853 ± 183  0.06
 b 
Sharpness (0-10)  3.86 ± 0.48  2.08 ± 0.40  0.07 
b 
       
Ipsilateral forehead hyperalgesia       
(ipsilateral vs. contralateral forehead)       
PPT (g)  142 ± 54  -40 ± 68  0.39 
b 
Sharpness (0-10)  1.76 ± 0.69  -0.50 ± 0.22  0.04
 b 
       
Hyperalgesia in the symptomatic limb       
(symptomatic vs. contralateral limb)       
PPT (g)  -843 ± 116  -717 ± 394  0.84
 b 
Sharpness (0-10)  2.24 ± 0.79  1 ± 1.51  0.21 
b 
       
Auditory discomfort (0-10)  5.87 ± 0.50  3.44 ± 1.05  0.04 
b 
       
Greater ipsilateral auditory discomfort (0-10)       
(ipsilateral vs. contralateral startle)  1.14 ± 0.41  -0.13 ± 0.30  0.13 
b 
       
Medication  71%  100%  0.18
a 
       
Pain aggravation history        
(when anxious, angry, upset, startled or frightened)  81%  17%  0.01
 a  
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Table 4 
Association (Spearman’s rank-order correlation coefficient) between greater ipsilateral startle hyperalgesia (compared with contralateral startle 
hyperalgesia) and age, limb pain (intensity, duration), asymmetry of sensations in the forehead, asymmetry of sensations in the limbs, and auditory 
discomfort (mean, asymmetry) 
               Ipsilateral forehead hyperalgesia     Hyperalgesia in the affected limb 
  
Auditory discomfort 
  Age  Pain  Pain   
(ipsilateral vs. contralateral 
forehead)   
(symptomatic vs. contralateral 
limb) 
 
Mean  Asymmetry  
      intensity  duration     PPT  Sharpness     PPT  Sharpness 
  
  
(ipsilateral vs. 
contralateral startle) 
 
Startle hyperalgesia asymmetry 
 
0.08 
 
0.34 
 
0.22 
 
 
 
-0.33 
 
0.18 
 
 
 
-0.07 
 
0.08 
 
 
0.52** 
 
0.68*** 
 
** p < 0.01; *** p < 0.001  
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Table 5 
Associations (Spearman’s rank-order correlation coefficient) between auditory discomfort (mean, asymmetry) and age, limb pain (intensity, duration), 
hyperalgesia in the forehead and hyperalgesia in the affected limb 
 
* p < 0.05; *** p < 0.001
               Forehead hyperalgesia     Ipsilateral forehead hyperalgesia     Hyperalgesia in the affected limb 
  Age  Pain  Pain    (overall mean)    (ipsilateral vs. contralateral forehead)    (symptomatic vs. contralateral limb) 
      intensity  duration     PPT  Sharpness     PPT  Sharpness     PPT  Sharpness 
 
Mean auditory discomfort  0.05  0.47*  0.15    -0.01  0.68***    -0.09  0.16    0.1  0.03 
 
Auditory discomfort asymmetry 
(ipsilateral vs. contralateral 
startle) 
 
0.2 
 
0.07 
 
0.36 
   
-0.31 
 
0.16 
   
-0.40* 
 
0.28 
   
-0.13 
 
0.25  
 
 
237  
 
 
 
 
 
 
 
 
Fig. 1. Pain ratings before and for 30 s after startle in the ear ipsilateral to the affected limb (filled circles) and the contralateral ear (clear circles) for 
the 21 startle-responders (A), the 6 non-responders (B) and the patient with a reduction in pain to startle (C). The pain increase was greater during 
ipsilateral than contralateral startle in startle-responders (# p < 0.01) and the pain following ipsilateral startle remained greater than the pain following 
contralateral startle for the entire 30 s post startle period (*** p < 0.001). Note that the y-axes differ in the three graphs. Error bars indicate standard 
errors and the arrow represents the loud tone.  
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Abstract 
 
Complex regional pain syndrome (CRPS) is characterized by sensory disturbances that 
spread in a hemilateral distribution on the affected side of the body, and by contralateral 
changes in the sensory and motor cortices. In addition, central inhibitory pain control is 
disrupted. The aim of this study was to determine whether the dysfunction in inhibitory 
control is limited to the affected side of the body. In 22 CRPS patients, sharpness 
sensations and pressure-pain thresholds were assessed on each side of the forehead and in 
the symptomatic and contralateral healthy limb before and after immersion of each limb in 
painfully-cold water for one minute (the cold pressor task). Immersion of the healthy limb 
produced bilateral forehead analgesia to pressure-pain and a reduction in clinical pain in the 
CRPS-affected limb. However, sensitivity to pressure-pain increased in the forehead after 
immersion of the symptomatic limb. The findings suggest that nociceptive stimulation of 
the CRPS-affected limb fails to evoke central inhibitory pain control processes. Disruption 
of inhibitory pain modulation may contribute to uncontrolled sensitization to incoming 
stimuli from the ipsilateral side of the body, and may account for hemilateral sensory 
changes ipsilateral to the affected limb in CRPS. 
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Introduction 
 
Noxious stimuli activate central facilitatory and inhibitory mechanisms that not only 
modify perception of the noxious stimulus but which also modify perception of pain more 
generally. For instance, diffuse noxious inhibitory controls (DNIC), which emanate from 
the caudal medulla, produce widespread inhibition of wide dynamic range neurons in the 
dorsal horn and trigeminal nucleus caudalis through a counter-stimulation process [6; 14; 
27]. Likewise, stress-induced analgesia (SIA), mediated by opioid and non-opioid 
mechanisms [35; 48], is thought to exert widespread inhibition of pain.  
  Complex regional pain syndrome (CRPS) is characterised by limb pain and motor, 
autonomic and sensory disturbances [3; 19; 55] which often spread to include other parts of 
the body particularly on the ipsilateral side [16; 43; 44; 49]. Pressure-pain thresholds, for 
instance, were found to be lower in the forehead ipsilateral to the affected limb than in the 
contralateral forehead, and hyperalgesia to punctuate stimulation in the ipsilateral forehead 
was associated with punctuate hyperalgesia in the affected limb [16]. A hemilateral loss of 
sensation to tactile stimuli has also been reported in CRPS [43; 44; 49]. Interestingly, 
CRPS pain is associated with hyperexcitability in the somatosensory and motor cortices 
that process input from and output to the symptomatic limb [17; 24; 30; 45], consistent with 
lateralised disturbances in neuronal pathways that subserve the pain. 
  CRPS pain increases in response to forehead cooling and to startle with a loud tone 
[15]. In contrast, capsaicin-induced thermal hyperalgesia decreases during such stimuli in 
healthy volunteers, thus implying that a disruption of central inhibitory pain control may 
contribute to the syndrome [15]. To our knowledge, only Seifert and colleagues [46] have 
assessed whether inhibitory pain control differs between the affected and unaffected limbs   241 
in patients with CRPS. They reported reduced inhibitory control (as exemplified by a 
slower decline in pain ratings) compared to controls during repetitive noxious electrical 
stimulation of both the CRPS-affected and unaffected limb. In addition, facilitation 
(indicated by a greater area of pinprick hyperalgesia) was enhanced in the affected limb. 
The aim of our study was to further investigate the apparent lack of inhibitory 
control in CRPS, in particular in terms of laterality. More specifically, we assessed the 
influence of unilateral noxious-cold stimulation of a limb on sensory disturbances in the 
limbs and forehead of patients with CRPS. We hypothesized that noxious stimulation of the 
healthy limb would evoke analgesia in the forehead (consistent with inhibitory pain 
control). In addition, we hypothesized that sensory disturbances in the forehead would 
persist or intensify during noxious stimulation of the CRPS-affected limb, due to failure of 
inhibitory pain control on this side of the body. 
 
Method 
 
Subjects 
Twenty-two patients (6 males) with a mean age of 40.05 ± 2.69 years (range 15-59) 
who met the International Association for the Study of Pain criteria [34] for CRPS I (21 
patients) or CRPS II (1 patient) participated in the study (Table 1). All but 1 patient met the 
more stringent criteria by Harden and colleagues [20]. The lower limb was affected in 11 
patients and the upper limb in the remaining 11 patients. The median duration of CRPS 
pain was 5.2 years (range 2 months – 19.2 years). Sixteen patients were receiving treatment 
with analgesics, anticonvulsants and/or anti-depressants and 6 other patients were 
medication-free. Due to ethical and practical concerns relating to discontinuation of   242 
medication, patients were not asked to abstain from routine medication during the trial. 
During an initial physical examination, sensory, vasomotor/sudomotor and motor/trophic 
disturbances were reported by patients and noted by an experienced medically-trained pain 
specialist. In addition, psychophysical assessments were performed to determine the 
presence of sensory disturbances (punctate hyperalgesia and dynamic allodynia) in the 
affected limb (Table 1). The procedures were approved by the Murdoch University Human 
Research Ethics Committee and informed consent was obtained from each participant. 
 
Procedures 
 
Procedures were performed in a laboratory maintained at 20 ± 2ºC.  
 
Sensory assessments. Sensitivity to blunt pressure and sharpness sensations to a 
firm bristle were assessed on each side of the forehead and on the CRPS-affected hand or 
foot and on the contralateral healthy limb. A spring-loaded algometer with a rounded tip (1 
cm diameter) was used to apply pressure in increments of 200 g on each limb and in 
increments of 80 g on each side of the forehead [18; 25]. This was done to a maximum of 
2.3 kg or until the participant felt pain. Sharpness was rated on a scale from 0 (not sharp) to 
10 (stabbing) at each site in response to a single application with a firm nylon bristle 
(Filament 17, Senselab von Frey Aesthesiometer, Somedic Sales AB, Sweden) [18; 25]. 
Enough force was applied to bend the bristle for 1 second. 
 
Cold Pressor. The cold pressor task involved immersion of the limb in a 2 ± 1ºC 
cold water bath for 1 min [25]. If the participant could not tolerate the 2ºC temperature,   243 
10ºC was used. An aquarium pump was used to circulate the water to avoid the build-up of 
heat around the limb. The patient reported the pain induced by the cold pressor verbally 
from 0 (no pain) to 10 (extremely severe pain) and also rated the level of distress caused by 
the immersion on a scale from 0 (no distress) to 10 (extremely severe distress). These scales 
were also used to rate pain and associated distress in the symptomatic limb. 
  
Trial. The cold pressor task was performed in both the CRPS-affected limb and the 
healthy limb. Sensory assessments were conducted before and after each cold pressor, and 
were repeated at 2 min intervals for 12 min after each cold pressor [25]. Pain and distress 
ratings were also obtained at these times as well as 30 s into the immersions. In half the 
patients, the CRPS-affected limb was immersed first followed by the contralateral healthy 
limb. The reverse order applied to the remaining participants. At least 15 min elapsed 
between the two cold pressor trials. 
 
Statistical analysis. Some of the score distributions did not fit a normal bell-shaped 
curve; thus, where appropriate, nonparametric statistical analyses were employed. As 
analysis of variance generally is robust to violations of normality, repeated measures 
analysis of variance was used to assess changes in pain and distress ratings to immersion of 
the healthy limb versus the CRPS-affected limb. Changes from baseline at each time point 
were investigated with simple contrasts. Repeated measures analysis of variance was also 
employed to detect any differential influences of immersion of the healthy limb versus the 
CRPS-affected limb on pressure-pain and sharpness sensations in the forehead (ipsilateral 
versus contralateral to the CRPS-affected limb). Changes in pressure-pain and sharpness 
sensations in the healthy and the CRPS-affected limb after the cold pressor task were   244 
assessed in a similar analysis of variance. The Huynh-Feldt epsilon was used to correct for 
violations of sphericity. Changes in clinical pain to immersion of the healthy limb were 
investigated in a one-way repeated measures analysis of variance. Wilcoxon’s matched 
pairs signed-ranks tests or analysis of variance were used, as appropriate, for post hoc 
analyses. Data is presented as the mean ± standard error of the mean. 
  
Results 
 
Limb pain induced by cold water immersion 
  Patients described their CRPS-affected limb as being moderately painful (mean 
rating 5.11 ± 0.61 on a 0-10 scale) and distress from the pain averaged slight to moderate 
(mean rating 3.49 ± 0.74 on a 0-10 scale). Only seven patients tolerated a water temperature 
of 2°C for their CRPS-affected limb while all but three patients tolerated this temperature 
for their contralateral healthy limb. Nonetheless, pain in the CRPS-affected limb during 
immersion of this limb (mean rating 8.10 ± 0.52) was similar to the pain in the healthy limb 
during healthy limb immersion (mean rating 7.91 ± 0.56) [Wilcoxon’s Z = -0.41, p = 
0.681]. Pain in the healthy limb decreased at a faster rate upon removal from the water 
[Time x Limb interaction F(2.92,61.28) = 9.98, p = 0.000] (Fig. 1A); straight after the cold 
pressor, the pain was significantly lower in the healthy limb than it was after the cold 
pressor in the CRPS-affected limb [Wilcoxon’s Z = -2.89, p = 0.004]. Distress ratings 
during immersion of the CRPS-affected limb (mean rating 6.21 ± 0.74) were similar to 
distress ratings during immersion of the healthy limb (mean rating 6.09 ± 0.78) 
[Wilcoxon’s Z = -0.51, p = 0.608]. However, distress decreased more rapidly following 
withdrawal of the healthy limb than following withdrawal of the CRPS-affected limb [Time   245 
x Limb interaction F(3.52,73.98) = 2.93, p = 0.032] (Fig. 1B). A difference in distress 
levels emerged immediately after the CP [Wilcoxon’s Z = -2.42, p = 0.016]. 
 
Effect of the cold pressor task on sensitivity to pain in the forehead  
Before the limb immersions, pressure-pain thresholds generally were lower on the 
forehead ipsilateral to the CRPS-affected limb (M = 529 ± 55 g) than on the contralateral 
forehead (M = 593 ± 55 g) [Wilcoxon’s Z = -1.86, p = 0.063], consistent with ipsilateral 
forehead hyperalgesia. This persisted during the limb immersions (Fig. 2) [main effect for 
Forehead F(1,21) = 9.04, p = 0.007]. Bilateral changes in forehead sensations to pressure-
pain, rather than unilateral changes, were detected during the limb immersions (Fig. 2A and 
2B). These changes differed between immersion of the healthy limb and the CRPS-affected 
limb [Time x Immersion (CRPS-affected Limb, Healthy Limb) interaction F(4.12, 86.57) = 
2.87, p = 0.027]. During immersion of the healthy limb, forehead sensitivity to pressure-
pain reached its highest point 2 min after the cold pressor [p = 0.07 compared with 
baseline], but then gradually decreased to a minimum 10 min after the cold pressor [p = 
0.06 compared with baseline] [main effect for Time (immersion healthy limb) 
F(4.95,103.87) = 3.52, p = 0.006]. In contrast, immersion of the CRPS-affected limb 
resulted in an immediate increase in forehead sensitivity [p = 0.016 compared with 
baseline] which persisted for the remainder of the forehead assessments [main effect for 
Time (immersion CRPS-affected limb) F(3.35,70.31) = 4.28, p = 0.006].  
  Sharpness sensations were symmetrical in the forehead ipsilateral (mean rating 3.84 
± 0.62) and contralateral (mean rating 2.99 ± 0.58) to the CRPS-affected limb before the 
limb immersions [Wilcoxon’s Z = -1.42, p = 0.155]. This did not change during immersion 
of either limb (Fig. 2) [main effect for Forehead F(1,21) = 1.15, p = 0.295]. In fact,   246 
sharpness sensations in general remained unchanged throughout both limb immersions 
(Fig. 2C and 2D).    
 
Effect of the cold pressor task on sensitivity to pain in the limbs  
  Pain in the CRPS-affected limb decreased during immersion of the healthy limb [p 
= 0.027 compared with baseline] but returned to pre-immersion levels immediately upon 
removal of the healthy limb from the water (Fig. 3) [main effect for Time F(2.37,49.68) = 
2.65, p = 0.072].  
Before the limb immersions, pressure-pain thresholds were lower in the affected 
limb (M = 520 ± 135 g) than the contralateral limb (M = 1214 ± 135 g) [Wilcoxon’s Z = -
3.68, p = 0.000] indicating pressure hyperalgesia in the CRPS-affected limb. This 
difference in pressure sensitivity between the two limbs persisted during the limb 
immersions (Fig. 4) [main effect for Limb (CRPS-affected Limb, Healthy Limb) F(1,21) = 
34.23, p = 0.000]. Immersion of the healthy limb did not influence pressure hyperalgesia in 
the CRPS-affected limb (as measured after healthy limb immersion) (Fig. 4A), and 
immersion of the CRPS-affected limb similarly did not influence sensations to pressure-
pain in the contralateral healthy limb (Fig. 4B).  
  Sharpness sensations were similar in the CRPS-affected limb (mean rating 3.49 ± 
0.65) and the contralateral limb (mean rating 2.55 ± 0.46) before the limb immersions 
[Wilcoxon’s Z = -1.36, p = 0.173] and throughout the trials (Fig. 4). Sharpness sensations 
both in the symptomatic limb and the healthy limb were unaffected by the limb immersions 
(Fig. 4C and 4D).  
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Discussion 
 
The main finding of this study was an analgesic effect of immersion of the healthy 
limb on general forehead sensitivity to pressure-pain and on pain in the CRPS-affected 
limb. In contrast, no analgesic effects were observed when the CRPS-affected limb was 
immersed. In fact, forehead sensitivity to pressure-pain increased. Together, these findings 
suggest that supraspinal inhibitory pain control processes remain intact, although slightly 
impaired, in CRPS. However, nociceptive afferent input from the CRPS-affected limb 
either fails to evoke these inhibitory processes or simultaneously evokes a pain facilitatory 
mechanism that masks inhibitory influences.   
When triggered by nociceptive stimulation, diffuse noxious inhibitory controls 
(DNIC) normally inhibit the activity of trigeminal [14; 37] and dorsal horn wide dynamic 
range neurons [27; 36] in a counter-stimulation process. The neurons that mediate DNIC 
originate in the subnucleus reticularis dorsalis of the caudal medulla, and operate in a 
supraspinal loop [5; 6; 13; 42; 56]. The diffuse inhibitory effects observed during painfully-
cold stimulation in healthy volunteers are largely attributed to DNIC [2; 15; 25; 26; 29; 39; 
57; 58; 60].  
The patients in the present study experienced severe pain in their CRPS-affected 
limb during cold water immersion which, under normal circumstances, would be expected 
to reduce pain sensitivity at remote sites in the body [25]. Nevertheless, stimulation of the 
CRPS-affected limb failed to induce inhibitory effects. As the 10°C cold water immersion 
of the CRPS-affected limb was as painful as the 2°C cold water immersion of the healthy 
limb, the temperature of the water is unlikely to account for the absence of DNIC. In 
contrast to the present findings, DNIC effects induced by stimulating the affected limb were   248 
found to be enhanced in animals with monoarthritis, polyarthirits or a peripheral 
mononeuropathy [4; 9; 11; 12; 28]. DNIC effects were also observed during normally non-
painful stimulation of an area of static allodynia in patients with peripheral nerve injury [7].  
The findings may indicate dysfunction in neuronal pathways or supraspinal sites 
subserving DNIC from the CRPS limb. In patients with unilateral lesions of the retro-
olivary portion of the medulla (Wallenberg’s syndrome), no DNIC effect was observed 
during heterotopic noxious stimulation of the symptomatic side of the body whereas 
stimulation of the sensate side elicited a DNIC response [13]. Such findings bear a striking 
resemblance to those of the CRPS patients in the present study. Since parts of the medulla 
play a major role in DNIC, deficits in inhibitory control from this region may account for 
the present findings. Nonetheless, the disparate pattern of sensory disturbances in the two 
conditions (hemilateral tactile deficits in CRPS compared with ipsilateral tactile forehead 
deficits in concert with below-neck contralateral tactile deficits in Wallenberg syndrome) 
seems inconsistent with this.  
DNIC is triggered by the activation of Aʴ- and C-fibers [4]. The ascending part of 
the DNIC loop occurs predominantly in the ventrolateral quadrant contralateral to the 
noxious stimulus [56]. Lesioning this quadrant of the cervical cord in rats produces a 
pattern of DNIC deficit similar to that in the present study [56]. In animals with left-sided 
lesions, the remote inhibitory DNIC effect from stimulation of the right hindpaw was 
strongly reduced whereas the lesion did not affect activation of DNIC from stimulation of 
the left hindpaw [56]. Lesions of the dorsal, dorsolateral and ventromedial parts of the 
cervical cord did not produce such effects [56]. Thus, the present findings suggest that 
DNIC-related transmission in the afferent pathway from the symptomatic limb (e.g., in the 
ipsilateral dorsal horn or contralateral ventrolateral quadrant) may be disrupted in CRPS.   249 
Both the spinothalamic tract (that relays nociceptive information to the cerebral cortex) and 
the spinoreticular tract involved in DNIC contain projections from lamina V wide dynamic 
range neurons [8]. Perhaps failure to inhibit activity in the wide dynamic range neurons that 
receive input from the CRPS-affected limb ultimately sensitizes thalamic or cortical 
neurons that receive convergent information from hemilateral body sites. This could 
account for heightened sensitivity to stimulation of not only the affected limb but also other 
hemilateral regions.  
The present findings also support the view that even more widespread disruptions of 
inhibitory pain control are involved in the pathogenesis of CRPS [47]. The inhibitory 
effects on forehead sensations during stimulation of the healthy limb were delayed and 
weak compared to those observed in healthy volunteers during a similar 2°C cold pressor 
[25]. In healthy volunteers, analgesia to pressure-pain sensations developed bilaterally in 
the forehead immediately after cold water immersion of the hand, whereas analgesia was 
absent until 10 minutes after the cold pressor in the CRPS patients in the present study. An 
immediate analgesic effect during the cold pressor was observed for pain in the 
symptomatic limb in the present study, but the reduction in pain subsided immediately 
upon removal of the healthy limb from the cold water. Together, these findings suggest that 
inhibitory pain control is compromised to stimulation of the unaffected side of the body in 
CRPS. The source of this deficit is uncertain but could involve cells in the subnucleus 
reticularis dorsalis that respond to stimulation at any body site, as DNIC was diminished 
both on the symptomatic and non-symptomatic sides of the body. It is interesting to note 
that noxious stimuli also evoke diffuse noxious excitatory controls from the dorsal reticular 
nucleus in the caudal medulla [1]. Thus a dysfunction in inhibitory control in CRPS may 
unmask pain facilitation. A shift toward facilitation in other diffuse bidirectional pain   250 
control mechanisms such as serotonergic projections from raphe nuclei [61] may also play 
a role in CRPS, in particular during immersion of the affected limb as immersion of this 
limb failed to inhibit pain elsewhere in the body.  
During cold water immersion in healthy volunteers, a stronger  analgesia to 
pressure-pain was observed in the forehead ipsilateral to the immersed hand than in the 
contralateral forehead [25]. This analgesic component was lacking in the present study. We 
speculated that coeruleospinal pain modulation normally acts in concert with DNIC and 
perhaps stress-induced analgesia to produce ipsilateral forehead analgesia in healthy 
volunteers. In coeruleospinal pain control, noradrenergic projections from the locus 
coeruleus (LC) produce central inhibition via actions at ʱ2-adrenoceptors [22; 23]. In a rat 
model of unilateral carageenan-induced hindpaw inflammation, activity emanating from the 
LC was observed proximally as well as distally in the ipsilateral dorsal horn, but not the 
contralateral dorsal horn [50-54]. Tsuruoka et al. [54] measured the thermal response 
threshold on all four paws of the rat during unilateral hindpaw inflammation and found 
shorter paw withdrawal latencies for both the inflamed hindpaw and the non-inflamed, but 
hyperalgesic, ipsilateral forepaw in rats with bilateral LC lesions than in sham-operated 
rats. Responses to contralateral stimulation remained unchanged. Curiously, CRPS patients 
display hyperalgesia of the ipsilateral forehead, in particular to pressure-pain [16], 
consistent with hemilaterally extending pain facilitation. Pressure hyperalgesia of the 
ipsilateral forehead was also present in the current sample of CRPS patients. The presence 
of hemilaterally descending facilitation in CRPS would be consistent with the findings by 
Seifert and colleagues [46] of heightened pain facilitation in the affected but not the 
unaffected limb.   251 
Differential analgesic effects to cold water immersion were observed for pressure-
pain and sharpness sensations. Dissociations between such sensations have been 
documented in healthy volunteers [25] and in clinical populations such as CRPS patients 
[16], central post-stroke pain patients [32] and patients with thalamic lesions [41]. Separate 
central representations may thus account for cutaneous versus deep tissue sensitivity. 
Consistent with this, cutaneous nociceptors appear to project predominantly to laminas I 
and II of the dorsal horn [59] whereas deep tissue nociceptors innervate laminas I and V 
[10; 33; 38]. In addition, different brain regions appear to be activated during superficial 
versus deep pain [21]. 
A limitation of this study is that patients remained on their usual pain medication. 
However, if anything, medication should have promoted analgesia during immersion of the 
CRPS-affected limb. A second limitation is that most patients were studied a year or more 
after CRPS onset, possibly when CRPS was maintained by secondary changes. It would be 
interesting to compare pain modulation processes in the early and advanced stages of 
CRPS.   
In conclusion, central inhibitory pain control appears to be disrupted in CRPS to 
noxious stimulation on the CRPS-affected side of the body whereas inhibitory pain control 
to stimulation on the healthy side seems to be intact, although somewhat impaired. This 
disruption could unmask pain facilitation and thus promote central sensitization in 
nociceptive pathways. Brain imaging studies have shown that cortical centres involved in 
nociceptive processing are hyperactive during painful stimulation of the affected limb [24; 
30; 31], consistent with central sensitization. In addition, the area in the somatosensory 
cortex representing the affected upper limb shrinks and shifts towards the adjacent cortical 
region representing the lip [24], particularly in patients with intense pain and mechanical   252 
hyperalgesia [30]. This cortical reorganization appears to disrupt normal sensory processing 
[40]. Uncontrolled sensitization of spinal and supraspinal neurons which receive 
convergent input from hemilateral body sites may contribute to the ipsilateral spread of 
hyperalgesia in CRPS.    253 
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Table 1 
Sensory, vasomotor/sudomotor and motor/trophic disturbances in CRPS patients 
   Limb  Pain duration     Sensory     Vasomotor/sudomotor     Motor/trophic 
    (months)    Hyperalgesia  Allodynia    Temp.  Dyschromia  Hyper-     Tremor  Dystonia  Hair  Nail  Skin  
                     sensation     hidrosis          growth  growth  changes 
1. F, 59  RU  25    hyperalgesia  allodynia    cold   flushed/cyanotic  sweats    resting  dystonia    fast   
2. F, 36  RU  35    hyperalgesia  allodynia    hot/cold    sweats    intention    more  fast  scaly 
4. M, 46  LL  24    hyperalgesia  allodynia      cyanotic  sweats             
6. M , 21  RL  16    hyperalgesia  allodynia    cold   flushed/cyanotic  sweats    resting    less  fast  scaly 
7. F, 29  RL  27    hyperalgesia  allodynia    cold   flushed/cyanotic      resting        yellow 
9. F, 45  LU  36    hyperalgesia  allodynia    cold   pale/flushed  sweats          fast   
10. M, 50  RU  230    hyperalgesia  allodynia    hot   flushed  sweats    resting    less  dystrophy  glossy 
11. M, 48  LU  24    hyperalgesia  allodynia    cold  flushed      resting      fast/brittle  scaly 
12. F, 35  RU  14    hyperalgesia  allodynia    cold   flushed/cyanotic  sweats    resting    less  slow  glossy 
13. F, 39  RU  71.5    hyperalgesia  allodynia    cold   flushed/cyanotic  sweats    intention      brittle  pigmented 
14. F, 20  LU  2    hyperalgesia  allodynia    hot/cold   flushed  sweats    resting  dystonia        
261  
21. F, 52  RU  202    hyperalgesia  allodynia    hot/cold  flushed/cyanotic  sweats    resting      fast  mottled 
23. F, 33  RU  71    hyperalgesia  allodynia    hot        resting    more     
24. F, 15  RL  13    hyperalgesia  allodynia    hot   flushed/cyanotic  sweats    resting        grey 
28. M, 48  RL  90    hyperalgesia  allodynia    cold  flushed/cyanotic  sweats    resting    less    scaly 
29. F, 34  RU  106    hyperalgesia  allodynia    cold  flushed/cyanotic      intention        scaly 
30. F, 55  RL  96    hyperalgesia  allodynia    hot  cyanotic  sweats          sensitive  glossy/scaly 
31. F, 59  LL  80    hyperalgesia  allodynia      flushed/cyanotic  sweats    resting      slow  glossy 
32. F, 49  LL  104    hyperalgesia  allodynia    cold  flushed      resting    less  fast   
35. F, 39  RL  97     hyperalgesia  allodynia     hot/cold  flushed/cyanotic  sweats     intention     more  fast  scaly 
36. F, 45  RU  204    hyperalgesia  allodynia    hot  pale/flushed      resting  dystonia    fast  mottled 
37. M, 25  LL  54    hyperalgesia  allodynia    hot/cold  cyanotic  less            scaly 
 
Symptom history as reported by patients. Signs of disturbances noted during the initial physical examination are italicized in bold. A blank space 
indicates a lack of that particular symptom. Limb LU, left upper extremity; RU, right upper extremity; LL, left lower extremity; RL, right lower 
extremity. Sensory disturbances reported by patients included hyperalgesia, allodynia and numbness. Numbness was reported by all but six patients 
(Nos. 4, 10, 23, 24, 30, 32). The extent of hyperalgesia (to punctate stimulation) and allodynia (to brushing) in the symptomatic and the contralateral 
healthy limb was determined during an initial physical examination. Sharpness was rated in response to a single application of a firm nylon bristle 
(Filament 17, Senselab von Frey Aesthesiometer, Somedic Sales AB, Sweden) on a scale from 0 (not sharp) to 10 (stabbing). The bristle was applied 
with sufficient force to bend it for 1 s. Punctate hyperalgesia was defined as a sharpness rating at least 2 higher on a 0-10 scale in the affected than  
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the unaffected limb. Patients rated the sensation to 3-4 light backwards-forwards strokes with a small brush as a normal or abnormal sensation. A 
qualitative description of the sensation was given by patients, when the brush felt abnormal. Descriptions of the brushing as uncomfortable, scratching 
or painful were regarded as allodynia. Two patients reported a numb sensation to the brushing (Nos. 24, 36). Vasomotor and sudomotor disturbances 
reported by patients were asymmetrical temperature sensations, dyschromia and hyperhidrosis. Limb temperature was also obtained from both the 
symptomatic and the equivalent healthy limb. This was done after the patient had rested quietly for at least 20 minutes in a room maintained at 20 ± 
2°C. The temperature of the first phalanx of each toe was determined in lower limb CRPS patients, whilst the equivalent was obtained in the fingers of 
patients with upper limb pain, using an infrared skin thermometer (Tempett IR Thermometer, Somedic Sales AB, Sweden). A temperature difference 
greater than 1°C was regarded as asymmetrical (e.g., a hot or cold limb) and is italicized in bold. Swelling was reported by all patients except one (No. 
28). A decreased range of movement was observed and reported by all but three patients (Nos. 7, 23, 28). Other motor disturbances reported by 
patients included weakness (all but patient no. 36), tremor and dystonia. Trophic changes (hair, nails, skin) varied greatly between patients.  
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Fig. 1. Pain and distress ratings in the healthy limb during healthy limb immersion and in the symptomatic limb during symptomatic limb 
immersion. A similar degree of pain and distress was experienced during immersion of the two limbs although both pain and distress 
decreased at a faster rate upon cold water removal of the healthy limb than the symptomatic limb resulting in greater pain and distress to 
immersion of the symptomatic limb after the CP and 2 min after the CP respectively. Error bars indicate standard errors and the arrow 
represents the CP.  
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Fig. 2. PPTs and sharpness ratings in the forehead ipsilateral and contralateral to the CRPS-affected limb before and for 12 min after cold 
water immersion of the healthy limb versus the symptomatic limb. During CP of the healthy limb, forehead sensitivity to pressure-pain 
initially increased (# p < 0.1 compared to baseline) but subsequently decreased (# p < 0.1 compared to baseline). In contrast, forehead 
sensitivity to pressure-pain increased and persisted immediately after immersion of the symptomatic limb (* p < 0.05 compared to baseline). 
No changes were observed for sharpness sensations. Error bars indicate standard errors and the arrow represents the CP.  
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Fig. 3. Clinical pain ratings in the symptomatic limb in response to cold water immersion of 
the contralateral healthy limb. Pain decreased significantly during immersion of the healthy 
limb (* p < 0.05), but returned to pre-immersion levels upon removal of the healthy limb 
from the water. Error bars indicate standard errors and the arrow represents the CP. 
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Fig. 4. PPTs and sharpness ratings in the healthy limb and the CRPS-affected limb before and for 12 min after cold water immersion of the 
healthy limb versus cold water immersion of the symptomatic limb. PPTs and sharpness ratings were not influenced during immersion of 
either limb. Error bars indicate standard errors and the arrow represents the CP.   269 
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Abstract 
 
Sensory disturbances commonly spread outside the affected limb to the ipsilateral 
forehead in patients with complex regional pain syndrome (CRPS). To investigate whether 
this is a unique characteristic of CRPS or whether it occurs in other pain conditions, 
pressure-pain thresholds and sharpness sensations to a firm bristle were assessed on each 
side of the forehead, at the pain site and at an equivalent site on the contralateral side of the 
body in 35 chronic pain patients without CRPS (with neuropathic or nociceptive limb pain, 
back pain, or acute herpes zoster/postherpetic neuralgia). Findings were compared with 
similar assessments in 34 patients with CRPS. Ipsilateral forehead hyperalgesia to pressure-
pain was present in a greater proportion of CRPS (59%) than non-CRPS patients (14%). 
Thirty-eight percent of CRPS patients also reported ipsilateral forehead hyperalgesia to 
sharpness. Ipsilateral forehead hyperalgesia both to sharpness and pressure-pain was, 
nonetheless, present in a minority of non-CRPS patients. In general, heightened sensitivity 
to pressure and sharpness in the ipsilateral forehead was present in patients with greater 
pain, sharpness hyperalgesia and swelling at the pain site. Inflammation-induced 
sensitization of spinal and supraspinal neurons, perhaps heightened by abnormal central 
pain control, could underlie the hyperexcitability to stimulation both at the pain site and in 
the ipsilateral forehead. Ipsilateral forehead hyperalgesia to pressure-pain was more 
prevalent in patients with a longer duration of CRPS, suggesting that mechanisms that 
predominate in the later stages of the disease mediate the spread of hyperalgesia from the 
affected limb to more distant sites.    271 
Introduction 
 
Complex regional pain syndrome (CRPS) is a condition characterised by regional 
pain and sensory disturbances (hyperalgesia, allodynia and sensory loss) as well as 
disturbances in autonomic and motor systems [2; 16; 44]. Theories about the pathology 
underlying CRPS include exaggerated neurogenic inflammation, sympathetic nervous 
system dysfunction (adrenergic supersensitivity, sprouting of adrenergic receptors) and 
central sensitization and disinhibition. 
In CRPS, sensory disturbances commonly spread outside the affected limb [11; 35; 
36; 40]. A hemilateral or quadratomal loss of sensitivity to tactile stimulation (pinprick, 
touch, thermal thresholds) was documented in 50% of CRPS patients [35; 36; 40] and 
hyperalgesia to pressure-pain was documented in the ipsilateral forehead in 78% of patients 
[11]. Sensations of sharpness to pinprick in the ipsilateral forehead were associated with 
similar sensations in the affected limb [11]. Hemilateral sensory disturbances were 
suggested to be characteristic of CRPS with a potential for diagnostic use [11].  
Sensory disturbances may also spread in chronic pain conditions other than CRPS 
[28]. Levy and Munchin [25] and Moldofsky and England [30] reported on small samples 
of ‘hysterical anesthesia’ patients (nine and five patients respectively) with hemianesthesia 
or hemihypoesthesia. Fishbain et al. [14] documented non-dermatomal sensory loss in 
40.4% of 247 patients with myofascial pain syndrome, but did not report the location of the 
abnormalities or the type of assessments conducted. In a study of 194 patients, most with 
fibromyalgia, 49 patients (25.3%) presented with deficits to pinprick in a hemilateral or 
quadratomal pattern on the side of pain or worst pain [29]. Pressure-pain thresholds were 
either elevated or reduced. Fibromyalgia, by definition, is a generalized pain condition 
which might explain the widely distributed sensory disturbances to pressure and pinprick.   272 
Similar arguments can be made for myofascial pain syndrome. Rommel et al. [37] have 
since described two radiculopathy patients with sensory loss to touch, pain and temperature 
on the entire ipsilateral side of the body; however, the case report nature of this study limits 
its generalisability.  
To determine the specificity of hemilateral sensory disturbances to CRPS, it is 
important to establish whether sensory disturbances occur outside the area of pain in a 
larger group of patients with more localized chronic pain than fibromyalgia or myofascial 
pain syndrome. The aim of this study was to investigate sensory disturbances to pressure 
and pinprick on each side of the forehead in patients with chronic non-CRPS pain limited to 
one side of the body, and to compare the findings with those of CRPS patients. In addition 
to shedding light on the diagnostic utility of hemilateral sensory disturbances for CRPS, 
such investigations may also help shed light on mechanisms underlying the spread of 
sensory disturbances. 
 
Method 
 
Participants 
Thirty-five chronic pain patients without CRPS participated in the study. They were 
recruited from local hospitals and pain clinics based on prior medical diagnoses. Unilateral 
pain was a pre-requisite in all patients. Three patients had acute herpes zoster (HZ) and 8 
had postherpetic neuralgia (PHN), 6 patients suffered from neuropathic limb pain and 11 
patients from nociceptive limb pain (8 osteoarthritis, 2 tendinosis, 1 blood clot). Another 7 
patients experienced lower back pain from disc protrusion/degeneration which radiated 
down to the toes (3 patients), knee (1 patient) or occasionally the thigh (2 patients) of one 
limb. These patients were compared to 34 patients with unilateral CRPS seen by the   273 
investigators over the past three years (CRPS I: 32 patients, CRPS II: 2 patients). 
Symptoms were assessed according to the CRPS criteria (Table 1) [17] to establish whether 
such symptoms were associated with unilaterally extending sensory disturbances. Patients 
were not required to abstain from routine medication during the trial due to the practical 
and ethical concerns relating to this. Medication use amongst CRPS and non-CRPS patients 
included analgesics, anticonvulsants and/or antidepressants. The proportion of patients on 
medication did not differ between CRPS patients and the other pain patients (Table 1), 
although fewer back pain patients received medication for their pain. The Murdoch 
University Human Research Ethics Committee approved the study and written informed 
consent was obtained from each participant. 
 
Procedure 
Tests of sensation. Pressure-pain thresholds (PPTs) and sharpness sensations to 
stimulation with a firm bristle were assessed on each side of the forehead, as well as at the 
site of pain [13]. In back pain patients, this was always the lumbar region. In HZ/PHN 
patients the upper back or chest was usually the site of testing. The dorsal hand or foot was 
assessed in limb pain patients. An equivalent location on the contralateral side of the body 
was also assessed. Pressure was applied using a spring loaded algometer with a rounded tip 
(1 cm in diameter). Pressure was applied in 80 g increments to the forehead and 200 g 
increments elsewhere until participants reported the onset of pain or to a maximum of 2.3 
kg [13]. Only 9 patients tolerated the maximum pressure, usually in the unaffected limb (8 
patients). Sharpness was rated on a scale from 0 (not sharp) to 10 (stabbing) in response to 
a single application with a firm nylon bristle (Filament 17, Senselab von Frey 
Aesthesiometer, Somedic Sales AB, Sweden) [13]. The bristle was applied until it bent for 
1 s. The bristle was tolerated by all patients.   274 
Statistical approach 
Differences in sensitivity to pressure-pain and sharpness between the ipsilateral and 
contralateral forehead of patients without CRPS were investigated in Forehead side 
(ipsilateral forehead versus contralateral forehead) x Pain location (limb pain versus torso 
pain) x Pain type (nociceptive pain versus neuropathic pain) analyses of variance. As 
findings from these analyses were similar irrespective of pain location or type of pain, the 
non-CRPS patients were grouped together in subsequent analyses. Thus, Forehead side 
(ipsilateral forehead versus contralateral forehead) x Pain group (non-CRPS versus CRPS) 
analyses of variance compared non-CRPS patients to CRPS patients on sensitivity to 
pressure-pain and sharpness in the ipsilateral versus the contralateral forehead. Analysis of 
variance generally is robust to violations of normality. However, as some data did not fit a 
normal bell-shaped curve, the non-parametric Wilcoxon’s signed-ranks sum test was 
employed to investigate significant interactions. 
Sensitivity to pressure-pain and sharpness normally differs slightly between the 
right and left side of the forehead in healthy individuals [22]. To determine the proportion 
of patients with ipsilateral forehead hyperalgesia or ipsilateral forehead analgesia amongst 
CRPS and non-CRPS patients, the absolute difference in sensitivity between the right and 
left side of the forehead in a sample of 141 healthy volunteers (96 females (68%), mean age 
= 24.00 ± 0.61 years), examined by the authors previously, provided a comparison. As the 
healthy sample data for pressure-pain was positively skewed, a difference outside that of 
the 80
th percentile of the healthy volunteers (160 g or above) was considered unusual (i.e., 
ipsilateral forehead hyperalgesia or ipsilateral forehead analgesia). As the absolute 
difference in forehead sensitivity to sharpness was more homogenous, the 90
th percentile 
provided the cut-off point for sharpness (a difference of 2 points on the VAS or above). 
Pearson’s chi-square, or in the case of small expected frequency counts, Fisher’s exact test,   275 
was used to explore differences in the proportion of patients with ipsilateral forehead 
hyperalgesia to pressure-pain, and sharpness, in the CRPS versus the non-CRPS group. 
Similar analyses were performed for ipsilateral forehead analgesia and symmetrical (within 
normal range) forehead sensitivity.  
To determine the factors (gender, age, pain intensity, pain duration, hyperalgesia to 
sharpness and pressure at the pain site, swelling, hyperhidrosis, dyschromia, motor 
disturbances (absent, mild, severe) and trophic disturbances (absent, present)) that 
distinguished people with ipsilateral forehead hyperalgesia from patients without, Mann-
Whitney U tests or Fisher’s exact tests, as appropriate, were employed. The presence of 
dystonia denoted severe motor disturbances while the presence of tremor and/or limited 
range of movement denoted mild motor disturbances. These analyses were performed 
separately for the CRPS patients and non-CRPS patients to determine whether similar 
factors were associated with ipsilateral forehead hyperalgesia in both groups. Back pain 
patients and HZ/PHN patients were excluded from the analyses of hyperalgesia at the pain 
site due to the potential confound of differences in sensitivity at the testing site (limbs vs. 
torso). Data is presented as the mean ± standard error of the mean. 
 
Results 
 
Irrespective of pain location (limb versus torso), and whether the pain was 
nociceptive or neuropathic in origin, no difference in sensitivity to pressure-pain was 
observed between the ipsilateral and contralateral forehead in the non-CRPS patients. 
However, greater sharpness ratings to pinprick in the ipsilateral forehead was observed 
(Fig. 1) [main effect for Forehead Side F(1,31) = 4.62, p = 0.039].    276 
In contrast, sensitivity to pressure-pain was greater in the ipsilateral than the 
contralateral forehead of patients with CRPS consistent with ipsilateral forehead 
hyperalgesia (Fig. 1A) [Wilcoxon’s Z = -3.12, p = 0.002] [Forehead Side x Pain group 
interaction F(1, 67) = 11.43, p = 0.005]. Like the non-CRPS patients, CRPS patients 
reported greater sharpness ratings to punctate stimulation in the ipsilateral forehead (Fig. 
1B) [main effect for Forehead Side F(1,67) = 9.80, p = 0.003].  
The proportion of patients with ipsilateral forehead hyperalgesia or analgesia to 
pressure-pain is shown in Figure 2. The majority of CRPS patients displayed ipsilateral 
forehead hyperalgesia to pressure-pain (59%) (Fig. 2A). This was a significantly greater 
proportion than in the non-CRPS group (14%) [X
2 =  14.81, p = 0.000]. Conversely, 
forehead sensitivity to pressure was symmetrical in the majority of non-CRPS patients 
(69%) (Fig. 2B). This was a greater proportion than in the CRPS group (26%) [X
2 = 12.25, 
p = 0.000]. The proportion of patients with ipsilateral forehead analgesia to pressure in the 
non-CRPS group (17%) was similar to that in the CRPS group (15%) (Fig. 2C).  
As shown in Figure 3, the CRPS patients did not differ greatly from the non-CRPS 
group in the proportion of patients with asymmetrical forehead sensations to sharpness. 
Ipsilateral forehead hyperalgesia to sharpness was present in 38% of CRPS patients and 
26% of non-CRPS patients (Fig. 3A), but symmetrical forehead sensitivity to sharpness 
generally seemed to dominate amongst both CRPS (50%) and non-CRPS patients (66%) 
(Fig. 3B). 
Both CRPS and non-CRPS patients with ipsilateral forehead hyperalgesia generally 
reported heightened sensitivity at the pain site (Table 2). CRPS patients with ipsilateral 
forehead hyperalgesia to pressure or sharpness reported, respectively, greater sharpness 
hyperalgesia in the affected limb and greater pain in the affected limb than the remaining 
CRPS patients. In addition, non-CRPS patients with sharpness hyperalgesia in the   277 
ipsilateral forehead reported greater hyperalgesia to sharpness at the pain site than non-
CRPS patients without ipsilateral forehead hyperalgesia. Non-CRPS patients with 
ipsilateral forehead hyperalgesia to pressure were also more likely to describe swelling at 
the pain site (Table 2). All CRPS patients with ipsilateral forehead hyperalgesia to pressure 
similarly reported swelling in their affected limb, but so did 93% of the remaining CRPS 
patients. Finally, CRPS patients with ipsilateral forehead hyperalgesia to pressure reported 
a longer duration of pain and, probably for similar reasons, were older than CRPS patients 
without ipsilateral forehead hyperalgesia to pressure (Table 2).  
 
Discussion 
 
 
This study confirmed previous findings of ipsilateral forehead hyperalgesia in 
CRPS [11; 13]. Ipsilateral forehead hyperalgesia to pressure-pain was present in the 
majority of CRPS patients (59%) and sharpness hyperalgesia was present in the ipsilateral 
forehead in 38% of patients with CRPS. In contrast, forehead sensitivity to pressure-pain 
and sharpness was symmetrical in most non-CRPS patients (69%). Ipsilateral forehead 
hyperalgesia both to sharpness (26%) and pressure-pain (14%) was, however, detected in a 
few of these patients. These findings suggest that the utility of ipsilateral forehead 
hyperalgesia to pressure-pain in the diagnosis of CRPS warrants further investigation.  
The mechanism underlying the ipsilateral forehead hyperalgesia is unclear, but a 
similar mechanism probably mediates heightened sensitivity at the pain site. Sharpness 
hyperalgesia at the pain site was greater both in CRPS patients with ipsilateral forehead 
hyperalgesia to pressure-pain and in non-CRPS patients with ipsilateral forehead 
hyperalgesia to sharpness than in other patients. In addition, CRPS patients with ipsilateral 
forehead hyperalgesia to sharpness reported greater pain in the affected limb. Ipsilateral   278 
forehead hyperalgesia to pressure-pain or sharpness was also previously associated with 
heightened sensitivity in the affected limb to stimuli such as pinprick or thermal hot or cold 
[11; 13].  
Possible mechanisms underlying the spread of hyperalgesia from the affected limb 
to the forehead in CRPS may include sensitization of spinal or supraspinal nociceptive 
neurons or disruption of central pain modulating processes. Cortical nociceptive input from 
the affected limb (e.g., during mechanical hyperalgesia) is heightened [21; 26; 27; 43] and 
cortical representation of the symptomatic limb is reduced [21; 26; 33]. Mean sustained 
pain levels over several weeks were associated with the extent of cortical reorganisation 
[33], consistent with sensitization of spinal or supraspinal neurons to nociceptive input 
from the CRPS-affected limb. Central pain modulating mechanisms also appear to be 
compromised in CRPS [9; 10; 39].  A dysfunction in inhibitory pain control could promote 
the transfer of nociceptive messages to higher brain centres. Increased excitability at brain 
sites that receive convergent input from hemilateral body sites such as the contralateral 
thalamus or somatosensory cortex could underlie the heightened sensitivity to stimulation 
both in the affected limb and the ipsilateral forehead. In addition, a shift toward facilitation 
for mechanisms with a bidirectional role in pain control, such as the noradrenergic actions 
from the locus coeruleus, the serotonergic actions from the raphe nuclei or diffuse noxious 
facilitatory versus inhibitory controls, may increase the excitability of both spinal and 
supraspinal neurons [1; 18; 20; 47; 48]. In particular, noradrenergic projections from the 
locus coeruleus, which were detected only in the ipsilateral and not in the contralateral 
dorsal horn during unilateral carageenan-induced hindpaw inflammation in the rat [41], 
could contribute to central facilitation hemilaterally via actions at α1-adrenoceptors in the 
dorsal horn [18].    279 
The majority of non-CRPS patients with ipsilateral forehead hyperalgesia to 
pressure-pain described swelling at the pain site. As all CRPS patients with ipsilateral 
pressure hyperalgesia in the forehead also described swelling, it is tempting to speculate 
that inflammation at the pain site, perhaps in conjunction with hyperalgesia, contributes to 
the spread of sensory disturbances. Exaggerated neurogenic inflammation is postulated to 
play a crucial role in the generation of CRPS [3; 4; 23; 45]. Many CRPS symptoms such as 
swelling, hyperhidrosis, dyschromia and trophic changes are consistent with inflammation. 
These symptoms were generally present in a greater proportion of CRPS patients than non-
CRPS patients in the present study, and could thus be linked with the increased prevalence 
of sensory disturbances in the forehead in the CRPS group. During inflammation, the 
activation threshold of dorsal horn neurons decreases and their receptive fields and 
responsiveness increase in response to continuous C fiber input to the superficial layers of 
the dorsal horn [6]. This could provide a mechanism by which inflammation facilitates the 
excitability of spinal and/or supraspinal neurons. Consistent with this, carageenan-induced 
hindpaw inflammation in the rat decreased paw withdrawal latencies to thermal stimuli 
both in the inflamed hindpaw and the non-inflamed ipsilateral forepaw [42]. However, 
inflammation alone cannot explain the ipsilateral spread of hyperalgesia in CRPS because 
the affected limb was swollen in most CRPS patients, including those without ipsilateral 
forehead hyperalgesia.  Ipsilateral forehead hyperalgesia to pressure-pain was associated 
with a greater duration of CRPS, suggesting that mechanisms that predominate in the later 
stages of the disease mediate the spread of hyperalgesia from the affected limb to more 
distant sites.  
Ipsilateral forehead hyperalgesia to pressure-pain or sharpness was detected in a 
minority of non-CRPS patients. Sensitization of spinal nociceptive neurons and   280 
reorganisation in the somatosensory cortex might also contribute to the spread of sensations 
in these patients [8; 12; 15; 32; 38] as may central disinhibition [5; 19; 24; 31; 46], perhaps 
maintained by inflammation (swelling) at the pain site.  
A hemilateral sensory loss, mainly to tactile stimuli, was reported previously in 
CRPS, fibromyalgia and myofascial syndrome patients [14; 29; 35]. Analgesia to pressure-
pain or sharpness was present in the ipsilateral forehead in a small number of CRPS 
(pressure: 15%; sharpness: 12%) and non-CRPS patients (pressure: 17%; sharpness: 8%) in 
the present study. The small proportion of patients with these sensory disturbances did not 
permit analysis of the factors contributing to this type of spread. However, brain imaging 
studies have shown that in CRPS patients with intense pain and hyperalgesia, the area in 
the somatosensory cortex representing the affected upper limb shrinks and shifts towards 
the adjacent cortical region representing the lip [21; 26]. Thus, cortical reorganization could 
disrupt normal sensory processing [34]. The involvement of cortical reorganisation in 
fibromyalgia and myofascial pain syndrome remains to be investigated.  
The present study assessed a similar number of CRPS and non-CRPS patients. The 
sampling of non-CRPS patients with a variety of pain types (e.g., neuropathic pain, 
nociceptive pain, back pain, HZ/PHN) is both a strength and a limitation of the study. 
Assessing forehead sensitivity across a variety of conditions provides an indication of the 
prevalence of hemilateral sensory disturbances in the general non-CRPS pain population, 
but the small number of participants within each diagnostic category limits the 
generalisability of the results for each of these diagnostic groups. Thus, further studies of 
ipsilateral forehead sensory disturbances in larger samples of each pain condition are 
encouraged. These studies should aim to employ objective measures of sign severity to 
investigate whether ipsilateral forehead sensory disturbances (i.e., hemilateral hyperalgesia)   281 
are better determined by such objective measures than the subjective symptom reports 
provided by patients in the present study.  
Due to the demographic features of CRPS [7], more females were present in the 
CRPS group than the non-CRPS group, and they generally were younger. The prevalence 
of CRPS in females is widely recognised and is unlikely to have contributed to the results 
as the proportion of males and females was similar in patients with and without ipsilateral 
forehead hyperalgesia. Age is also unlikely to underlie the greater occurrence of ipsilateral 
forehead hyperalgesia in CRPS patients as patients with ipsilateral forehead hyperalgesia 
were generally older, not younger. Finally, although medication use may have affected the 
results, medication use was similar in the CRPS and non-CRPS conditions and is thus 
unlikely to account for the increased prevalence of sensory disturbances in the ipsilateral 
forehead of CRPS patients. 
In conclusion, the majority of CRPS patients reported ipsilateral forehead 
hyperalgesia to pressure-pain whereas differences in sensitivity to pressure-pain in the 
ipsilateral and contralateral forehead were within the normal range in the majority of non-
CRPS patients. Sensitization of spinal and/or supraspinal neurons that receive convergent 
input from hemilateral body sites could explain hyperexcitability both to stimulation in the 
affected limb and the ipsilateral forehead, and could arise from a failure of pain control 
mechanisms to control the sensitization of central nociceptive neurons during 
inflammation. A shift toward facilitation in pain control mechanisms could further 
contribute to increased excitability of central nociceptive neurons.    282 
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 Table 1  
Sensory, vasomotor/sudomotor and motor/trophic disturbances reported by CRPS patients 
and patients with neuropathic limb pain, HZ/PHN, nociceptive limb pain and back pain 
  
Pain Groups 
  
    Neuropathic pain  Nociceptive pain 
  CRPS  Limb  HZ/PHN  Limb  Back 
   N = 34  N = 6  N = 11  N = 11  N = 7 
Females
a  82%  0%***  36%**  46%*  29%** 
Age (years)
b  40.38 ± 2.11  51.33 ± 3.57***  70.00 ± 3.39***  45.91 ± 4.55  58.57 ± 6.68* 
Pain intensity (0-10)
b  5.13 ± 0.37  5.50 ± 0.41   3.86 ± 0.72  4.27 ± 0.78  4.36 ± 0.94 
Pain duration (months)
b  24.50  49.50   3.00  32.00   24.00  
  (range 2-186)  (range 17-420)  (range 0.50-132)**  (range 3-216)  (range 6-90) 
Symptoms            
           
Sensory changes           
Hypoesthesia
a  79%  83%  36%*  46%*  29%* 
Hyperalgesia
a  97%  67%*  64%**  73%*  29%*** 
Allodynia
a  97%  67%*  82%  36%***  0%*** 
           
Vasomotor/sudomotor           
Swelling
a  97%  33%***  27%***  55%**  29%*** 
Temperature sensation           
Cold
a  56%  0%*  0%***  18%*  0%** 
Hot
a  18%  33%  36%  27%  14% 
Interchanging temperature
a  21%  0%  0%  0%  0% 
Dyschromia           
Flushed
a  15%  17%  36%  27%  0% 
Cyanotic
a  15%  17%  9%  18%  0% 
Interchanging dyschromia
a  53%  0%*  9%**  0%***  0%** 
Hyperhidrosis
a  79%  17%**  0%***  18%***  0%*** 
Hypohidrosis  0%  0%  0%  0%  0% 
           
Motor/trophic           
Limited range of movement
a  91%  67%  9%***  64%*  71% 
Weakness
a  97%  67%*  9%***  91%  57%** 
Tremor
a  79%  33%*  18%***  46%*  0%*** 
Dystonia
a  12%  0%  0%  9%  0% 
Hair growth           
Less
a  18%  17%  0%  0%  0% 
More
a  12%  0%  0%  0%  0% 
Nail growth           289 
 
Slow
a  24%  0%  0%  0%  0% 
Fast
a  38%  0%  0%*  0%*  0%* 
Brittle
a  29%  0%*  0%*  0%*  0% 
Skin changes           
Scaly
a  35%  17%  0%*  9%  0%
# 
Glossy
a  18%  0%  9%  0%  0% 
Mottled
a  3%  0%  0%  0%  0% 
Dark
a  6%  0%  0%  0%  0% 
           
Medication
a  79%  50%  100%  73%  29%* 
 
Symptom percentages indicate the percentage of patients in the pain group who reported 
the presence of the respective symptom. 
 aFisher’s exact test. 
bWilcoxon test. Significantly 
different from the CRPS group. 
 # p < 0.07; * p < 0.05; ** p < 0.01; *** p < 0.001. 
 
 
  
 
Table 2 
Factors distinguishing patients with ipsilateral forehead hyperalgesia to pressure-pain or sharpness from patients without ipsilateral forehead 
hyperalgesia, in the CRPS and non-CRPS conditions 
   Ipsilateral forehead hyperalgesia to pressure-pain     Ipsilateral forehead hyperalgesia to sharpness 
  CRPS    Non-CRPS    CRPS    Non-CRPS 
  
Present 
(N = 20) 
Absent 
(N = 14)    
Present 
(N = 5) 
Absent 
(N = 30)    
Present 
(N = 13) 
Absent 
(N = 21)    
Present 
(N = 9) 
Absent 
(N = 26) 
Females
a  85%  79%    40%  30%    85%  81%    44%  27% 
 
Age (years)
b  44.25 ± 1.88*  34.86 ± 4.00    64.20 ± 6.34  55.73 ± 3.05    40.77 ± 2.39  40.14 ± 3.12    54.67 ± 7.08  57.73 ± 2.92 
 
Pain intensity (0-10)
b  5.33 ± 0.52  4.86 ± 0.51    5.60 ± 0.81  4.17 ± 0.42    6.35 ± 0.54**  4.38 ± 0.42    4.83 ± 0.79  4.21 ± 0.44 
 
Pain duration (months)
b  56.65 ± 10.65**  26.29 ± 9.46    29.60 ± 16.83  55.38 ± 15.37    58.00 ± 14.84  35.57 ± 8.25    65.11 ± 23.04  47.06 ± 16.35 
                       
Symptoms (pain site)                       
                       
Pressure hyperalgesia (g)
b,c                       
(affected limb compared with 
unaffected limb)  -896 ± 143  -864 ± 160    -300 ± 100  -285 ± 168    -1092 ± 183  -753 ± 123    -180 ± 258  -333 ± 154 
                       
Sharpness hyperalgesia (0-10)
b,c                       
(affected limb compared with 
unaffected limb)  3.73 ± 0.83
#  1.00 ± 1.15    3.06 ± 1.39  1.60 ± 0.78    3.81 ± 1.11  1.86 ± 0.89    4.00 ± 0.70*  1.08 ± 0.80 
                       
Swelling
a  100%  93%    80%*  30%    100%  95%    22%  42% 
                       
Dyschromia
a  75%  93%    60%  33%    85%  81%    33%  39% 
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Hyperhidrosis
a  80%  79%    20%  7%    85%  76%    11%  8% 
                       
Motor  (present (severe))
a  90(10%)  86(14%)    60%(0%)  50%(3%)    85%(15%)  91%(10%)    44%(0%)  54%(4%) 
                       
Trophic
a   90%  86%     20%  7%     92%  86%     0%  12% 
 
aFisher’s exact test, 
bMann-Whitney U test. 
CBack pain patients and HZ/PHN patients excluded from analyses. Difference statistically 
significant. # p < 0.07; * p < 0.05; ** p < 0.01.  
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Fig. 1. Pressure-pain thresholds and sharpness ratings in the affected and unaffected pain site and in the ipsilateral and contralateral forehead 
in each pain group (CRPS, neuropathic limb pain, HZ/PHN, nociceptive limb pain and back pain). 
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A. Ipsilateral Forehead Hyperalgesia
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B. Symmetrical Forehead Sensations
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C. Ipsilateral Forehead Analgesia
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Fig. 2. Proportion of CRPS, neuropathic limb pain, HZ/PHN, nociceptive limb pain and 
back pain patients with ipsilateral forehead hyperalgesia, symmetrical forehead sensations 
and ipsilateral forehead analgesia to pressure-pain.  
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A. Ipsilateral Forehead Hyperalgesia
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B. Symmetrical Forehead Sensations
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C. Ipsilateral Forehead  Analgesia
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Fig. 3. Proportion of CRPS, neuropathic limb pain, HZ/PHN, nociceptive limb pain and 
back pain patients with ipsilateral forehead hyperalgesia, symmetrical forehead sensations 
and ipsilateral forehead analgesia to sharpness.  
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CHAPTER 12 
CONCLUSIONS 
 
12.1 Summary of the seven studies 
The aim of this thesis was to investigate potential mechanisms involved in the 
spread of sensory disturbances outside the affected limb in complex regional pain syndrome 
(CRPS). The experiments in chapter 5 investigated the effect of experimental limb pain 
(cold-induced limb pain) on sensory changes outside the limb on each side of the forehead 
in healthy volunteers. Prior to pain induction, differences in pressure-pain or sharpness 
sensitivity between the left and right side of the forehead were generally small or non-
existent. The induction of limb pain in healthy volunteers produced a bilateral reduction in 
forehead sensations to pressure-pain and sharpness with greater analgesia to pressure in the 
ipsilateral forehead.  
  The second study attempted to disrupt inhibitory pain control prior to inducing limb 
pain (via cold noxious stimulation) in a sample of healthy volunteers, and investigated the 
effects of these procedures on sensitivity to pressure-pain and sharpness on each side of the 
forehead. The use of optokinetic stimulation to disrupt inhibitory control was based on 
previous findings of increased forehead sensitivity following this form of motion sickness-
inducing stimulation [12; 13]. As in Study one, differences in forehead sensitivity to 
pressure-pain or sharpness between the left and right sides of the forehead were small or 
non-existent upon commencing the study. Despite a replication of increased forehead 
sensitivity to pressure-pain and sharpness during residual motion sickness, cold-induced 
limb pain reduced forehead sensitivity to these stimuli in the most pain sensitive 
participants, suggesting that inhibitory pain control mechanisms remained intact.   
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  The third study performed in healthy volunteers explored the possibility of an 
association between limb inflammation and hemilateral hyperalgesia. Differences in 
sensitivity to pressure-pain or sharpness between the two sides of the forehead in this group 
of healthy volunteers were again generally small or non-existent, and the application of 
topical capsaicin, an inflammatory agent, to the forearm failed to produce an ipsilateral 
spread of hyperalgesia to the forehead. Instead, participants reported a reduction in 
sharpness ratings in the forehead bilaterally 6 hours after treatment, and a reduction in 
sensitivity to pressure-pain ipsilaterally when the treated area was heated after 48 hours of 
treatment. 
  Limitations of these three studies performed in healthy volunteers included the 
sample characteristics: mostly young, educated females. Nonetheless, gender and age did 
not appear to be a factor in the development of forehead analgesia. Besides, as CRPS is 
more prevalent in females [10], such characteristics are unlikely to account for any 
contrasting findings. Study three was also limited by a small sample size (17 participants). 
Nonetheless, the findings were consistent with those detected in the larger samples in Study 
one and two. Other limitations in these studies included reliance on self-report measures 
and that the experimenter was not blinded to the hypotheses. However, as patients were 
unaware of the specific hypotheses of the studies such influences were probably small. 
Finally, acute experimental pain in healthy volunteers may not be comparable to chronic 
pain. 
CRPS patients were assessed in the remaining studies. In a double-blind placebo-
controlled trial in Study four, the NMDA antagonist, topical ketamine, was applied to the 
affected or unaffected limb of patients with CRPS and the effect on sensitivity to a range of 
sensory stimuli (touch, pinprick, thermal, pressure, brushing) was investigated in the 
affected and unaffected limb and on each side of the forehead. Hyperalgesia to sharpness,  
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pressure, cold and heat, and allodynia to brushing, were detected in the ipsilateral forehead 
before treatment. This was generally associated with heightened sensitivity in the affected 
limb. The topical application of ketamine reduced allodynia and sharpness hyperalgesia in 
the affected limb. In some patients with allodynia in the forehead, forehead allodynia was 
also reduced following treatment of the affected limb with ketamine. 
Study five investigated whether the increase in pain to acoustic startle is lateralized 
in CRPS patients. Acoustic startle in the ear ipsilateral to the affected limb induced greater 
pain than startle in the contralateral ear. In addition, auditory discomfort was greater to 
ipsilateral than contralateral ear stimulation and in patients with increased pain to startle 
than in a small group of non-responders.  
Study six further explored the laterality of a dysfunction in inhibitory pain control in 
CRPS. Pressure-pain and sharpness sensations were investigated on each side of the 
forehead in CRPS patients during noxious cold stimulation of the affected limb versus 
noxious cold stimulation of the contralateral unaffected limb. Cold water immersion of the 
healthy limb produced bilateral forehead analgesia to pressure-pain and a reduction in 
clinical pain in the affected limb. However, pressure-pain increased in the forehead after 
immersion of the symptomatic limb. Sharpness ratings in the forehead remained unchanged 
to immersion of either limb.  
Finally, pressure-pain and sharpness sensations were investigated on each side of 
the forehead in chronic pain patients without CRPS (neuropathic or nociceptive limb pain, 
back pain or acute herpes zoster/postherpetic neuralgia) and compared to similar 
measurements obtained in patients with CRPS. Ipsilateral forehead hyperalgesia to 
pressure-pain appeared to be more common in CRPS patients (59%) than patients without 
CRPS (14%) who generally reported symmetrical (within normal range) forehead 
sensations. Ipsilateral forehead hyperalgesia to sharpness occurred in 38% of CRPS patients  
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which was similar to that in patients without CRPS. However, symmetrical sharpness 
sensations dominated in both groups. In general, heightened sensitivity to pressure and 
sharpness in the ipsilateral forehead was present in patients with greater pain, sharpness 
hyperalgesia and swelling at the pain site.  
The main limitation of these studies included the recruitment of patients from pain 
specialists which may have resulted in a non-representative sample of severely-affected 
patients. In addition, some patients participated in more than one study which may have 
overemphasized the consistency of findings of ipsilateral forehead hyperalgesia in CRPS 
patients across studies (see Appendix A for details about which patients participated in 
which studies). Regular medication use was maintained by medicated patients in all studies 
and potentially could have affected the results. However, the main focus of this thesis was 
the hemilateral disturbances in the patients which are unlikely to have been influenced by 
the systemic effects of medication. Finally, limitations of self-report measures and lack of 
blinding of the experimenter also apply to the studies in CRPS patients. However, like the 
healthy volunteers, patients were unaware of the purpose of the studies rendering such 
influences unlikely. Both patients and the experimenter were blinded to the treatment with 
topical ketamine in Study four. 
 
12.2 Implications for CRPS 
Taken together the findings of this thesis suggest that:  
1.  ipsilateral forehead hyperalgesia, in particular to pressure-pain, may be specific to 
CRPS;  
2.  central sensitization evoked by nociceptive input from the inflamed CRPS limb may 
underlie the hyperalgesia at hemilateral body sites; and   
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3.  dysfunction in generalized and hemilateral pain control mechanisms, in particular to 
stimulation of the affected limb, may contribute to the hemilateral spread of sensory 
disturbances in CRPS.  
 
1. Ipsilateral forehead hyperalgesia, in particular to pressure-pain, may be specific to 
CRPS.  
  As demonstrated in Study one, two, and three, healthy volunteers generally report 
no or very little difference between the sides of the forehead in sensitivity to pressure-pain 
or sharpness. Symmetrical forehead sensitivity to pressure-pain and sharpness also 
dominated in chronic pain patients without CRPS (Study seven). In contrast, ipsilateral 
forehead hyperalgesia to pressure-pain was present in the majority of CRPS patients (Study 
seven). In a previous study, pressure-pain thresholds were similarly lower in the ipsilateral 
than contralateral forehead in 78% of patients with CRPS [14]. Although Study seven 
demonstrated ipsilateral forehead hyperalgesia to sharpness in only 38% of CRPS patients, 
Study four demonstrated greater sensitivity in the ipsilateral than the contralateral forehead 
of CRPS patients across a range of sensory modalities including sharpness (pressure-pain, 
cold pain, heat pain and allodynia to brushing). Thus, the further exploration of the utility 
of ipsilateral forehead hyperalgesia, in particular to pressure-pain, in the diagnosis of CRPS 
is warranted. Such diagnostic assessments are easily applied by health professionals in the 
clinical setting and could provide a viable diagnostic tool. 
 
2. Central sensitization evoked by nociceptive input from the inflamed CRPS limb may 
underlie the hyperalgesia at hemilateral body sites.  
  As described in chapter 3, exaggerated neurogenic inflammation to trauma or injury 
may be involved in the development of CRPS [4; 5; 25; 39; 40]. The sensitization of  
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peripheral nociceptors during inflammation results in increased nociceptive input to the 
dorsal horn which, in turn, promotes central sensitization [8]. Peripheral NMDA-receptors 
are involved in the sensitization of primary afferent nociceptors during inflammation [6; 15; 
21] and could thus indirectly be involved in the sensitization of central neurons in CRPS. 
The topical application of the NMDA-antagonist, ketamine, to the CRPS-affected limb, in 
Study four, reduced allodynia and sharpness hyperalgesia in the affected limb. As allodynia 
to brushing the skin and sharpness hyperalgesia are mediated by sensitized spinal 
nociceptive and wide dynamic range neurons that receive input from nociceptive A-delta 
fibers and non-nociceptive A-beta fibers [26; 27], peripheral NMDA-receptors may play a 
role in the sensitization of central neurons in CRPS. The loss of allodynia in the ipsilateral 
forehead in some patients following the topical application of ketamine to the affected limb 
in Study four suggests that a similar mechanism may contribute to the heightened 
sensitivity in the forehead. 
In CRPS, inflammatory processes may sensitize neurons in the dorsal horn and 
neurons at supraspinal sites that receive input from the affected limb such as the 
contralateral thalamus. Convergence of input from the affected limb and the ipsilateral 
forehead at this site could explain findings of an association between heightened sensitivity 
in the affected limb and heightened sensitivity in the ipsilateral forehead (Study four, five, 
and seven). Associations between heightened sensitivity in the affected limb and in the 
ipsilateral forehead were also demonstrated in a previous study [14].  
 In further support of a link between inflammatory processes and hemilateral 
hyperalgesia, swelling was present in all CRPS patients with ipsilateral forehead 
hyperalgesia to pressure-pain. Similarly, swelling was associated with ipsilateral forehead 
hyperalgesia to pressure in non-CRPS patients. Inflammation could thus play a role in the 
spread of hyperalgesia from the affected limb to the forehead in CRPS. Nonetheless, the  
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contribution of inflammation in the affected limb to the spread of hyperalgesia in CRPS 
requires further investigation. The topical application of capsaicin to the forearm in healthy 
volunteers in Study three failed to induce hyperalgesia in the ipsilateral forehead. It would 
be interesting to see whether inflammation of deeper tissue such as that induced by 
intramuscular capsaicin injection produces hemilateral hyperalgesia. As discussed earlier, 
carageenan injection in the rat hindpaw produced hyperalgesia not only in the injected 
hindpaw but also in the ipsilateral forepaw [36]. Furthermore, additional factors may 
contribute to the spread of hyperalgesia in CRPS as a large proportion of CRPS patients 
without ipsilateral forehead hyperalgesia to pressure-pain also reported swelling in their 
affected limb (Study seven). Such factors may involve mechanisms that become more 
prominent with the progression of the disease as CRPS patients with ipsilateral forehead 
hyperalgesia to pressure-pain reported a greater pain duration than patients without 
ipsilateral forehead hyperalgesia (Study seven). 
 
3. Dysfunction in generalized and hemilateral pain control mechanisms, in particular to 
stimulation of the affected limb, may contribute to the hemilateral spread of sensory 
disturbances in CRPS.  
As described in chapter 2, diffuse noxious inhibitory controls (DNIC) denote the 
mechanism by which a noxious stimulus reduces pain sensitivity at remote body sites [29]. 
This mechanism probably contributed to the bilateral reduction in pain sensitivity in the 
forehead of healthy volunteers during cold-induced limb pain (Study one and two) and 
capsaicin-induced inflammatory limb pain (Study three). In CRPS patients, noxious cold 
stimulation of the unaffected limb also reduced forehead sensitivity to pressure-pain (Study 
six), although the effect was weaker (delayed) than the reduction of forehead sensitivity in 
healthy volunteers (Study one). Interestingly, the DNIC effect did not appear to be evoked  
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during noxious cold stimulation of the affected limb in the CRPS patients (Study six). Thus 
the DNIC effect seems to be compromised in patients with CRPS, in particular to 
stimulation of the affected limb. This is consistent with previous findings that forehead 
cooling increases, rather than decreases, CRPS pain [11].  
DNIC is served by a supraspinal loop with ascending and descending pathways in 
the ventrolateral quadrant and the dorsolateral funiculus respectively [9; 38]. As discussed 
in chapter 10, left-sided lesions of the ventrolateral quadrant in the cervical cord in animals 
reduced the remote inhibitory DNIC effect from stimulation of the right hindpaw whereas 
the activation of DNIC from stimulation of the left hindpaw was unaffected [38]. Thus 
DNIC related transmission in the afferent pathway from the affected limb (e.g., in the 
ipsilateral dorsal horn or the contralateral ventrolateral quadrant) could be disrupted in 
CRPS.  
Both the spinothalamic tract (that relays nociceptive information to the cerebral 
cortex) and the spinoreticular tract involved in DNIC contain projections from wide 
dynamic range neurons in lamina V. A failure to inhibit activity in wide dynamic range 
neurons that receive input from the CRPS-affected limb could sensitize neurons in the 
thalamus or cerebral cortex that receive convergent information from hemilateral body 
sites. As discussed in chapter 10, this could account for heightened sensitivity to 
stimulation of not only the affected limb but also areas outside the limb on the ipsilateral 
side of the body. A dysfunction in inhibitory control in CRPS could also unmask diffuse 
pain facilitation, thus promoting the further transfer of nociceptive messages to higher brain 
sites [3].  
In healthy volunteers, the reduction in forehead sensitivity to pressure-pain during 
cold-induced limb pain was greater in the ipsilateral than contralateral forehead (Study 
one). Similarly, capsaicin-induced inflammatory limb pain was associated with a reduction  
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in pressure-pain sensations in only the ipsilateral forehead (Study three). This ipsilateral 
response was not seen in the forehead of CRPS patients during noxious cold stimulation of 
the affected or the unaffected limb (Study six). As discussed in chapter 5 and 7, 
noradrenergic activity emanating from the locus coeruleus (LC) may underlie the reduction 
of pain sensitivity in the ipsilateral forehead during cold-induced and capsaicin-induced 
limb pain in healthy volunteers. This mechanism could be compromised in CRPS patients. 
Study five provided further indications of a dysfunction in inhibitory pain control 
from the LC in CRPS. Acoustic startle in the ipsilateral ear increased pain in the CRPS-
affected limb more so than startle in the contralateral ear, and auditory discomfort was 
similarly greater to startle in the ipsilateral than contralateral ear suggestive of dysfunction 
in a mechanism that influences central processing hemilaterally. As the LC projects both to 
the cochlear nucleus in the auditory system and the dorsal horn in the spinal cord and has 
the potential to produce facilitation at both of these sites via actions at α1-adrenoceptors [7; 
17; 19; 22; 28; 33], a shift toward facilitation from the LC could explain the greater 
increase in CRPS to stimulation in the ipsilateral than the contralateral ear as well as the 
greater auditory discomfort to ipsilateral startle. 
Serotonergic pain modulation from raphe nuclei such as the rostral ventromedial 
medulla (RVM) may also be compromised in CRPS patients. As mentioned in chapter 2, 
serotonergic projections from the RVM may have inhibitory or facilitatory actions 
depending on the receptors activated [32; 42]. Similar to the LC, raphe nuclei innervate the 
cochlear nucleus in addition to the dorsal horn [16; 42]. Thus a dysfunction in inhibitory 
control from this site could unmask generalized facilitation of activity both in the cochlear 
nucleus and dorsal horn neurons, and could explain the increase in CRPS pain to acoustic 
stimulation in both ears. The recent findings by Seifert et al. [34] that pain ratings to 
repetitive noxious electrical stimulation of both the affected and unaffected limb decreased  
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more slowly in CRPS patients than controls  is consistent with a generalized dysfunction in 
inhibitory pain control. 
Thus a number of central pain control mechanisms may be compromised in CRPS. 
A failure of these mechanisms to control the central transfer of nociceptive messages from 
the affected limb, and even more so a shift toward facilitation of such messages, may 
promote activity in wide dynamic range neurons that receive input from the CRPS-affected 
limb and ultimately contribute to sensitization of neurons in the thalamus or cerebral cortex. 
Hyperexcitability in thalamic nuclei contralateral to the affected limb which receive 
convergent input from hemilateral body sites could not only explain the presence of 
hemilateral hyperalgesia but could also explain heightened sensitivity to other forms of 
sensory input. Brain imaging studies have demonstrated hyperexcitability in somatosensory 
and motor cortices corresponding to the affected limb in CRPS [18; 23; 31; 37]. It would be 
interesting to determine whether a similar pattern exists in the auditory cortex. 
The involvement of these pain control mechanisms in the generation and spread of 
hyperalgesia in CRPS should be explored further. Future studies could employ more 
invasive measures such as PET scans using radioactively-labeled neurotransmitters to 
assess changes in the central release of noradrenaline and serotonin following startle with a 
loud tone and noxious cold stimulation to confirm the involvement of such mechanisms. 
Attempts could also be made to disrupt such mechanisms in healthy volunteers to 
determine whether this evokes a spread of hemilateral sensory disturbances. Study two 
attempted to do this by employing optokinetic stimulation. However, this did not appear to 
be an adequate procedure for doing so. Instead the pharmacological administration of drugs 
such as the opioid receptor antagonist naltrexone, the α2-adrenoceptor antagonist 
yohimbine, or the benzodiazepine valium, which enhances the effects of GABA thereby 
reducing the central release of noradrenaline and serotonin, could be employed in an 
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Fig. 1. Ascending pain pathway from the CRPS limb and coeruleospinal pain 
modulation. Heightened nociceptive input from the CRPS limb (red) may produce 
hyperexcitability both in the dorsal horn (DH) and the contralateral thalamus (TH) in 
patients with CRPS. A disruption of descending inhibitory control from the locus coeruleus 
(LC) (purple) may unmask the further facilitation of neurons in the ipsilateral dorsal horn. 
In addition a shift toward facilitatory control from the LC may facilitate neurons in the 
ipsilateral trigeminal nucleus caudalis (TNC) that transmit nociceptive messages from the 
forehead to the thalamus (blue), and may also facilitate neurons in the ipsilateral cochlear 
nucleus (CN) that transmit auditory impulses from the ipsilateral ear to thalamic nuclei 
(green). This could explain the heightened sensitivity both to sensory and auditory stimuli 
on the symptomatic side of the body in CRPS. The convergence of these stimuli in an 
already hyperexcitable thalamus may also explain such findings. The shift from inhibitory 
to facilitatory pain control in diffuse bidirectional pain control mechanisms such as diffuse 
noxious facilitatory versus diffuse noxious inhibitory controls or serotonergic projections 
from raphe nuclei may explain findings of generalized sensory disturbances in CRPS 
patients. For clarity, descending influences from the LC are presented schematically.   
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attempt to block mechanisms such as stress-induced analgesia, coeruleospinal and DNIC 
pain control. Such studies may also help shed light on whether the lack of inhibitory control 
or presence of facilitatory control is a preemptive factor in the development of CRPS or a 
consequence of the condition. Forehead sensitivity was generally symmetrical in healthy 
volunteers, but ipsilateral forehead hyperalgesia to pressure-pain or sharpness was present 
in a minority of healthy volunteers. It is tempting to speculate that disturbances in the 
central processing of nociceptive input could mediate such effects and could be a 
predisposing factor for the development of CRPS. Findings that some patients develop 
recurrent episodes of CRPS sometimes in a different limb [1; 2; 24] similarly suggest that 
something may predispose certain individuals to develop this condition. Exaggerated 
neurogenic inflammation has also been proposed as a predisposing factor for the 
development of CRPS as enhanced reflex vasodilatation was present in former CRPS 
patients [30]. Exaggerated neurogenic inflammation could sensitize peripheral and central 
neurons and activate facilitatory mechanisms, or perhaps inhibitory pain control 
mechanisms become fatigued over time unmasking facilitatory control.  
In conclusion, the findings presented in this thesis suggest that heightened 
nociceptive traffic in the CRPS-affected limb may contribute to heightened sensitivity both 
in the CRPS affected limb and the ipsilateral forehead by inducing sensitization in spinal 
and supraspinal pathways subserving the affected limb. This hypothesis is presented in 
Figure 1. In particular, sensitization of the contralateral thalamus, which receives 
convergent input from hemilateral body sites, could explain the hyperalgesia at various 
body sites ipsilateral to the affected limb. In CRPS, this process may be further exacerbated 
by a failure of central pain control mechanisms to inhibit nociceptive activity in the spinal 
cord. More importantly, a shift toward facilitatory control in pain control mechanisms, with 
a bidirectional role such as the noradrenergic actions from the LC, the serotonergic actions  
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from raphe nuclei or diffuse noxious facilitatory versus inhibitory controls [3; 19; 22; 41; 
42], may promote the further facilitation of nociception. The facilitation of more 
generalized mechanisms could explain reports by some researchers that sensations are also 
more generally disturbed in patients with CRPS [20; 35].  
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Appendix A 
 
Patient participation in Study four, five, six and seven 
Patient ID.  Study four  Study five  Study six  Study seven 
1  x  x  x  x 
2  x  x  x  x 
3  x  x     
4  x  x  x  x 
5  x      x 
6  x  x  x  x 
7  x  x  x  x 
8  x      x 
9  x  x  x  x 
10  x  x  x   
11  x  x  x  x 
12  x  x  x  x 
13  x  x  x  x 
14  x  x  x  x 
15  x       
16  x      x 
17  x       
18  x      x 
19  x  x    x 
20  x  x    x 
21    x  x  x 
22    x    x 
23    x  x  x 
24    x  x  x 
25    x    x 
26    x    x 
27    x    x 
28    x  x  x 
29    x  x  x 
30    x  x  x 
31    x  x  x 
32    x  x  x 
33    x    x 
34    x    x 
35      x  x 
36      x   
37      x   
38        x 
39        x 
40        x 